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Abstract 
Epithelial cells are characterised by a tight intercellular adhesion. Disassembly 
of E-cadherin-mediated cell-cell adhesion can induce a transition from a benign 
epithelial phenotype to an invasive mesenchymal phenotype. Therefore, 
understanding the underlying mechanisms leading to adherens junction disruption 
will provide insights into potential therapeutic agents to prevent tumour metastasis. 
The small GTPases Arf6 and Rac can each disassemble E-cadherin-based 
junctions, upon which epithelial cells scatter. Preliminary results in our lab showed 
that Rac requires PAK function during junction disassembly and that Arf6 disrupts 
keratinocyte junctions in a process dependent on Rac signalling. Crosstalk between 
Arf6 and Rac has been described previously, but the exact molecular mechanisms 
involved during Arf6-induced junction disassembly are not known. A good candidate 
molecule to provide the link between Arf6 and Rac is GIT1. GIT1 interacts with active 
Arf6 by an ArfGAP domain and induces Rac activation via binding to the Rac GEF ß- 
PIX. 
Rac regulates many cellular processes in which no effector proteins have been 
yet identified, including perturbation of cell-cell contacts. Using a keratinocyte cDNA 
library screen with active Rac as bait, a new Rac binding protein named Armus has 
been isolated previously. This protein is interesting as in addition to binding 
specifically to active Rac, it contains a TBC/RabGAP domain at its C-terminus which is 
predicted to inactivate Rab small GTPases. Armus function is currently unknown. 
The aim of my PhD project was to test the involvement of GIT1, PAK and 
Armus in the disassembly of E-cadherin junctions induced by active Arf6 and Rac. I 
found that GIT1 and p-PIX might provide the link towards Rac signalling during Arf6- 
induced junction disassembly. Furthermore, expression of Armus TBC/RabGAP 
domain can block Arf6-induced junction disruption by inactivating Rab7. In contrast, 
the Rac effector PAK does not play a role in Arf6-dependent junction disassembly. 
Moreover, I found that Armus and GIT1 are distributed on similar vesicular structures, 
suggesting that these proteins are spatially and functionally linked. 
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1.1 Epithelial tissue 
Epithelium is a coherent sheet of cells which covers the external surface of the 
body and lines the internal cavities forming the barrier to retain body fluids and 
excludes harmful pathogens. Epithelial cells rest on a supporting bed of connective 
tissue separated by a thin mat composed of extracellular matrix, called the basal 
lamina. Skin epithelium consists of two types of proliferating keratinocytes in the 
basal layer called stem cells and transit amplifying cells. Stem cells have an unlimited 
self-renewal capacity. Transit amplifying keratinocytes are daughters of stem cells that 
migrate upwards from the basal layer and undergo morphological changes to 
eventually form cornified keratinocytes committed to terminal differentiation and 
release from the skin (Watt, 1998). 
Epithelial cells are characterised by a cuboidal cell shape accompanied by an 
asymmetrical distribution of proteins along the apical (top) and basal lateral (bottom) 
membrane of the cell. This phenomenon is defined as cell polarity (Nelson, 2003). 
Maintenance of the typical epithelial polarity is crucial for proper function and is 
provided by strong attachment of epithelial cells to their neighbouring cells via cell-cell 
junctions and to the basal lamina via cell-extracellular matrix (ECM) adhesions (Braga, 
2000a). 
1.2 Adherens junctions 
There are three main types of adhesive structures known as desmosomes, 
adherens junctions and tight junctions (Perez-Moreno and Fuchs, 2006). In this PhD 
project I will focus on adhesive structures mediated by cadherins in keratinocytes. 
1.2.1 Cadherin-mediated cell-cell junctions 
Assembly of adherens junctions is mediated by classical cadherins, a family of 
calcium-dependent cell-cell adhesion molecules (Takeichi, 1990). The group of classical 
cadherins is part of a large superfamily that additionally includes atypical cadherins, 
desmosomal cadherins, protocadherins and Flamingo cadherins (Nollet et al., 2000; 
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Wheelock and Johnson, 2003). The classical cadherins consist of three distinct parts: (i) 
an extracellular domain, (ii) a single-pass transmembrane domain and (iii) a 
cytoplasmic domain. The large extracellular domain contains five tandem repeats, 
each about 110 amino acids long. The first extracellular repeat on cadherins is 
responsible for homophilic interaction between the same type of extracellular domain 
of a cadherin receptor on adjacent cells and thus mediates adherens junction structures. 
Binding sites for calcium are situated between the repeats (Figure 1.1). In the absence 
of calcium, cadherin molecules are degraded by proteolytic enzymes resulting in weak 
cell-cell adhesion (Takeichi, 1990; Gumbiner, 1996). 
The classical cadherin epithelial (E-)cadherin is typically found in epithelial 
cells, although placenta (P-)cadherin is also expressed (Furukawa et al., 1997). E- 
cadherin is the most studied cadherin receptor and is important for the establishment 
and maintenance of epithelial cell polarity, tissue morphology and function 
(Gumbiner, 1996). 
1.2.2 Cadherin-catenin complex 
For full functionality of the E-cadherin-mediated contacts, structural linkage 
with the cytoskeleton is necessary. This is provided by the cytoplasmic side of 
cadherins, as cadherins that lack their cytoplasmic domain cannot hold cells strongly 
together (Nagafuchi and Takeichi, 1988). Linkage of E-cadherin with the actin 
cytoskeleton is facilitated through binding proteins of the catenin family (Figure 1.1). 
Beta-catenin and plakoglobin (y-catenin) are highly homologous (65%) members 
of the armadillo repeat family (Fouquet et al., 1992). These catenins can interact 
directly to a 30 amino acid distal region of the cytoplasmic tail of cadherin (Jou et al., 
1995; Stappert and Kemler, 1994). In addition to ß-catenin and plakoglobin, another 
member of the armadillo family, p120ctn binds to the highly conserved juxtamembrane 
region of cadherin (Reynolds et al., 1994; Jou et al., 1995; Shibamoto et al., 1995; Yap et 
al., 1998). Only (3-catenin and plakoglobin can bind a-catenin which in turn links the 
cadherin to the actin cytoskeleton (Aberle et al., 1994; Hülsken et al., 1994; Jou et al., 
1995). 
Alpha-catenin directly interacts with actin filaments (nimm et al., 1995; Pokutta 
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F-actin ýi-c ýtýrdn ß p12üctn b cc-ýctinin 
u-catAnin pcCZ..; 
%E-cadhAdn 
Vincuhn VASP 
Figure 1.1: Composition of adherens junctions. 
The extracellular domain of cadherin is folded into five cadherin repeats. 
In the presence of calcium, dieters of cadherins can cluster at sites of cell- 
cell adhesion. p120ctn and (3-catenin interact directly to the cytoplasmic 
domain of the cadherin receptor and (3-catenin links to the actin 
cytoskeleton via a-catenin. Alpha-catenin binds actin directly or can 
interact with the actin-binding proteins such as vinculin and a-actinin. 
However, the traditional model proposed above is under scrutiny as recent 
data suggest that binding of a-catenin to actin or actin-binding proteins 
does not occur simultaneously. From Fuchs and Raghavan (2002). 
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et al., 2002) or indirectly through actin-binding proteins such as vinculin, a-actinin, ZO- 
1, Ajuba and formin-1 (Watabe-Uchida et al., 1998; Knudsen et al., 1995; Nieset et al., 
1997; Itoh et al., 1997; Marie et al., 2003; Kobielak et al., 2004). However, recent data 
suggests that binding of a-catenin to actin (directly or indirectly) and a-catenin to p- 
catenin is mutually exclusive (Yamada et al., 2005a). Thus, the understanding of how 
cadherins link to the actin cytoskeleton is not yet fully understood. Of the a-catenin- 
binding proteins, vinculin and a-actinin also play a role in linking actin to integrin 
receptors in focal adhesion contacts (Lo, 2006). The protein Vasp/Mena is a mediator of 
linear actin cable organisation that is required during the assembly of E-cadherin- 
mediated cell-cell contacts and also localises to focal contacts. The interacting protein 
responsible for the specific localisation of Vasp/Mena at adherens junctions is not 
known, although Vasp/Mena fails to localise properly in the absence of a-catenin 
(Vasioukhin et al., 2000). 
Other cadherin-associated proteins include receptor tyrosine kinases, tyrosine 
phosphatases and serine/threonine kinases. Phosphorylation of the cadherin-catenin 
complex proteins is critical for strong cell-cell adhesion as well as disassembly of 
junctions by increasing or decreasing the interaction between proteins (Gumbiner, 
2005). 
1.2.3 Intracellular trafficking of E-cadherin receptors 
The normal turnover rate of E-cadherin receptors at the membrane is high (týz 
5h; Shore and Nelson, 1991). Internalisation of E-cadherin from the plasma membrane 
via endocytosis is a mechanism for regulation of adherens junctions (Figure 1.2). This 
endocytosis can occur via a clathrin-dependent pathway, but E-cadherin can also 
be 
internalised independently of clathrin (Le et al., 1999; Akthar and Hotchin, 2001; 
Paterson et al., 2003; Ivanov et al., 2004; Izumi et al., 2004; Xiao et al., 2005). Adherens 
junctions are renewed via endosomal trafficking to lysosomes where they are 
proteolytically degraded and replaced by de novo synthesised receptors 
(Bryant and 
Stow, 2004). Newly synthesised E-cadherin receptors are transported towards the 
basolateral plasma membrane via a recycling endosome compartment 
(Lock and Stow, 
2005). Correct targeting is dependent on a dileucine motif in the cytoplasmic tail of E- 
cadherin, as removal of this dileucine motif results 
in mistargeting to the apical cell 
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surface (Miranda et al., 2001,2003). Furthermore, it has been demonstrated that the 
transport of newly synthesised E-cadherin receptors is facilitated by (3-catenin. Shortly 
after synthesis, cytosolic (3-catenin binds the cytoplasmic domain of E-cadherin and 
mediates correct transport to the basolateral plasma membrane. Once arrived at the 
plasma membrane, linkage to other catenins, a-catenin-binding proteins and actin 
occurs (Hinck et al., 1994; Chen et al., 1999; Miranda et al., 2003). 
Self-renewal of adherens junctions occurs by continuous disassembly and 
assembly of adherens junctions. It has been speculated that by recycling E-cadherin, a 
rapid change in cell morphology in response to extracellular stimuli can be achieved 
(Bryant and Stow, 2004; Yap et al., 2007). In fact, E-cadherin receptors are not static at 
the plasma membrane or at an intracellular location, but are highly dynamic by 
constitutively transported through an endocytic recycling pathway while strong cell- 
cell adhesion is maintained (Le et al., 1999). Epithelial cells cultured in low calcium 
contain a prominent intracellular pool of E-cadherin that is recruited to the cell surface 
when cell-cell contacts are induced (Mc Neill et al., 1993; Adams et al., 1996). In turn, 
chelation of calcium causes internalisation of E-cadherin receptors and an increase in 
the endocytic recycling pool (Kartenbeck et al., 1991; Le et al., 1999; Ivanov et al., 2003). 
1.3 Dysregulation of E-cadherin-catenin complex in tumours 
The epithelial to mesenchymal transition (EMT) is an important developmental 
process in many animal species, for example in the formation of tissues during 
gastrulation, neurulation and organogenesis. During EMT, epithelial cells convert to a 
mesenchymal phenotype in which cells lose most of their epithelial characteristics, 
become dedifferentiated and more motile (Figure 1.3; Thiery, 2002; Gumbiner, 1996). 
EMT is important during tumour progression but in this case EMT is uncontrolled 
when compared to developmental events. EMT is particularly relevant for carcinomas, 
tumours originated from epithelial cells and by far the most common type of human 
cancer (Thiery, 2002; Sahai and Marshall, 2002). During EMT, destabilisation of E- 
cadherin-mediated cell-cell adhesion correlates with loss of epithelial morphology and 
acquisition of metastatic potential by carcinoma cells. Forced expression of E-cadherin 
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Figure 1.2: Intracellular trafficking of E-cadherin receptors. 
(1) In the presence of calcium, E-cadherin forms adherens 
junctions via interaction of similar E-cadherin molecules on 
adjacent cells. (2) Renewal of cell-cell junctions occurs via 
endocytosis of E-cadherin into early/sorting endosomes, (3) 
followed by degradation to lysosomes via late endosomes or (4) 
by recycling of the receptor. (5) Newly synthesised E-cadherin 
proteins are transported from the Golgi complex to the plasma 
membrane. Figure obtained from Yap et al. (2007). 
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in cultured cancer cells or transgenic mouse models reverses this process and prevents 
tumour invasiveness (Vleminckx et al., 1991; Frixen et al., 1991; Perl et al., 1998). 
Therefore, E-cadherin has emerged as a tumour suppressor of metastasis and growth 
of epithelial cancers (Christofori and Semb, 1999). 
Because of the importance of the breakdown of E-cadherin-mediated junctions 
during tumour progression, there is much interest in determining the key pathways 
that result in E-cadherin disassembly. Understanding of the underlying mechanisms 
will contribute to the identification of prognostic markers and novel therapeutic 
targets. So far)multiple ways to regulate the stability of E-cadherin-catenin complex at 
junctions have been characterised. 
1.3.1 Gene regulation and proteolysis of E-cadherin 
Inactivating coding mutations in the E-cadherin gene have been detected in 
many cancer types including lobular breast and diffuse gastric cancers (Berx et al., 
1998). These mutations comprise mainly splice site and truncation mutations caused 
by insertion, deletions and missense mutations. Besides somatic mutations, epigenetic 
silencing of the E-cadherin gene by promoter hypermethylation has been reported in 
breast, prostate, colon cancers and gastric cancers (Yoshiura et al., 1995; Graff et al., 
1995; Suzuki et al., 1999). The transcription factor Snail has been found over-expressed 
in different tumour types and can also repress the transcription of E-cadherin by 
binding to three E-boxes within the E-cadherin promoter (Battle et al., 2000). 
In other cancer types, truncated forms of E-cadherin by proteolytic cleavage 
have been detected. Metalloproteinases (MMPs) can cleave E-cadherin near the plasma 
membrane on the extracellular domain. The release of E-cadherin extracellular 
domain, also called soluble E-cadherin, reduces adherens junction strength and can 
increase cell invasion. The protease calpain cleaves E-cadherin at the cytoplasmic tail 
resulting in destabilisation of adherens junctions and its over-expression is implicated 
in prostate tumorigenesis (Masterson and O'Dea, 2007). 
1.3.2 Phosphorylation of E-cadherin 
The integrity of cell-cell junctions is regulated through phosphorylation events on 
cadherin-catenin complex (Gumbiner, 2005). Cadherin-based adhesive structures are 
CHAPTER 1 127 
Normal epithelium Imasiv(ý cal cinorm 
Etý1T O0 
On 0 
o 
Figure 1.3: Tumour progression in epithelial cells. 
Normal epithelial cells are characterised by cell polarity and strong cell-cell junctions. An adenoma 
develops by hyperproliferation of tumour cells, but maintains a differentiated morphology. Further 
transformation involves cell dedifferentiation leading to carcinoma in situ. As a result of EMT, 
invasive tumours without cell-cell junctions acquire increased cell motility and eventually invade 
through the basal membrane to metastasise. Figure obtained from Thiery (2002). 
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major sites for tyrosine kinase and serine/threonine kinase signalling, which can 
contribute negatively or positively to stable junctions. The importance of a tight 
regulation of phosphorylation levels is reflected in the number of phosphatases that co- 
localise or associate with cadherin complexes (Sallee et al., 2006; Gumbiner, 2005). 
Breakdown of adherens junctions have been shown following treatment with 
HGF/SF (hepatocyte growth factor/scatter factor) that is the ligand for the HGFR 
(hepatocyte growth factor receptor). HGF/SF treatment induces phosphorylation of 
tyrosine residues on E-cadherin that subsequently result in loss of junctional integrity 
and cell scattering via ubiquitination, increased endocytosis and degradation of E- 
cadherin in lysosomes (Palacios et al., 2001,2002; Kamei et al., 1999). For example, 
HGF/SF activates the E3 ubiquitin-ligase Hakai that binds phosphorylated E-cadherin 
tyrosine residues on position 755 and 756 and facilitates ubiquitination and increased 
endocytosis of E-cadherin (Fujita et al., 2002). In addition, activation of the tyrosine 
kinase v-Src or adhesion receptors also results in disassembly of cell-cell contacts and 
requires a step mediated by the proteasome (Tsukamoto and Nigam, 1999). On the 
other hand, however, Weidner and collegueas (1990) showed that the level of 
phosphorylation on E-cadherin does not change with the HGF/SF-induced invasive 
phenotype of MDCK cells. 
The cytoplasmic tail of E-cadherin harbours a cluster of eight serine 
phosphorylation sites that is important for the interaction with (3-catenin. Preventing 
phosphorylation on these residues abolishes association of E-cadherin with ß-catenin 
and results in reduced cell-cell junctions (Stappert and Kamler, 1994). In vitro studies 
showed that the serine/threonine kinase casein kinase II (CK2) can phosphorylate 
mainly three serines (S840, S853, and S855) on E-cadherin that increases the interaction 
with ß-catenin and strengthens cell-cell junctions (Lickert et al., 2000). CK1, another 
casein kinase family member can also phosphorylate the cytoplasmic tail of E-cadherin 
as well as a- and (3-catenin. The major phosphorylation site for CK1 on E-cadherin 
involves a highly conserved serine residue present in classical cadherins (S846 on E- 
cadherin) and its phosphorylation weakens cell-cell junctions as a result of enhanced 
internalisation of E-cadherin receptors (Dupre-Crochet et al., 2007). Thus, a balance of 
CK1- and CK2-dependent phosphorylation may determine the binding affinity 
between E-cadherin and (3-catenin and as a consequence adhesive strength. In 
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addition, serine/threonine protein kinase D1 (PKD1) co-localises with E-cadherin- 
mediated cell-cell contacts in prostate cancer cells and phosphorylates directly E- 
cadherin. Inhibition of phosphorylation activity by PKD1 results in decreased 
aggregation of cells and increased cell motility, whereas an increase of PKD1 activity 
resulted in an opposite effect. PKD1 is often downregulated in invasive human 
prostate cancer and this may contribute to metastatic progression through reduced 
phosphorylation of E-cadherin (Jaggi et al., 2005). 
1.3.3 pl20c n 
Changes in the stoichiometry of proteins bound to the E-cadherin cytoplasmic 
tail can influence the stability of cell-cell interactions. For example, p120cIncan stabilise 
adherens junctions by binding to the juxtamembrane region of the E-cadherin 
cytoplasmic tail (Yap et al., 1998). In endothelial cells, the absence of this interaction 
triggers internalisation and degradation of vascular endothelial (VE)-cadherin, 
whereas over-expression of p120ctn has an opposite effect (Xiao et al., 2003). This role of 
p120ctn in cadherin turnover has also been demonstrated for E-, P- and neuronal (N)- 
cadherins (Davis et al., 2003). 
Interestingly, cytoplasmic p120ctn can translocate to the nucleus by interaction 
with the transcription factor Kaiso. Some of Kaiso's target genes, such as cyclinDl and 
MMP7 regulate cell proliferation or tumour metastasis, respectively, suggesting that 
pl20c,, ' can play a role during tumorigenesis in multiple ways (Daniel, 2007). 
p120cm is phosphorylated on multiple tyrosine, serine and threonine sites 
during homeostasis. There are different tyrosine kinases identified that phosphorylate 
p120cm directly, like Fyn (Calautti et al., 1998), Fer (Piedra et al., 2003) and v-Src 
(Reynolds et al., 1989; 1994). Tyrosine residues on p120ctn that are phosphorylated by 
these tyrosine kinases are mostly unknown, although v-Src has been shown to 
phosphorylate eight tyrosines on p120cIn in vitro (Mariner et al., 2001). The binding of 
unphosphorylated p120ct" to the E-cadherin tail is weak but can be increased by 
tyrosine phosphorylation events on p120ctn. This suggests that tyrosine 
phosphorylation on p120ct" promotes strong cell-cell adhesion as shown in 
different 
studies (Papkoff, 1997; Calautti et al., 1998; Calautti et al., 2002). 
On the other hand, 
increased p120ct" tyrosine phosphorylation can also decrease the affinity for cadherins 
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and plays a role during cellular transformation (Reynolds et al., 1989; Ozawa and 
Ohkubo, 2001). Moreover, no significant changes in the association of pl20ctn to E- 
cadherin have been obtained even in instances in which p120ctn is heavily 
phosphorylated by Src (Reynolds et al., 1994). 
Furthermore, the role of p120cI phosphorylation on serine and threonine 
residues is also controversial. Extensive serine and threonine phosphorylation of 
p120ctn causes reduction of adhesive strength in colon carcinoma Colo-205 cells (Aono 
et al., 1999). Other data suggest that p120c'n serine/threonine phosphorylation or 
dephosphorylation on four major sites (S268, S288, T310 and T910) does not influence 
the stability of the cadherin-catenin complex (Xia et al., 2006). 
Together, the contrasting results with phosphorylation events on p120ctn most 
probably reflect a complex and fine regulation of the association of p120cth with E- 
cadherin. It is possible that individual tyrosine phosphorylation sites differentially 
affect the binding of p120ctn to E-cadherin as well as additional phosphorylation events 
on other components of the E-cadherin-catenin complex. 
1.3.4 Beta-catenin 
Beta-catenin interacts directly to E-cadherin and is necessary for linking 
adherens junctions to the cytoskeleton (Aberle et al., 1994; Hülsken et al., 1994; Jou et al., 
1995). On the other hand, ß-catenin can also function in the Wnt signalling pathway as 
a transcriptional activator by binding in the cytoplasm to transcription factors of the 
LEF/TCF (lymphocyte enhancer factor/T cell factor) family. The (3-catenin- 
transcription factor complex promotes transcription of genes responsible for 
proliferation. In normal tissues, there is a tight balance between the dual role of ß- 
catenin in cell-cell adhesion and gene transcription. However, in many tumours 
oncogenic mutations of (3-catenin are observed that stabilise the protein in the 
cytoplasm and promotes gene transcription rather than adhesive strength (Brembeck et 
al., 2006). 
Amino terminal serine/threonine phosphorylation of (3-catenin occurs by CK1 
and glycogen synthase kinase 3(3 (GSK-3p) via a complex containing additionally 
adenomatous polyposis coli (APC) and axin. Phosphorylated ß-catenin is then 
ubiquitinated and targeted for rapid degradation by the proteasome system (Schwarz- 
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Romond et al., 2002; Aberle et al., 1997; Liu et al., 2002; Behrens et al., 1998). Activation 
of Wnt signalling in tumour cells inhibits GSK-3(3 and results in accumulation of (3- 
catenin in the nucleus and the expression of target genes involved in cellular 
proliferation. In addition, tyrosine phosphorylation of (3-catenin by v-Src or growth 
factors can also lead to destabilisation of E-cadherin junctions (Behrens et al., 1993; 
Shibamoto et al., 1994). 
1.3.5 Alpha-catenin 
It has been proposed that a-catenin also has a tumour suppressor role. Indeed, 
loss of a-catenin in some tumours and tumour cell lines correspond with reduced cell- 
cell adhesion (Shimoyama et at., 1992; Morton et at., 1993; Kadowaki et al., 1994). 
Conversely, re-expression of a-catenin can restore E-cadherin-mediated junctions in 
cancer cells (Ewing et at., 1995; Bullions et al., 1997). The most significant effects of 
targeted deletion of the a-catenin gene in the epidermis were increased cell migration, 
shortening of cell cycle, increased proliferation and decreased apoptosis rather than 
just disruption of cell-cell adhesion (Vasioukhin et at., 2001; Lien et al., 2006). Taken 
together, these results imply that loss of a-catenin may contribute to tumorigenesis. 
1.3.6 Alpha-catenin binding proteins 
Vinculin can provide the link between a-catenin and actin at sites of cell-cell 
contacts (Watabe-Uchida et al., 1998; Figure 1.1). Vinculin is also regarded as a tumour 
suppressor as over-expression of exogenous vinculin in some tumour cell lines result in 
decrease of tumorigenic and metastatic potential (Rodriguez Fernandez et al., 1992). In 
addition, disruption of the vinculin gene causes decreased adhesion and enhanced 
motility of embryonic stem cells (Coll et al., 1995). 
Alpha-actinin binds a-catenin as well as filamentous actin at sites of cell-cell 
contacts (Figure 1.1). In different cancer cell lines an isoform of a-actinin, a-actinin-4, 
localises in the cytoplasm rather than at adherens junctions. Accompanied by 
increased expression and alternative slicing, a-actinin-4 has been associated with cell 
motility and cancer metastasis (Honda et al., 1998,2004). 
Vasp/Mena localises to adherens junctions and is important for actin 
reorganisation during adherens junction assembly 
(Vasioukhin et al., 2000; Figure 1.1). 
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Interestingly, Vasp/Mena is reported to be over-expressed in breast cancer (Di 
Modugno et al., 2004) and lung adenocarcinomas where in the latter case it may 
regulate the invasive behaviour of lung tumour cells (Dertsiz et al., 2005). Participation 
of the a-catenin binding protein Ajuba (Marie et al., 2003) in cancer has not been 
reported. Implication of ZO-1 in tumorigenesis has only been described in the context 
of tight junctions (Polette et al., 2007). 
1.4 Small GTPases 
As described above, it is clear that tumorigenesis can be promoted by 
modulating the E-cadherin/catenin complex in different ways. Although gene 
mutations have been reported to weaken the interaction between the E-cadherin- 
catenin complex and actin (Pecina-Slaus, 1998; Brembeck et al., 2006), a significant 
number of tumours encode normal E-cadherin and catenin genes. This suggests that 
posttranscriptional processes that regulate adherens junction stability account for 
disassembly of cell-cell contacts in developing tumours. A growing number of studies 
point to the participation of small guanosine triphosphatases (GTPases) in the 
modulation of E-cadherin-mediated cell-cell adhesion. 
1.4.1 Ras superfamily of small GTPases 
Small GTPases are monomeric proteins with molecular masses of -20kDa that 
relay signals from cell surface receptors. Small GTPases have been conserved in 
evolution with mammalian orthologs found in many vertebrates and invertebrates. To 
date, more than 150 members of the small GTPase superfamily including isoforms 
have been identified in mammals (Wennerberg et al., 2005). This superfamily of small 
GTPases is also referred as the "Ras superfamily" and is classified in five main branches 
called Ras, Rho, Rab, Arf and Ran proteins (Figure 1.4). These proteins control a wide 
variety of cellular processes and each subfamily has a main function. 
The Ras family 
proteins are responsible for a variety of signalling pathways resulting 
in transcription 
and cell growth. Ran family members regulate nucleocytoplasmic transport, 
regeneration of the nuclear envelope and microtubule organization 
during the cell 
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Figure 1.4: Phylogenetic tree of human Ras superfamily members. 
The Ras superfamily of GTPases can be divided in five main branches called Rab (red), Ras (blue), Arf 
(green), Rho (olive) and Ran (orange). Subfamily members and isoforms within each branch are shown 
and numbers are summarised in the table. Figure obtained from Wennerberg et al. (2005). 
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cycle (Takai et al., 2001; Wennerberg et al., 2005). The Rho family regulates the cell 
shape by modulating the actin cytoskeleton, whereas the Arf and Rab families control 
the formation and traffic of intracellular vesicles. Although each subfamily has a main 
role, often their functions overlap. For example, Arf, Rab and Rho proteins are known 
to regulate proliferation, vesicular transport, migration and attachment to substrata or 
neighbouring cells (D'Souza-Schorey and Chavrier, 2006; Jaffe and Hall, 2005; Bryant 
and Stow, 2004; Lozano et al., 2003; Zerial and McBride, 2001; Qualmann et al., 2003). 
1.4.2 Structure of small GTPases 
GTPases are molecular switches that cycle between an active GTP-bound and 
inactive GDP-bound conformation. GTPases consist of a six-stranded p-sheet 
surrounded by five a-helices. The characteristic interaction of each GTPase with GDP 
and GTP is facilitated by five universal GTP/GDP-binding domains called the G1-G5 
regions (Bourne et al., 1991). The G1-region or "P-loop" is responsible for the binding of 
the a- and f3-phosphate groups of GTP/GDP. The G2-region or "effector region" is the 
part of the molecule which undergoes the most extensive changes upon GTP 
hydrolysis and is thought to bind effector proteins. The conserved threonine residue in 
this region (Thr35 in Ras) binds a Mg2+ ion, which is coordinated to the oxygens of the 
(3- and y-phosphates of GTP. The G3-region binds the -y-phosphate of GTP and the 
glutamine in this region (G1n61 in Ras) is critical for GTP hydrolysis. The G4-region 
binds the guanine ring of GTP/GDP whereas the G5-region is required for stabilization 
of the G4-interactions (Figure 1.5; Bourne et al., 1991; Vetter and Wittinghofer, 2001). 
The structures of the G1-G5 regions are similar in the GDP- or GTP-bound 
form, but nucleotide exchange induces a conformational change of two distinct loop 
regions referred to as switch I and switch II. Switch I overlaps with the G2 region, and 
switch II with the G3 region. The trigger for the conformational change is most 
likely 
universal among GTPases, but the extent of this change in the switch regions 
is 
different for each protein. In addition, Arf proteins contain additional N-terminal 
sequences and Ran extra C-terminal sequences that undergo significant conformation 
changes (Figure 1.5; Colicelli, 2004; Vetter and Wittinghofer, 
2001). 
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Figure 1.5: Structure of small GTPases. 
Ribbon plot of the minimal G-domain in monomeric 
GTPases. The six-stranded p-sheets and five a-helices are 
indicated with black and blue/white numbers, respectively. 
P-loop provides the binding towards GDP/GTP and the 
conserved threonine 35 binds a Mg2+ ion. Nucleotide 
exchange induces conformational changes in the switch I and 
switch II regions. Figure obtained from Vetter and 
Wittinghofer (2001). 
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1.4.3 Lipid modifications 
The majority of small GTPase family members undergo lipid posttranslation 
modifications, a process crucial for biological function. As small GTPases are 
hydrophilic and do not contain a transmembrane domain, the attachment of one or 
more lipid groups is necessary for localisation at distinct cellular membranes. 
Substitution of cysteine or glycine amino acids necessary for lipid modification can 
partially inhibit the function of the GTPase due to reduced membrane association 
(Takai et al., 2001; Wennerberg et al., 2005). Prenylation is the linkage of either farnesyl 
or geranylgeranyl moieties to cysteine residue at or near the C-terminus of a GTPase. 
For example, farnesyl can be linked to Ras and Rho whereas a geranylgeranyl group 
can be attached to Ras, Rho and Rab proteins (Seabra, 1998). Myristoylation and 
palmitoylation are the two major acetylation mechanisms that attach the fatty acid 
myristate at an N-terminal glycine residue or palmitate to internal cysteine residues, 
respectively. Members of the Arf subfamily of GTPases are myristolated and Ras and 
Rho subfamily members can be palmitoylated (Resh, 1996). Some small GTPases (e. g. 
Rit and Sari) are not modified by lipids but still associate with membranes whereas 
others members (e. g. Ran and Rerg) are not membrane-bound (Wennerberg et al., 
2005). 
1.5 Regulation of GTPase activity 
The activity status of small GTPases is tightly regulated by guanine nucleotide 
exchange factors (GEFs) and GTPase activating proteins (GAPs) (Figure 1.6). 
Exceptions are Rac1b, RhoH and members of the Rnd family (Rndl, Rnd2 and 
Rnd3/RhoE) that do not detectably hydrolyse GTP and are probably regulated at 
transcriptional level and by protein localisation (Fiegen et al., 2003; Guasch et al., 1998). 
In addition, activity of Rho and Rab proteins regulation occurs by GDP-dissociation 
inhibitors (GDIs, Figure 1.6). 
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1.5.1 GEFs 
The high affinity of GTPases for GDP nucleotides results in a slow GDP to GTP 
exchange rate. Therefore, GEF activity is required to accelerate this exchange. In 
general, GEFs catalyse the dissociation of GDP from the GTPase by altering the 
nucleotide-binding site via direct remodelling of the switch I and II regions. As a 
result, the nucleotide affinity is decreased upon GDP is released and subsequently 
replaced. In general the affinity of GDP and GTP to a GTPase is similar, but due to the 
higher cytosolic concentration of GTP compared to GDP, GTP will then bind quickly to 
the nucleotide-free GTPase. GEF dissociation occurs subsequently because the bound 
GTP nucleotide weakens the interaction of the GEF with the GTPase. The small 
GTPase is in an active GTP-bound conformation competent to transduce a signal 
through a specific pathway (Figure 1.6, Bos et al., 2007; Vetter and Wittinghofer, 2001; 
Cherfils and Chardin, 1999). 
While the mechanism of GDP to GTP exchange is common to all GEFs, different 
GEFs are not structurally related. Most GEFs can be classified into families according 
to sequence similarity in their catalytic domain and the interacting GTPase within a 
given subfamily. Ras GEF proteins typically have a Cdc25 domain, Rho GEFs a Dbl 
homology (DH) domain and Arf GEFs a Sec7 domain. Only the RCC1 GEF protein has 
been discovered for the Ran subfamily. A couple of structurally unrelated GEFs for 
Rabs have been identified that contain a MSS4, Sec2 or VSP9 catalytic domain. Most 
GEFs show substrate specificity to several small GTPases, although some act 
specifically on one member of the superfamily (Bos et al., 2007; Wennerberg et al., 2005). 
1.5.2 GAPs 
Hydrolysis of a GTP-bound GTPase results in a GDP-bound GTPase and a free 
inorganic y-phosphate, resulting in inactivation of the GTPase and termination of 
signalling to downstream effectors. Acceleration of the normally slow or lack of 
intrinsic hydrolysis of GTPases is provided by a GAP. First insights into the 
mechanism of GAP-mediated hydrolysis were obtained from biochemical 
data and the 
crystal structure of Ras in complex with the Ras GAP p120GAP 
(Scheffzek et al., 1996). 
Aluminium fluoride (AIFX) can mimic the y-phosphate transferred in GTP hydrolysis 
and can be used to form a ternary complex of 
GDP-bound GTPase-AIF,, -GAP 
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Figure 1.6: Model of small GTPase regulation. 
Small GTPases cycle between an active GTP-bound state and an 
inactive GDP-bound state. When bound to GDP, GDI can 
sequester members of the Rab and Rho family. A GEF stimulates 
the dissociation of GDP, which is followed by binding of GTP. 
GTP-bound small GTPases can interact with a range of effector 
proteins that transduces the signal. GTP hydrolysis is stimulated 
by a GAP and results in an inactive GTPases. Figure obtained 
from Takai et al. (2001). 
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(Ahmadian et al., 1997a). This stable complex is called the transition state as it mimics 
the GAP-induced conversion from GTP to GDP in the GTPase. In the GTPase switch 
regions, a conserved glutamine residue (G1n61 in Ras) situated near the -y-phosphate of 
GTP together with a glycine (G1y12 in Ras) is crucial for stabilising the GTPase-GTP- 
GAP interaction. 
In addition, a so-called arginine finger is supplied by the GAP and provides the 
scaffold for the active site (Ahmadian et al., 1997b; Vetter and Wittinghofer, 2001). 
Together with Ras GAPs, the Rho GAPs and Rab GAPs contain an arginine finger. 
This mechanism of GTP hydrolysis is universal among GAPs but the residue for the 
critical finger can differ. For example, the Ras subfamily member Rap has a catalytic 
RapGAP domain that contains an asparagine as a catalytic residue. No catalytic 
residue is provided by Ran GAPs whereas Arf GAP activity is assisted by coatomers 
that may provide a catalytic residue (Scheffzek et al., 1998; Scheffzek and Ahmadian, 
2005). 
1.5.3 Regulation of GEF and GAP activity 
Besides regulation of GEFs and GAPs at transcriptional levels, the activity of 
these proteins is tightly regulated by different intracellular mechanisms including 
protein-protein interactions, protein-lipid interactions, second messengers and 
posttranslation modification. 
First, an interaction of a protein can directly stimulate catalytic activities of a 
GEF or GAP protein. For example, APC can interact via its armadillo repeat domain 
with the N-terminal Abr region of the Rac GEF protein Asef, thereby stimulating its 
GEF activity (Kawasaki et al., 2000). Arf GAP proteins such as GIT1, CENTG2 and 
DDEF2 contain two or three ankyrin repeats that are predicted to interact with proteins 
to localise specifically (Bernards and Settleman, 2004). 
Second, an intra-molecular protein-protein interaction of two domains within a 
GEF can stimulate its nucleotide exchange activity. For instance, 
Sos1 contains a 
catalytic core domain responsible for Ras interaction and an upstream 
REM domain. 
Interaction of the REM domain with the catalytic region is 
found critical for Sos1 
activity (Sacco et al., 2006). In addition, 
dimerisation of several GEFs have been 
reported, such as the Arf GEF family members 
BIG and GBF. Dimerisation of these 
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proteins is crucial for yeast viability, suggesting that it is important for proper GEF 
function (Ramaen et al., 2007). 
On the other hand, intra-molecular conformation of proteins can also exhibit an 
auto-inhibition mechanism (Pufall and Graves, 2002). The Rho GEF Vav is auto- 
inhibited by interaction of the N-terminal domain with a region close to the DH 
domain (Llorca et al., 2005). Removal of the N-terminal sequence leads to constitutive 
activation when Vav is expressed in vivo (Katzav et al., 1991). Rho GAP activity of Rap- 
activated (RA)-RhoGAP is normally inhibited through binding of its RA domain to the 
catalytic core domain (Yamada et al., 2005b). Also the N-terminal domain of the Rho 
GAP Oligophrenin-1 has an auto-inhibitory role on its GAP activity (Fauchereau et al., 
2003). 
Third, GEF/GAP activation is restricted to specific locations in the cell where 
the target GTPase needs to be activated or inactivated. Specific membrane localisation 
can be facilitated via specialised membrane anchorage domains on the GEF or GAP. 
For example, Rho GEFs usually have a pleckstrin homology (PH) domain located 
adjacent to the DH domain. The PH region is commonly considered as a 
phosphatidylinositol (PtdIns)-binding region (Halet, 2005) and often mediates 
interaction of a Rho GEF with membrane lipids (Schmidt and Hall, 2002). The Arf GEF 
ARNO also contains a PH domain that mediates membrane localisation (Santy et al., 
1999). However, the PH domain of p120GAP does not promote proper localisation. 
Intrjmolecular binding of this domain towards the catalytic Ras GAP domain regulates 
the activity of p120GAP (Drugan et al., 2000). A Binl/amphiphysin/Rvs167 (BAR) 
domain found in Arf GAPs and Rho GAPs also links proteins to membranes (Bernards 
and Settleman, 2004). 
Fourth, GEFs can be directly regulated by second messengers like cAMP, Ca2+ 
or diacylglycerol. Examples are the Rap GEF proteins Epac1 and Epac2 that can both 
be activated by cAMP (De Rooij et al., 1998). Not much is known yet about the 
regulation of GAPs by second messengers. A reported example is the Rac-specific 
GAP ß2-chimaerin. This Rac GAP contains a C1 domain that is responsible for 
diacylglycerol binding. Binding of diacylglycerol results in enhancement of GAP 
activity in vitro and causes translocation of (32-chimaerin to the plasma membrane 
(Caloca et al., 2003). 
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Fifth, phosphorylation events play a role in either activating or inactivating 
GAP and GEF proteins. For example, GAP activity of tuberin on Rheb is regulated by 
phosphorylation, on many serine and threonine residues. Phosphorylation by the 
AMP-activated protein kinase (AMPK) enhances tuberin GAP activity (Inoki et al., 
2003) whereas the kinase Akt can inactivate tuberin by phosphorylation events that 
cause instability and degradation (Dan et al., 2002). Protein kinase C (PKC)-mediated 
phosphorylation of ARNO has been shown to reduce its specific localisation at the cell 
membrane (Santy et al., 1999). In addition, nucleotide exchange on Rac in vivo is 
dependent on phosphorylation of tyrosine residues in the Vav protein (Crespo et al., 
1997). 
Finally, little is known about the inactivation mechanisms when stimulation is 
terminated. However, inhibitors of GEFs have been found for the Rho GEFs Vav and 
Tiam1. Cbl-b and hSiah2 can inactivate Vav signalling by binding to its C-terminus 
(Bustelo et at., 1997; Germani et al., 1999), while Tiam1 activity is blocked by binding of 
Nm23-H1 to its N-terminus (Otsuki et al., 2001). GEF and GAP inactivation can also be 
regulated by protein degradation although the knowledge about this is very limited. 
One example is the binding of suppressor of cytokine signaling-1 (SOCS1) to the N- 
terminus of Vav that stimulates the polyubiquitination and degradation of Vav (De 
Sepulveda et al., 2000). Neurofibromin, which functions as a GAP for Ras, can undergo 
rapid degradation upon treatment of cells with various growth factors. This might 
explain the observed increase and duration of Ras activation in response to growth 
factors (Cichowski et al., 2003). Another mechanism involves caspase cleavage and 
degradation of p120GAP that results in inhibition of apoptosis (Yang et al., 2001). 
In summary, the possible intracellular mechanisms of GEF/GAP regulation 
described above can induce re-localisation of the GEF/GAP to a specific compartment 
in the cell, release-of auto-inhibition conformation or allosteric modifications that 
change the catalytic activity of GEFs/GAPs (Bos et al., 2007). 
1.5.4 GDIs 
Rho and Rab GTPases are also regulated by a third class of proteins, the 
GDIs. 
Three RhoGDI family members exist, whereas two RabGDIs have been identified. 
Interaction with a GDI masks the lipid modification on the 
GTPase, thereby preventing 
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anchorage to membranes and conversion of the nucleotide-bound state. It is believed 
that in this way, the GDI can deliver the small GTPase to the correct membrane. The 
main function of GDIs is to recycle GTPases which have already been involved in a 
cellular function at a particular membrane (Seabra and Wasmeier, 2004; Dovas and 
Couchmau, 2005). 
1.6 Small GTPases and adherens junction disassembly 
Emerging data implicates an aberrant signalling of various small GTPases in 
many cancer types. Here I will give an overview of the implication of the small 
GTPases Rac, Arf6 and different Rab proteins in tumorigenesis and will specifically 
focus on their role in the regulation of the E-cadherin-mediated cell-cell junctions. 
1.6.1 Rac small GTPase 
The Rho family of small GTPases consists of at least 22 members in mammals, 
of which the subfamilies RhoA (RhoA, RhoB, RhoC), Cdc42 and Rac (Rac1 (hereafter 
called Rac), Rac1b, Rac2, Rac3) are the most widely studied. These proteins were first 
identified for their ability to modulate the actin cytoskeleton in response to 
extracellular growth factors. In fibroblasts, over-expression of active RhoA promotes 
formation of stress fibers, Cdc42 induces filopodia formation and Rad triggers 
lamellipodia and membrane ruffle formation (Ridley and Hall, 1992). It is not 
surprising that these GTPases are implicated in cell motility, as the driving force for 
this event is provided by the dynamic organisation of the actin cytoskeleton. At the 
leading edge the delivery of membrane components in the direction of movement is 
driven by Cdc42 and Rac1, whereas RhoA generates myosin-based contractility for 
moving the cell body forward towards the leading edge (Hall, 1998). Besides 
remodelling of the actin cytoskeleton, Rac coordinates diverse cellular functions such 
as cell polarity, development, vesicular trafficking, gene transcription and cell growth 
(Van Aelst and D'Souza-Schorey, 1997). 
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1.6.1.1 Rac and adherens junctions 
Several members of the Rho GTPase family including RhoA, Rac and Cdc42, 
localise to cadherin-based cell-cell contacts (Braga, 2000a). Interestingly, Racl is a 
major regulator of adherens junctions. Under normal circumstances, Rac localises to 
adherens junctions and regulates the endocytosis of E-cadherin receptors (Akthar et al., 
2000; Izumi et al., 2004). Studies have shown that Rad activation is induced by the 
assembly of E-cadherin-mediated cell-cell contacts and is required for their 
maintenance (Braga et al., 1997; Takaishi et al., 1997; Nakagawa et al., 2001; Noren et at., 
2001; Kovacs et al., 2002). The association of p120 catenin with E-cadherin tail has been 
found essential for this activation of Rac (Goodwin et at., 2003). Participation of Rac in 
adherens junction regulation suggests that Rac may mediate the reorganisation of actin 
filaments at sites of cell-cell contacts (Izumi et al., 2004). This thought is supported 
from observations showing that recruitment of actin to cadherins that are clustered by 
antibodies is specifically blocked by dominant-negative Rac (Braga et al., 1997). 
In normal keratinocytes, sustained activation of Rac either by itself or 
downstream of Ras can abolish cell-cell adhesion (Braga et al., 2000b; Akthar and 
Hotchin, 2001) and is consistently observed with T47D mammary carcinoma cells and 
primary epithelial breast cells (Keely et al., 1997; Quinlan, 1999). This disruption 
process in keratinocytes is distinct from lamellipodia formation and specific for E- 
cadherin, as these receptors are removed from the plasma membrane prior to integrins 
(Braga et al., 2000b). The underlying mechanism during Rac-induced destabilisation of 
keratinocyte junctions is not known. An increase in E-cadherin endocytosis followed 
by receptor degradation and cell spreading has previously been observed after 
adherens junction disassembly induced by increased Rac signalling (Kamei et al., 1999; 
Akthar and Hotchin, 2001; Izumi et al., 2004). In addition, confocal microscopy 
performed in our lab revealed that small vesicles containing E-cadherin and tagged- 
Rac4611- were formed upon Rac activation (E. Lozano, unpublished data). 
However, the influence on mature cell-cell junctions by sustained Rac signalling 
per se (by over-expressing non-hydrolysable mutants RacQ61L or RacGl2'), or 
downstream of growth factors or oncogenic Ras, seems contradictory in MDCK cells. 
Several reports show that inhibition of Rac signalling induces E-cadherin junction 
disassembly and cell scattering (Hordijk et al., 1997; Sander et al., 1999; Zondag et al., 
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2000; Kamei et al., 1999), whereas in other reports Rac activation is necessary to require 
the same phenotype (Sander et al., 1999; Ridley et al., 1995; Edme et al., 2002; Quinlan, 
1999). However, these opposing effects of Rac on adherens junctions in immortilised 
MDCK cells are dependent on the cell substratum. Cells cultured on laminin and 
fibronectin have intact E-cadherin junctions in the presence of constitutively active 
Racl, while in cells grown on collagen E-cadherin-mediated adhesion is prevented 
(Sander et al., 1999). 
Thus besides requirement of Rac signalling in the formation and maintanence 
of cell-cell contacts, a sustained activation of Rac destabilises adherens junctions in 
keratinocytes but has opposing effects in MDCK cells. These discrepancies on junction 
stability may depend on the amount of active Rac present and in addition the cell-type 
regulation of junctions (Braga et al., 1999a; Braga, 1999b). 
1.6.1.2 Rac signalling in cancer 
In contrast to what observed for Ras, no activating mutations of Rac have been 
found in tumours. Yet, Rac seems to be aberrantly regulated in various cancer types. 
Over-expression of different Rac subfamily members, Rac1, Rac1b and Rac2, has been 
found in breast cancer, colorectal tumours and in head and neck squamous cell 
carcinomas (Fritz et al., 1999; Jordan et al., 1999; Schnelzer et al., 2000). Furthermore, 
Rac has been found a critical regulator during oncogenic Ras-induced transformation 
(Zohn et al., 1998). 
An upregulation of Rac GEF activity in cancer could be accountable for an 
increased activation of Rac. Indeed, Rac GEFs including Lfc, Vav and Ect2, were 
originally isolated as oncogenes using in vitro NIH3T3 fibroblast transformation assays 
with DNA derived from various tumours (Whitehead et al., 1995; Katzan et al., 1989; 
Miki et al., 1993). Over-expression of the Rac GEFs p-PIX and Tiam1 have been 
observed in human breast cancer (Ahn et al., 2003; Minard et al., 2004). Tiam1 was first 
identified in invasive T cell lymphomas and has been implicated in cell migration, 
invasion and tumorigenesis. Moreover, a point-mutant of Tiam1 expressed in renal 
cell carcinomas induces transformation of normal NIH3T3 fibroblasts but over- 
expression of wild-type Tiam1 fails to do so (Engers et al., 2000). 
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Downregulation of Rac GAP activity could also participate in sustained 
activation of Rac. Chimaerins are specific Rac GAP proteins and low expression levels 
have been reported in human brain tumours and breast cancer cells (Yang et al., 2005a). 
Heregulin (31, a ligand for epithelial growth factor receptors (EGFRs), causes sustained 
activation of Rac in breast cancer cell lines that induces cell migration and proliferation. 
This heregulin (31-induced phenotype is suppressed when (3-2 chimaerin is over- 
expressed through the inactivation of Rac (Yang et al., 2006). Furthermore, 
proteasome-mediated degradation is another possible mechanism to inhibit Rac 
signalling during tumorigenesis, as this event has been reported during cell scattering 
of MDCK cells (Lynch et al., 2006). 
1.6.1.3 Involvement of Rac effectors during junction destabilisation 
Specific effectors identified for Rac include Arfaptin2/POR1 (Partner of Rac1), 
SynJ2 and JNK1 (c-Jun N-terminal Kinase 1). Several other targets can associate with 
more members of the Rho subfamily of GTPases. For example, p21-activated kinase 
(PAK), IQGAP and MEKK4 interact with both Cdc42 and Rac (Bustelo et al., 2007). 
A downstream effector of Rac that has been implicated in the regulation of E- 
cadherin endocytosis is IQGAP. IQGAP localises to adherens junctions in MDCK cells 
and by interacting with (3-catenin it competes with a-catenin for binding at E-cadherin 
complexes (Kuroda et al., 1996,1998). Upon over-expression of IQGAP, dissociation of 
a-catenin mediates destabilisation of cell-cell adhesion, which can be counteracted by 
co-expression of dominant-activated Rac (Fukata et al., 1999). In this model, however, 
constitutively active Rac mediates strong cell-cell adhesion by sequestering IQGAP 
from adherens junctions w hich is opposed to the effect of Rac461L on keratinocyte 
junctions. 
Work in our laboratory has focussed on the downstream signalling target 
important for Raca6"--induced junction disruption. Initial experiments showed that 
PAK signalling is essential during Rac-dependent junction destabilisation, 
but not the 
effectors JNK1, CrkII and ROCK (Lozano et al., 2008). PAK is a well-studied effector of 
Rac and consists of six subfamily members (Jaffer and Chernoff, 
2002; Bokoch 2003). 
Class I subfamily members . 
(PAK1, PAK2 and PAK3) all contain high sequence 
homology in their regulatory and catalytic domain, but class II members (PAK4, PAK5 
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and PAK6) differ significantly in structural organisation and regulation. Upon Rac 
binding, a series of conformational changes induces dissociation of auto-inhibited PAK 
homodimers and activates the catalytic domain of PAK by auto-phosphorylation 
events. Phosphorylation at threonine residue 423 in the PAK catalytic domain is 
important for maintaining the relief of the auto-inhibition state. Subsequently, PAK 
mediates Rac signalling through its serine/threonine kinase activity on target proteins 
mainly involved in cellular processes such as cytoskeletal remodelling, cell motility, 
proliferation and apoptosis (Bokoch, 2003). 
Of interest is that PAK activity is also implicated in tumour formation and cell 
invasiveness by promoting the above mentioned processes (Kumar and Vadlamudi, 
2002). Both increased activation of PAK1 proteins and its target substrates have been 
observed in various cancers. PAK1 gene amplification or protein over-expression is 
found in human breast, colon, ovarian, bladder and brain cancer (Balasenthil et al., 
2004; Holm et al., 2006; Carter et al., 2004; Schraml et al., 2003; Kumar et al., 2006). PAK1 
effectors like vimentin, merlin, Eilamin A and LIM kinase have been implicated in 
progression or formation of tumour types including melanomas, neurofibromatosis 2, 
breast and prostate cancer (Kumar et al., 2006). 
1.6.2 Arf6 small GTPase 
ADP-ribosylation factors (Arfs) were initially discovered for their role in 
stimulating the ADP-ribosyltranferase activity of the cholera toxin A subunit (Moss 
and Vaughan, 1979). Currently, the Arfs represent a family of Ras-related GTPases 
that are mainly involved in the regulation of membrane trafficking (Donaldson, 2003; 
Chavrier and Goud, 1999). In mammals, there are six Arf proteins which can be 
classified into class I (Arf1, Arf2, Arf3), class II (Arf4, Arf5) and class III (Arf6) based on 
size, sequence identity, phylogenetic analysis and gene structure (Tsuchiya et al., 1991). 
Arf6 proteins are ubiquitously expressed and enriched at the plasma membrane 
and endosomal structures (Peters et al., 1995). In different cell types, Arf6 regulates the 
internalisation and recycling of several cell surface receptors via clathrin-dependent as 
well as clathrin-independent pathways (D'Souza-Schorey and 
Chavrier, 2006). Arf6- 
GTP at the plasma membrane promotes the recruitment of coat proteins 
from the 
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cytosol to the membrane. After budding, Arf6 proteins dissociate from vesicles, like 
the coat proteins (Chavrier and Goud, 1999). 
Arf6 is also involved in actin cytoskeletal remodelling. Activation of Arf6 can 
stimulate cortical actin rearrangement with the formation of lamellae and membrane 
ruffles, similarly as observed with exogenous active Rac expression (Radhakrishna et 
al., 1996; D'Souza-Schorey et al., 1997; Frank et al., 1998; Ridley and Hall, 1992). 
However, this effect of activated Arf6 on the actin cytoskeleton does not always require 
downstream signalling to. Rac and may be stimulus-specific, over-expression of the 
Arf6 GEF protein ARNO (Santy and Casanova, 2001) versus Arf6Q67f- (D'Souza-Schorey 
et al., 1997) or G protein activator aluminium fluoride (Radhakrishna et al., 1999). 
It is possible that the roles of Arf6 in endocytosis and actin rearrangements at 
the cell surface are mediated through the metabolism of phospholipids. Arf6 has been 
shown to activate phospholipase D (PLD; Brown et al., 1993; Melendez et al., 2001; 
Powner et al., 2002) and phosphatidylinositol 4-phosphate 5-kinase (PIP5K1; Honda et 
al., 1999; Krauss et al., 2003). Activation of these enzymes lead to accumulation of 
phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) at the cell periphery that can promote 
vesicular trafficking and actin filament assembly (Martin, 2003). 
1.6.2.1 Arf6 and adherens junctions 
In epithelial cells, Arf6 is an important regulator of endocytosis of E-cadherin 
receptors. When an inactivated mutant of Arf6 (Arf6T17N) is expressed in MDCK cells, 
E-cadherin endocytosis is inhibited resulting in more E-cadherin receptors at the 
plasma membrane. In contrast, expression of constitutively-active Arf6 (Arf6Q67L) per se 
leads to an increase of E-cadherin endocytosis followed by loss of adherens junction 
and degradation of E-cadherin in lysosomes (Palacios et al., 2001,2002,2005). 
However, in a MCF-7 breast cancer cell line Arf6Q67L-stimulated loss of adherens 
junctions resulted in accumulation of E-cadherin receptors in peripheral structures 
(Paterson et al., 2003). The process of adherens junction destabilisation induced 
by 
Arf6-GTP appears to be independent of actin rearrangements and is specific towards 
adherens junctions as tight junction assembly and cell polarity are not affected. 
After 
loss of adherens junctions by Arf6467L the cells are more motile and are spreading 
(Palacios et al., 2001,2002,2005). Constitutively activated 
Arf6 by itself or downstream 
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of oncogenic signals like HGF/SF and v-Src lead to adherens junction stability and 
increased cell motility of MDCK cells (Paterson et al., 2003; Palacios et al., 2001,2002, 
2005). In MDCK cells, expression of the Arf6 GEF ARNO stimulates the activation of 
Arf6 accompanied by flattening and increased motility of cells positioned at the cell 
periphery of the colony (Santy and Casanova, 2001). These observations are analogous 
to that induced by treatment with HGF/SF (Weidner et al., 1990; Ridley et al., 1995). 
1.6.2.2 Ar L6 signalling in cancer 
As observed for Arf6 (Brown et al., 1993; Melendez et al., 2001; Powner et al., 
2002), H-Ras can also activate PLD and latter activation is accompanied by fibroblast 
transformation (Xu et al., 2003). Interestingly, PLD activation stimulated by H-Ras is 
found dependent on Arf6 signalling. No other reports have implicated Arf6 
downstream of oncogenic Ras signalling. Taken together, the above observations 
indicate that an aberrant Arf6 signalling can affect tumorigenesis. Indeed, sustained 
Arf6 activation enhances the invasion potential of melanoma cells and breast tumour 
cell lines, and higher Arf6 proteinlevel is observed in invasive human breast cancer cell 
lines. In the latter, depletion by siRNA or an inactivated form of Arf6 can effectively 
block invasion of these cells (Tague et al., 2004; Hashimoto et al., 2004). 
The Arf6 GEF protein GEP, oo/BRAG2 can bind a-catenin and its GEF activity 
towards Arf6 is enhanced in vitro in the presence of a-catenin. HepG2 cells depleted of 
GEP, oo/BRAG2 shows a three fold increase in E-cadherin proteins and resistance 
towards HGF/SF-induced adherens junction disassembly (Hiroi et al., 2006). These 
results are consistent with Arf6 involvement downstream of HGF/SF treatment 
(Palacios et al., 2001). Recently, Morishige and colleagues (2007) showed that the PH 
domain of GEP, oo/BRAG2 can directly bind to phosphorylated EGFR upon EGF 
treatment. The role of GEP1ooBRAG2 in Arf6 activation upo n EGFR signalling is 
crucial for EGF-mediated invasive activities of some breast cancer cells. Interestingly, 
depletion of nine other expressing Arf GEF proteins containing a Sec7 domain could 
not block the invasion activity in these breast cancer cells (including ARNO, cytohesin 
and BIG2; Morishige et al., 2007). Whether the link of GEP100/BRAG2 to a-catenin and 
EGFR can facilitate disassembly of E-cadherin upon growth factor treatment remains to 
be investigated. 
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1.6.3 Rab small GTPases 
Numerous studies have established that Rab small GTPases regulate the 
transport between distinct intracellular compartments (Zerial and McBride, 2001). In 
vesicular transport, cargo and membranes are transported from one donor 
compartment to an acceptor compartment. First, the formation of a vesicle from the 
donor compartment containing cargo has to be made. Thereafter, movement of the 
vesicle along cytoskeletal filaments towards its acceptor compartment occurs followed 
by tethering/docking with the target membrane and eventually fusion of the two 
membranes (Stenmark and Olkkonen, 2001; Zerial and Mc Bride, 2001). 
It is well-established that a Rab in its GDP-bound state is delivered to the donor 
compartment and activated by its GEF protein. When bound to GTP, the Rab can 
interact with the cytoskeleton and motor proteins to promote vesicle movement to the 
acceptor compartment. Vesicle fusion with the acceptor membrane is accompanied by 
GTP-hydrolysis from the Rab which requires its GAP protein followed by GDI- 
mediated retrieval (Zerial and McBride, 2001; Pfeffer and Aivazian, 2004). 
The general vesicular transport routes in a cell are displayed in Figure 1.7. 
Material internalised from outside the cell reaches first early endosomes and can be 
recycled back to the cell surface either directly or indirectly via late endosomes and a 
perinuclear recycling endosome compartment. From late endosomes, molecules can 
also be transported via multiple vesicular bodies (MVBs) to the lysosomes, where 
cargo is proteolytically degraded. This cargo may be molecules internalised by 
endocytosis and material delivered by fusion with autophagosomes derived from the 
biosynthetic pathway. In the secretory pathway, newly synthesized proteins move 
from the endoplasmic reticulum (ER) via the Golgi apparatus to the plasma membrane. 
Transport from the trans-Golgi network towards the endocytic pathway occurs, and 
visa versa. Furthermore, cell-type specific transport can occur like melanosome 
transport in melanocytes for pigmentation (Stenmark and Olkkonen, 2001; Segev, 
2001). 
The largest branch of the small GTPase superfamily is formed by Rab GTPases 
which have been found in all eukaryotes described. As estimated 
from the sequenced 
human genome, there are over . 
6o different Rab members, including isoforms, many of 
which have a cell-type specific distribution. 
The large number of Rabs may reflect the 
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complexity of the different trafficking routes in the cell in which each Rab is restricted 
to a particular compartment (Figure 1.7; Stenmark and Olkkonen, 2001; Zerial and Mc 
Bride, 2001). For example, Rab5 is the best characterised member of the Rab family and 
is the major regulator of early endocytosis (Bucci et al., 1992), whereas Rab11 is 
controlling recycling endocytosis (Ullrich et al., 1996). Rab7 regulates the trafficking of 
cargo in vesicles destined for degradation in the lysosomes (Feng et al., 1995; Meresse et 
al., 1995) as well as autophagosomes (Gutierrez et al., 2004). 
1.6.3.1 Rabs and adherens junctions 
Rab proteins play a role in the continuous transport of E-cadherin molecules 
that normally takes place in the cell (see section 1.2.3). Endocytosis of E-cadherin 
occurs via Rab5-positive endosomes and its recycling is regulated via Rab11 in 
recycling endosomes. Exocytosis of newly synthesised E-cadherin receptors from the 
Golgi involves Rab11-dependent trafficking to the plasma membrane via recycling 
endosomes (Lock and Stow, 2005). 
However, Rabs also play a role in increased endocytosis of E-cadherin receptors 
upon disassembly of adherens junctions by various upstream signals. In MDCK cells, 
Palacios et al. (2005) described that upon v-Src expression, ubiquitination of E-cadherin 
receptors followed by lysosomal degradation occurs in order to disrupt stable adherens 
junctions. These receptors are internalised in Rab5-positive endosomes and targeted to 
Rab7-positive late endosomes and lysosomes. Internalisation of E-cadherin molecules 
by v-Src expression is attenuated by dominant-negative Rab5. However, activation of 
Rab5 independently of v-Src expression could not affect the stability of E-cadherin 
junctions (Palacios et al., 2005). The inactive form of Rab7 did not inhibit the 
internalisation of E-cadherin receptors mediated by v-Src, but these receptors 
accumulate in large intracellular vesicles and do not undergo degradation. This 
suggests that dominant-negative Rab7 prevents the shuttling of E-cadherin from late 
endosomes to lysosomes (Palacios et al., 2005). Similarly, in response to HGF/SF, E- 
cadherin and c-Met receptors have been found to co-endocytose via a Rab5-dependent 
pathway and accumulate in a perinuclear area that partly overlaps with Rab7 (Kamei et 
al., 1999). 
CHAPTER 1 151 
Rabb 
RV 
Q 40 
CV, 
Rab8 o 
oA 
TGN 
Golgi 
Ra bF 
Rab2(/o c Rab1 
o 
ER 
,+ t1 
Nucleus 
FJ 
11 ý. 
/ 
Rabil --_, 
1 
Rabb 
1 
RibQ 
% Raba .'i o 
Do LE 
cJ 
Lysosonic 
, 
Rab4 
Rab 11 
EE 
()Rabb 
RE 
ýl 
Figure 1.7: Intracellular vesicle transport and localisation of several Rabs. 
Material internalised via early endosomes (EE) is recycled back to the 
plasma membrane directly or via recycling endosomes (RE). Material 
destined for degradation is transported through late endosomes (LE) to 
lysosomes. Anterograde transport occurs from the Golgi network towards 
the endocytic pathway, and retrograde transport vice versa. Molecules 
from the endoplasmatic reticulum (ER) transported through the trans-Golgi 
network (TGN) reach the plasma membrane by constitutive secretion 
vesicles (CV) or regulated secretory vesicles (RV). Melanosomes (M) 
regulate the transport in melanocytes for generating pigmentation. Figure 
taken from Stenmark and Olkkonen (2001). 
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1.6.3.2 Rab signalling in cancer 
Only a few studies demonstrate increased expression of Rabs in different types 
of tumour and tumour cell lines. For example, upregulation of Rab5a and Rab7 occurs 
in thyroid autonomous adenomas (Croizet-Berger et al., 2002) and Rab2 in lung 
tumours (Yao et al., 2002). Enhanced protein expression is observed for Rab11 in skin 
carcinomas and breast tumours, and inhibition of Rab11 signalling interferes with EGF- 
induced proliferation and motility of immortalized MCF10A breast cells (Gebhardt et 
al., 2005; Palimieri et al., 2006). Elevated Rab25 levels have been detected in prostate, 
ovarian and breast cancer cell lines (Calvo et al., 2002; Cheng et al., 2004), although loss 
of Rab25 expression was also found in other human breast cancer cell lines or breast 
tumours (Cheng et al., 2006). Reduced expression of Rab32 by hypermethylation has 
frequently been detected in colon cancers (Shibata et al., 2006). 
Upregulation of a GEF protein for Rab5, Rabex-5, has been reported in 
colorectal tumour cells (Nimmrich et al., 2000). Another Rab5GEF, RIN1, has the ability 
to interact directly with Ras and can mediate Ras-activated endocytosis (Tall et al., 
2000). This GEF protein has also been found over-expressed in some colorectal cancer 
tissues (Senda et al., 2007) although suppression of RIN1 transcription is reported in 
breast cancer cells (Milstein et al., 2007). 
From a panel of prostate tumours, PRC17 has been identified as a GAP protein 
for Rab5. Expression of PRC17 transforms 3T3 fibroblasts and stimulates tumour 
formation in nude mice, which is prevented by mutation in PRC17 catalytic GAP 
domain (Pei et al., 2002). PARIS-1, a protein with a conserved TBC/RabGAP domain 
but unknown Rab substrate has been identified by protein expression cloning using 
sera from prostate tumour patients (Zhou et al., 2002). Although the Tre2 oncogene is 
expressed in a variety of cancers (Nakamura et al., 1992; Otano-loos et al., 2000), it does 
not contribute to increased Rab inactivation as it is diminished of GAP activity due to 
mutations in its catalytic domain (Bizimungu et al., 2003; Bizimungu and Vandenbol, 
2005). 
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1.7 Signalling cascades via small GTPases 
A small GTPase can induce a signal cascade in order to transduce its signal to 
downstream effectors, which frequently involves activation or inactivation of 
additional small GTPases. Destabilisation of cell-cell contacts in epithelial cells is one 
such process in which multiple GTPases play a role. It has become apparent that there 
are different mechanisms of how GTPase signalling cross-talks to other GTPases. 
These mechanisms include binding to common effector proteins, common GAP and 
GEF regulatory proteins, or a direct interaction between two different GTPases. These 
mechanisms are discussed below. 
1.7.1 Common effectors of different GTPases 
Common effectors for members within a subfamily of GTPases is often 
observed, like the Wiskott-Aldrich syndrome protein (WASP) and PAK interact with 
both Rac and Cdc42 (Van Aelst and D'Souza-Schorey, 1997) and Rabaptin-5 with Rab4 
and Rab5 (Vitale et al., 1998). Binding of GTPases from different families to the same 
effector is rarer. For example, both Arf6 and Rab11 interact with the effectors FIP3 and 
FIP4 that are implicated in cytokinesis. This interaction of these small GTPases can 
occur simultaneously at distinct binding sites on FIP3 and FIP4 (Fielding et al., 2005). 
1.7.2 Signalling cascades via GEFs and GAPs 
GEFs and GAPs regulate the activity status of small GTPases. Some GEFs and 
GAPs participate in cross-talk between distinct small GTPases by (i) exhibiting two 
catalytic domains, (ii) interacting with other GEFs or GAPs and (iii) functioning as an 
effector protein for a small GTPase. 
Although most GEFs and GAPs contain one catalytic domain, some proteins 
may have two different catalytic domains. This can directly provide an 
interconnection of two different signalling processes from distinct GTPases. For 
instance, Sos1 contains two GEF domains, one for Ras and one for Rac activation. 
Binding of Grb2 to Sos1 is required for Ras activation (Aronheim et al., 1994) and 
interaction with a complex of Eps8 and Abil/ESB1 induces Rac activation (Scita et al., 
1999). Upon PDGF stimulation, the Eps8-Abil/ESB1-Sosl complex is stable while the 
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Grb2-Sos1 complex is disrupted. This might contribute to the short-lived activation of 
Ras and sustained activation of Rac upon treatment with growth factors. These results 
further indicate that Sos1 can coordinate activation of Ras and Rac and their signalling 
duration within the cell (Innocenti et al., 2002). Similarly, proteins of the ARAP family 
contain two GAP domains for Rho and Arf. In vitro, the Arf GAP activity is stimulated 
by phosphoinositols (Miura et al., 2002) whereas Rho GAP activity is enhanced by 
binding of Rapt (Krugmann et al., 2004). 
Besides above phenomenon, several GEF and GAP proteins can interact directly 
with each other. The p190GAP protein for Rho GTPases can form a complex with 
p120GAP that is a GAP specific for Ras (Settleman et al., 1992). It appears that this 
interaction attenuates the hydrolysis activity of p190GAP towards Rho GTPases, whose 
latter signalling is essential for Ras-induced cellular transformation (Wang et al., 1997). 
Furthermore, GTPases can also interact directly with GAPs and GEFs, 
indicating that they might function as an effector molecule and as a consequence can 
stimulate or prevent the (in)activation of a certain GTPase. For example, Rapla 
stimulates integrin-mediated adhesion and cell spreading, a process that requires Rad 
activity in HeLa cells. During this event, activation of Rac occurs via direct binding of 
Rapt to the PH-domain of the Rac GEF Vav2 that first localises at sites of cell-ECM 
contacts and subsequently stimulates Rac activation (Arthur et al., 2004). In addition, 
Rapl binds to RA-RhoGAP as an upstream activator and thereby releases the auto- 
inhibited state of RA-RhoGAP that induces the catalytic activity. This event is 
important in the control of neurite outgrowth (Yamada et al., 2005b). 
1.7.3 Direct binding of two distinct GTPases 
The direct binding of two distinct GTPases as a means of connection signalling 
of distinct GTPases is very rare but has been reported. For example, binding between 
Arf6-GTP and Rac-GDP GTPases has been shown from both pull-down experiments of 
purified proteins as well as endogenous proteins from angiotensin II-stimulated 
HEK293 cells. By interaction of Arf6 with Rac, Arf6 can regulate actin remodelling 
important during membrane ruffling and cell migration (Cotton et al., 2007). 
Furthermore, the yeast Ras-like Rsr1p/Budlp GTPase interacts directly with the Rho- 
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like Cdc42p GTPase and appears to be involved in the establishment of cell polarity 
(Kozminski et al., 2003). 
1.8 Connecting Arf6-dependent signalling of Rac at membrane ruffling and 
contact disruption 
Preliminary experiments in the Braga laboratory shows that in keratinocytes, 
Arf6Q67L disruption of E-cadherin junctions is efficiently blocked by inhibition of Rac 
signalling (E. Lozano, unpublished data). Although these results still need verification, 
it is in contrast to what has been demonstrated in MDCK cells, where Arf6-induced 
junction disassembly requires inactivation of Rac signalling (Palacios et al., 2002,2003). 
The opposing requirement for Rac signalling after Arf6 activation during 
destabilisation of adherens junctions in MDCK cells and keratinocytes could depend 
on cell-type specific regulation mechanisms or the cell substratum used, as described 
previously for activated Rac and junction stability (see section 1.6.1.1 and Sander et al., 
1999). However, Arf6 clearly can activate Rac in different cellular processes and Rac 
function is required downstream of Arf6 (Franco et al., 1999; Brown et al., 2001; Santy 
and Casanova, 2001). Several reports provide evidence for the mechanisms by which 
Arf6 is involved in the regulation of Rac activation during cellular events, including 
actin cytoskeleton remodelling resulting in membrane ruffles and lamellae formation, 
cell motility, adherens junction disruption and regulation of focal contacts. The 
connectors DOCK180/Elmo, Arfaptin2/POR1, Nm23-H1, Kalirin-5 and GIT1-(3-PIX 
involved in the cross-talk of Arf6 and Rac are described below. 
1.8.1 Connecting Arf6 and Rac via DOCK180/Elmo 
In HeLa cells, over-expression of an Arf6 GEF, ARNO (Frank et al., 1998a), leads 
to the development of broad lamellipodia (Frank et al., 1998b). In MDCK cells, ARNO 
causes besides lamellipodia formation the separation of neighbouring cells and 
increase in cell migration. Downstream of ARNO, Arf6 is directly activated and in 
addition endogenous Rac and PLD. Rac and PLD activity are both essential 
for cell 
motility. Yet, PLD inhibition cannot block Arf6-dependent activation of endogenous 
Rac (Santy and Casanova, 2001). Here, the link between Arf6-dependent Rac activation 
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is made via the bipartite Rac GEF DOCK180/Elmo (Lu et al., 2004; Brugnera et al., 2002). 
DOCK180 and Elmo co-localise with ARNO at the leading edge of migrating cells and 
the attenuation of DOCK180/Elmo signalling blocks migration and activation of Rac. 
This participation of DOCK180/Elmo is specific as the catalytically inactive Rac GEF (3- 
PIX mutant does not inhibit the ARNO-induced Rac activity (Santy et al., 2005). 
Together, ARNO signals through Arf6 via DOCK180/Elmo to Rac in order to promote 
cell motility. 
1.8.2 Connecting Arf6 and Rac via Arfaptin2/POR1 
In quiescent REF-52 cells, constitutive activation of Rac modulates the actin 
cytoskeleton to induce membrane ruffles which can be inhibited by the Rac-interacting 
protein Arfaptin2/POR1 (Van Aelst et al., 1996). The binding of Arfaptin2/POR1 to Rac 
has been well-established, but the GDP- or GTP-dependence for Rac association is still 
controversial as the affinity to both states appears similar (Van Aelst et al., 1996; Shin 
and Exton, 2001; Tarricone et al., 2001). Arfaptin2/POR1 also interacts with active Arf6 
(Van Aelst et al., 1996; D'Souza-Schorey et al., 1997; Shin and Exton, 2001; Tarricone et 
al., 2001). In Chinese hamster ovary (CHO) cells and HeLa cells, activation of Arf6 
induces the formation of lamellipodia. As dominant-negative Rac cannot block Arf6 in 
this process, this indicates that Arf6 regulates actin cytoskeleton organisation 
independently of Rac (D'Souza-Schorey et al., 1997; Radhakrishna et al., 1999). This is 
in contrast to the Rac-dependent lamellipodia formation after Arf6 activation reported 
by Santy and Casanova (2001) in Hela cells and may be depending on the stimulus 
used. Co-expression of Arfaptin2/POR1 deletion mutants with Arf6-GTP inhibits Arf6- 
induced actin rearrangements in CHO cells. Thus, this report shows that Arf6 and Rac 
both function independently on different pathways to mediate actin cytoskeletal 
remodelling, although Arfaptin2/POR1 may be an important regulatory element of 
both pathways (D'Souza-Schorey et al., 1997). 
1.8.3 Connecting Arf6 and Rac via Nm23-H1 
Arf6 activation per se or activation of endogenous Arf6 by HGF/SF or v-Src 
treatment result in increased internalisation of E-cadherin receptors leading to junction 
disassembly and scattering of MDCK cells. This process occurs independently of Arf6- 
CHAPTER 1 157 
induced ruffling of the plasma membrane via actin remodelling (Palacios et al., 2001). 
Initially, in order to dissociate cell-cell contacts a decrease of Rac activation is 
necessary. Subsequently, cell motility depends on restoration of Rac activity levels and 
continuous Arf6 activity (Palacios et al., 2003). Arf6-GTP can interact with the kinase 
Nm23-H1 that provides the source of GTP for dynamin-dependent endocytosis. As a 
result, Nm23-H1 can prevent Rac activation by sequestering the Rac GEF Tiam1 
through a direct association (Otsuki et al., 2001; Palacios et al., 2002). Thus, during E- 
cadherin junction destabilisation Arf6 signals via Nm23-H1 to transiently reduce Rac 
activity levels. In agreement with these results, sustained activation of Rac increases 
cell-cell adhesiveness of MDCK cells opposed to keratinocytes (Hordijk et al., 1997; 
Sander et al., 1999; Akthar and Hotchin, 2001; Braga et al., 2000b). 
1.8.4 Connecting Arf6 and Rac via Kalirin-5 
EFA6 is an exchange factor for Arf6 that contains a Sec7 catalytic domain. 
Membrane ruffling induced by EFA6 is dependent on its GEF activity towards Arf6, 
and can be blocked by dominant-negative Arf6 and Rac (Franco et al., 1999; Brown et 
al., 2001). The link between Arf6 and Rac in this process may be Kaiirin-5. Kaiirin-5 
belongs to the Kalirin/Trio Rho family GEFs and acts specifically on Rac (Debant et al., 
1996). When over-expressed in HeLa cells, Kalirin-5 by itself induces lamellipodia 
formation that is dependent on Rac activation (Koo et al., 2007). EFA6-induced 
membrane ruffles can in turn be inhibited by Kalirin-5. Furthermore, Kalirin-5 
interacts with Arf6-GDP and a dominant-negative form of Arf6 diminishes Kalirin-5- 
induced Rac activation. Interestingly, although Kalirin-5 is recruited to the membrane 
by direct binding to Arf6-GDP, the nucleotide exchange activity of Kaiirin-5 on Rac is 
stimulated by active Arf6. Therefore, the GTPase cycle of Arf6 has been suggested to 
be essential for Kalirin-5-mediated Rac activation to induce membrane ruffles (Koo et 
al., 2007). 
1.8.5 Connecting Arf6 and Rac via GIT1-ß-PIX 
GIT1 contains an Arf6GAP domain and a Spa2-homology domain that binds ß- 
PIX and thus directly connects to Rac activation (Figure 1.8, Manser et al., 1998; 
Bagrodia et al., 1999; Zhao et al., 2000b). GIT1 has been implicated in the regulation of 
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endocytosis of different signalling receptors via GAP activity on Arf6 (Premont et al., 
1998,2000; Claing et al., 2001) and cytoskeletal dynamics during cell spreading and 
migration, likely through downstream activation of Rac (Di Cesare et al., 2000; Zhao et 
al., 2000b). GIT1-(3-PIX complexes localise at focal contacts, cell periphery and 
cytoplasmic complexes (Loo et al., 2004; Kim et al., 2001; Turner et al., 1999) and their 
distribution is mediated through interaction with proteins including paxillin, FAK and 
PAK (Figure 1.8, Manser et al., 1998; Turner et al., 1999; Zhao et al., 2000b; West et al., 
2001). Localisation of GIT1-(3-PIX to focal complexes results in the recruitment of PAK 
and localised activation of Rac at the cell membrane at focal contacts (West et al., 2001). 
PAK and (3-PIX translocation from focal complexes towards cell-cell junctions 
was observed during wound healing in MDCK cells. This event is important to receive 
growth-inhibitory signals from neighbouring cells (Zegers et al., 2003). Moreover, the 
GIT1-ß-PIX-PAK complex has been shown to localise at cell-cell junctions in 
endothelial cells and this intact complex is critical for vascular permeability, a process 
regulated by tight junctions (Stockton et al., 2007). At present, GIT1 and p-PIX have not 
been further implicated in epithelial cell-cell junction. 
Preliminary results in our lab show that over-expression of GIT1 per se is able to 
destabilise E-cadherin junctions. In addition, GIT1 can inhibit the Arf6-induced 
perturbing effect on junctions specifically (E. Lozano, unpublished data). These results 
are very exciting as GIT1 and p-PIX may provide the link between Arf6 and Rac 
activation regarding E-cadherin stability. 
1.8.6 Implication of PAK during Arf6-induced disruption of adherens junctions 
PAK can be activated by direct interaction of active Rac or Cdc42 (Bokoch, 
2003). However, PAK can also be activated independently of active Rac or Cdc42 via a 
mechanism that requires GIT1 and p-PIX (Manser et al., 1998; Loo et al., 2004). PAK has 
been shown to exhibit scaffolding functions for GIT1 and (3-PIX, although activated 
PAK can no longer associate with (3-PIX (Brown et al., 2002; Zhao et al., 2000b). 
Previous data has shown that PAK is required for Rac-induced keratinocyte junction 
destabilisation (section 1.6.1.3; Lozano et al., 2008). In particular with the PAK 
activation mechanism induced by GIT1 and p-PIX, it would be interesting to test 
whether PAK also functions downstream of Arf6-induced junction disruption. 
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GITI 
11 1 
Arf6-GTP Art6. GDP FAK 
I 
Paxillin 
Figure 1.8: Protein domains of GIT1 and ß-PIX with some interacting proteins mapped to specific 
domains. 
The Arf6 GAP protein GIT1 associates with proteins like (3-PIX, paxillin and PAK and mediates 
homo- or hetero-dimerisation via its coiled-coil domain. Beta-PIX is a Rac GEF that binds PAY, via 
its N-terminal and forms homodimers. A, ankyrin repeat; C, coiled-coil; DH, Dbl homology; PBD, 
paxillin binding domain; PH, pleckstrin homology; SH3, Src homology 3; SHD, Spa2 Homology 
domain. 
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1.9 Connection of Rac with Rab GTPases during adherens junction disassembly 
Different Rab small GTPases have been implicated during endocytosis of E- 
cadherin in homeostasis, as well as junction disruption downstream of different 
signalling molecules (see section 1.6.3.1). In addition, Rac small GTPase is a major 
regulator of E-cadherin-mediated cell-cell contacts and has also been shown to mediate 
endocytic events of E-cadherin receptors (see section 1.6.1.1). 
1.9.1 Connecting Rab5 and Rac via Eps8 and ALS2/Alsin 
A direct connection between Rab5 and Rac occurs through Eps8. Eps8 interacts 
with the Rab5 GAP protein RN-Tre and can influence Rab5-dependent endocytosis. 
Over-expression of ectopic RN-Tre by itself blocks endocytosis of EGF and transferrin 
receptors (Lanzetti et al., 2000). On the other hand, Eps8 in complex with Abil/ESB1 
and Sos1 is a Rac GEF protein (Scita et al., 1999). Thus, Eps8 can participate in 
endocytosis via the GAP activity of RN-Tre and in actin cytoskeletal rearrangements 
through the binding with Abil/ESB1 and Sos1. However, this proposed model for a 
connection betwen Rab5 with Rac is under dispute, as a recent study provided 
evidence that RN-Tre does not function as a GAP protein for Rab5. Instead, it 
stimulates the GTP hydrolysis of Rab43 more efficiently than hydrolysis of Rab5-GTP 
(100-fold; Haas et al., 2005). Moreover, RN-Tre with Rab43 was shown to control 
retrograde transport from the Golgi to the ER, where no function for Rab5 has been 
described (Haas et al., 2007). 
In addition, Rac and Rab5 signalling have also been linked by ALS2/Alsin. 
ALS2/Alsin is a GEF for Rab5 (Topp et al., 2004) and can interact preferentially with the 
GTP-bound form of Rac. Rac-GTP recruits ALS2/Alsin to the plasma membrane and 
localises at Rac-dependent macropinosomes. Subsequently, ALS2 promotes the fusion 
of macropinosomes with endosomes via its GEF activation Rab5 (Kurvita et al., 2007). 
1.9.2 Connecting Rab11 and Rho proteins via p50RhoGAP 
p50RhoGAP increases the GTPase activity towards Rho, Rac and Cdc42 in vitro, 
although its specific substrate in vivo is still unclear (Barfod et al., 1993; Lancaster et al., 
1994). Distribution of p50RhoGAP is restricted to endosomal membranes and it co- 
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localises with internalised transferrin and EGF receptors during endocytosis. 
Interestingly, endogenous p50RhoGAP shows high level of co-localisation with 
exogenously expressed Rab11 in the perinuclear region of the cell and bioluminescence 
resonance energy transfer (BRET) studies demonstrated that p50RhoGAP and Rab11 
forms a molecular complex. Thus, p50RhoGAP integrates distinct pathways by 
participating in GAP activity towards Rho GTPases and interaction with Rab11 
GTPases during receptor-mediated endocytosis (Sirokmäny et al., 2006). 
1.9.3 Connecting Rab and Rac via the novel protein Armus 
For many of the processes regulated by Rac there has been no identification of 
specific effector proteins involved. In search for epithelia-specific Rac effectors, a yeast 
two-hybrid screen using activated Rac as bait and a human keratinocyte cDNA library 
was performed in our lab. Using this technique, a novel Rac binding protein named 
Armus has been isolated (M. Betson, unpublished data). 
Armus is 2784 base pairs long and encodes a translation product of 928 amino 
acids with an estimated molecular mass of 102kDa. The gene contains 13 exons and 12 
intros and has four predicted splice variants (Genbank AL137073). Additional searches 
in the Genbank database revealed that Armus is identical to the predicted TBC1D2 
protein and highly homologous to the previously identified PARIS-1 protein (thou et 
al., 2002). These proteins contain a Tre2/Bub2/Cdcl6 (TBC)/RabGAP domain at the C- 
terminus and are potentially able to inactivate Rab GTPase(s). Because Armus contains 
a TBC/RabGAP domain and binds specifically to active Rac, it is predicted to integrate 
signaling pathways of Rab and Rac proteins. 
1.9.3.1 PH domain of Armus 
Primary structure analysis revealed that Armus contains an N-terminal PH 
domain, stretching from amino acid 47 to 143 (Figure 1.9). PH domains are 
approximately 100 amino acids long and found in many proteins involved in 
intracellular signalling. The function of the PH domain often involves specific 
localisation of the protein at the cell membrane by binding to phosphorylated Ptdlns 
(Halet, 2005). Contribution to the catalytic activity by interaction of the PH domain 
with Ptdlns or with a protein has been reported previously for various GEFs and GAPs 
CHAPTER 1 162 
(Bernards and Settleman, 2004; Bos et al., 2007). On the other hand, the PH domain can 
also exhibit an auto-inhibitory function, as described for p120GAP by direct association 
and regulation of the the PH domain with the p120GAP catalytic domain (Drugan et 
al., 2000). However, preliminary experiments did not show an interaction of purified 
Armus PH domain to different phosphorylated derivates of Ptdlns in vitro (R. Francis, 
unpublished data). Further experiments are required to identify binding partners for 
Armus PH domain. 
1.9.3.2 Coiled-coil domains of Armus 
A coiled-coil domain folds as a a-helical structure formed by seven (heptad) 
hydrophobic repeats in the protein sequence. Coiled-coils are known to interact with 
each other in homotypic and heterotypic complexes and are perhaps the most well- 
known motif used to hold proteins together. Many signalling proteins have a coiled- 
coil domain, although their exact function in signalling has not been studied 
extensively (Gromiba and Parry, 2004). 
Structure analysis revealed that Armus contains three predicted coiled-coil 
domains: two lay adjacent in the centre of Armus and one at the very C-terminus 
(Figure 1.9). Armus had over 90% probability of forming a dimer with its first coiled- 
coil domain and a low probability of forming a trimeric protein, as assessed by 
Multicoil (Wolf et al., 1997). This suggests that the Armus protein may dimerise using 
this first coiled-coil. 
t 
Interestingly, the binding site for active Rac lies in the Armus' central coiled-coil 
domains. This region is unique for Rac interaction as it contains no consensus 
sequences similar to CRIB motifs or other known Rac1-binding domains (Bishop and 
Hall, 2000). Moreover, only Rac-GTP can bind Armus and none of the Rho proteins 
RhoA or Cdc42 (R. Francis, unpublished data). 
The region spanning the first 550 amino acids of Armus (Armusl_550) includes 
the PH domain and central coiled-coils. Expression of Armus 1.550 induces the 
formation of vesicle-like structures when over-expressed in cells, suggesting that 
Armus may regulate vesicular trafficking. No co-localisation of transferrin or Rab5 
with these vesicles induced by Armus1550 is observed, indicating that these vesicles are 
not early endosomes (Bucci et al., 1992). These typical structures are also not positive 
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I Rac-GTP 
Figure 1.9: Protein structure of Armus. 
The novel protein Armus is predicted to contain a pleckstrin homology (PH) 
domain, three coiled-coil (C) domains and a TBC/RabGAP (RabGAP) domain. 
Active Rac binds specifically to the central coiled-coil regions on Armus. 
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for the lysosomal-associated proteins LAMP1 and CD63 (M. Finelli, unpublished data). 
However, endogenous Rabl1 associates with Armus-induced vesicles and the latter are 
disrupted by activated Rab11 or Rab25 (R. Francis, unpublished data). 
Whether Armus proteins can dimerise remains to be determined. In addition, 
the mechanism underlying the induction of vesicular structures by Armus 1550 is not 
known and requires further investigation. Participation of both the PH domain and a 
possible dimerisation by the coiled-coil domains could be involved here. Some 
proteins have been shown to require their coiled-coil domain with or without a 
membrane-binding domain to localise to restricted sites (Gillingham and Munro, 2003). 
1.9.3.3 TBCIRabGAP domain of Armus 
The TBC/RabGAP domain on Armus (amino acid 622 to 828) might be able to 
inactivate Rab small GTPases, but whether the TBC/RabGAP of Armus is functional 
remains to be determined. The human genome predicts 52 genes to encode TBC- 
containing proteins (Bernards, 2003) of which the target Rabs of 33 TBCRabGAP 
proteins still need to be identified. The fact that over 70 Rab proteins (including 
isoforms) together with 52 TBC/RabGAP proteins are predicted suggests high 
specificity of the GAP towards the Rab, possibly depending on cellular localisation and 
cell-type specific expression. To date, 22 Rab GAP proteins have been identified in 
humans of whom p85a, p120GAP and Rab3GAP are not structurally related to other 
Rab GAP proteins (Table 1.1; Chamberlain et al., 2004; Burstein et al., 1990; Fukui et al., 
1997; Liu and Li, 1998). The remaining 19 characterised human Rab GAPs share high 
sequence homology in their catalytic domain. 
Remarkably, Rab5 has been shown to be the preferred substrate for the three 
TBC/RabGAPs RN-Tre (Lanzetti et al., 2000), RabGAP-5/CIP85 (Haas et al., 2005), 
TBC1D3/PRC17 (Pei et al., 2002) as well as two non-TBC/RabGAPs p120GAP (Liu and 
Li, 1998) and p85a (Chamberlain et al., 2004). However, whether all these 
Rab GAPs 
are specific for Rab5 in vivo is not clear. Different examples of 
discrepancy between 
TBC/RabGAP and Rab specificity are shown in Table 1.1. 
For instance, RN-Tre can 
hydrolyse Rab5-GTP (Lanzetti et al., 2000; Fritolli et al., 2008) but has been shown to 
display preference for Rab43 and Rab30 as substrates and not 
Rab5 in a different study 
(Haas et al., 2005). Despite the fact that 
TBC1D3/PRC17 does not contain the critical 
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arginine residue in its catalytic domain, it displays activity towards Rab5 (Pei et al., 
2002). However, in another study, TBC1D3/PRC17 is inactive towards 13 tested Rabs, 
including Rab5 (Frittoli et al., 2008). The cause of these discrepancies between the Rab 
substrate of TBC/RabGAPs is not known. Certainly, it is important to present a 
complete study showing the activity of a TBC/RabGAP towards a particular Rab 
substrate using both biochemical and in vivo methods. 
1.9.3.3.1 Structural properties of TBC/RabGAP proteins 
Neuwald (1997) first identified the homology between the yeast Rab GAP 
proteins Gyp6p and Gyp7p, the human Tre-2 oncogene and the spindle assembly 
checkpoint proteins Bub2p (from S. cerevisiae) and Cdc16 (from S. pombe). Therefore, 
this region was accordingly called the Tre2/Bub/Cdc16 (TBC) domain. Six conserved 
sequence motifs (A-F) are typically found within the catalytic TBC domain (Neuwald, 
1997). Work on TBC/RabGAP proteins from yeast origin showed that these motifs do 
not represent the complete catalytic domain as flanking regions are required for GAP 
activity. A conserved arginine residue in motif B was found critical for the catalytic 
activity (Albert et al., 1999). Furthermore, crystal structure analysis revealed that Rab 
GAPs have a similar mechanism to accelerate GTP hydrolysis as observed for GAPs 
with specificity for Ras and Rho family members (Rak et al., 2000; Ahmadian et al., 
1997b; Scheffzek et al., 1998). 
Armus alignment with characterised mammalian TBC/RabGAP proteins shows 
that it contains all the required motifs and critical arginine residue on amino acid 
position 676, suggesting that it may function as a TBC/RabGAP protein in vivo (Figure 
1.10; Neuwald et al., 1997). 
1.9.3.3.2 Identifcation of TBC/RabGAP proteins 
The cellular function and substrate of several TBC/RabGAPs have been 
identified (Table 1.1) using different techniques. With biochemical methods, 
TBC/RabGAP proteins can be shown in complex with its substrate using AIF,, 
(Ahmadian et al., 1997a) and the hydrolysis of GTP can be measured using different 
methods (Scheffzek and Ahmadian, 2005). Furthermore, yeast two-hybrid and binding 
techniques are used to show an interaction between a dominant-active Rab with its 
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wild-type or catalytically inactive TBC/RabGAP (Cuif et al., 1999; Haas et al., 2005; Itoh 
et al., 2006). The inactivation mutation involves replacement of the critical arginine in 
motif B (see above) often with a smaller alanine residue where the TBC/RabGAP-Rab 
interaction still can occur although no hydrolysis is facilitated (Albert et al., 1999; Rak et 
al., 2000). Interaction of a wild-type TBC/RabGAP and Rab is believed to be transient 
as after GTP hydrolysis GAPs do not stay bound to the GTPase. Therefore, co- 
localisation of these proteins should not be observed in vivo. However, TBC/RabGAPs 
can be used to specifically inactivate the endogenous pool of a Rab, interfere with the 
trafficking process that this Rab is involved in and redistribute Rab effector proteins 
(Haas et al., 2005,2007). 
1.9.3.3.3 The role of TBC/RabGAPs in cellular events 
TBC/RabGAP-containing proteins have also been shown to interact with 
proteins that could contribute to Rab-dependent cellular events, possibly through 
contributing of the localisation or regulation of the GAP activity. First, 
TBC1D11/GAPCenA mostly localises in the cytosol but a small fraction is associated 
with the centrosome where it binds to y-tubulin (Cuff et al., 1999). 
TBC1D11/GAPCenA has been shown to play a role via Rab6 in the transition of 
metaphase to anaphase during mitosis (Miserey-Lenkei et al., 2006). Second, TBC1D20 
(a GAP for Rab1) controls Golgi organisation and the trafficking of cargo from the 
endoplasmatic reticulum (ER) to the cell surface (Haas et al., 2007). TBC1D20 interacts 
with the hepatitis C virus phoshoprotein NS5A (HCV NS5A; Sklan et al., 2007a), 
whereby HCV takes advantage of the host cell by favouring HCV RNA replication 
through increasing Rabl-GTP (Sklan et al., 2007b). Third, RN-Tre interacts with both F- 
actin and a-actinin-4, and thereby links Rab5-dependent endocytosis and actin 
cytoskeleton rearrangements at the plasma membrane (Lanzetti et al., 2000,2004). 
Fourth, EVI5 binds Rab11-GTP and its GAP activity towards Rabli has been shown in 
one study (Dabeekeh et al., 2007) but not another (Westlake et al., 2007). EVI5 also 
interacts with the INCENP Aurora B kinase-survivin complex, a- and y-tubulin and 
plays a role in the completion of cytokinesis (Faitar et al., 2005,2006). Rabil 
has also 
been shown required during cytokinesis (Wilson et al., 2005). 
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Table 1.1: Overview of identified Rab GAP proteins with their Rab substrates and cellular function. 
TBC/RabGAP domain 
Gene Protein 
Substrate Cellular function References 
name 
EVI5 EV15 Rabl 1 Cytokinesis Dabeekeh et al., 2007; 
Faitar et al., 2005,2006 
Rab35 ND Fuchs et al., 2007 
EVI5-like EVI5-like RablO ND Itoh et al., 2006 
Rab23 Primary cilium formation Yoshimura et al., 2006 
HHL/FLJ38519 FLJ38519 
RUTBC3 
TBC1D3 
TBC1D4 
RabGAP-5 
CIP85 
PRC17 
TBCID3 
AS160 
TBC1 D7 
TBC1D10A 
TBC1 D10B 
TBC1 D11 
TBC1 D15 
TBC1 D17 
TBC1 D20 
TBCI iD22A 
TBC1D22B 
TBC1 D25 
USP6 
USP6NL 
TBC1 D7 
EP164 
TBCI DIOB 
GapCenA 
TBC1Dli 
TBCID15 
TBC1 D17 
TBC1 D20 
TBC1 D22A 
TBCI D22B 
OALT1 
USP6 
Tre2/Tre 17 
RN-Tre 
Rab22a, 34, 
39b 
Rab5a-c 
ND 
Rab5 
Inactive 
Rab2a, 8a, 10, 
14 
Rab17 
Rab27a 
ND 
Rab22a, 31 
Rabb, 4,2 
Rab4,11 
Rab7,11 
Rab2l 
Rabl, 2 
Rab1,2 
Rab33a-b 
Rab33a-b 
Rab2a, 34 
Inactive 
Inactive 
Rab5 
ND Itoh et al., 2006 
Endocytosis Haas et al., 2005; Fuchs 
et al., 2007 
Connexin43 Lan et al., 2005 
ND 
Macropinocytosis 
Exocytosis 
Primary cilium formation 
Melanosome transport 
Microvilli 
ND 
Cytokinesis 
ND 
ND 
ND 
Antrograde transport 
HCV replication 
ND 
ND 
ND 
Ubiquitin-specific protease 
Endosomal recycling 
Endocytosis, 
macropinocytosis 
Pei et al., 2002 
Frittoli et al., 2008 
Miinea et al., 2005; 
Larance et al., 2005 
Yoshimura et al., 2006 
Itoh and Fukuda, 2006 
Hanono et al., 2006 
Fuchs et al., 2007 
Cuif et al., 1999; Miserey- 
Lenkei et al., 2006 
Fuchs et al., 2007 
Zhang et al., 2005 
Fuchs et al., 2007 
Haas et al., 2007 
Sklan et al., 2007a, 2007b 
Pan et al., 2006 
Pan et al., 2006 
Itoh et al., 2006 
Papa et al., 1993 
Martinu et al., 2004 
Lanzetti et al., 2000,2004 
Rab43 Retrograde transport Haas et al., 2005,2007 
Rab5a, 1,2, ND Frittoli et al., 2008 
3,28 
XM037557 XM_037557 Rab8a Primary cilium formation Yoshimura et a!., 2006 
Non-TBC/RabGAP Substrate Cellular function References 
domain 
Rab3-GAP Rab3a-d Exocytosis (synapses) Fukui et al., 1997; Sakane 
et al., 2006 
Rab3a, 10,22 ND Itoh et al., 2006 
p120GAP Rab5, Ras Endocytosis Liu and Li, 1998 
p85a Rab5,4,6, Endocytosis Chamberlain et al., 
2004 
Cdc42, Rac1 
ND, not determined. 
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Another set of TBC/RabGAP proteins have been shown to link to the GTPase 
Arf6. Arfs control the formation of transport vesicles whereas Rabs regulate different 
aspects of vesicular trafficking including the formation, transport, docking and fusion 
of vesicles (Chavrier and Goud, 1999; Zerial and McBride, 2001). The overlap between 
Arf6 and Rab function at sites where vesicle formation occurs supports the idea that 
cross-talk between these GTPases may exist. Different TBC/RabGAP proteins have 
been shown to mediate such cross-talk. For example, the TBC/RabGAP domain of 
USP6/Tre2/Trel7 binds Arf6-GDP and this interaction activates Arf6 at the plasma 
membrane that promotes endosomal trafficking (Martinu et al., 2004). EP164 also 
interacts with Arf6-GTP in its TBC/RabGAP domain. Both EP164 and active Arf6 are 
necessary for the regulation of microvilli (Hanono et al., 2006). TBC1D3/PRC17 
regulates macropinocytosis in a pathway involving Arf6 and Rab5. In addition, 
TBC1D3/PRC17 binds and localises with the Arf6 adapter protein GGA3 in an active 
Arf6-dependent manner (Frittoli et al., 2008). Therefore, by association with Arf6 or 
Arf6 effectors, TBC/RabGAP family members may integrate Arf6 function with Rab 
inactivation. 
1.9.3.3.4 Armus TBC/RabGAP domain 
When the Armus C-terminal domain is over-expressed, it localises in the 
cytosol and is concentrated at adherens junctions in 38% of the expressing 
keratinocytes (R, Francis, unpublished data). Furthermore, no localisation with 
LAMP1, Calnexin and transferrin is observed. 
Using a yeast two-hybrid assay, the TBC/RabGAP region of Armus has been 
shown to bind weakly to Rab11a and the close family member Rab25 (M. Frasa, 
unpublished data). These Rabs are members of the Rab11 subfamily and have a typical 
epithelial-specific expression profile (Goldenring et al., 1993). In addition, Armus 
TBC/RabGAP domain co-localised with dominant-active Rab11 and Rab25 on tubular 
structures. These data together with the co-localisation of Rab11 at Armus-induced 
vesicles suggests that these molecules may be functionally linked. These results imply 
that Rab11 can potentially be a substrate for Armus GTPase activity. However, co- 
localisation of a Rab GAP with its substrate has not previously been observed as their 
interaction is believed to be very transient. 
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1.9.3.4 Expression pro 'le of Armus 
Armus is expressed in keratinocytes and in other epithelia-containing organs, 
including kidney, liver, placenta and lung (M. Betson, unpublished data). 
Furthermore, screening of Armus in different tumours shows upregulated levels in 
lymphoma, ovarian, prostate, breast, lung, colon and brain tumours compared to 
normal tissue (Figure 1.11; D. Rimm, Yale University, unpublished data). The over- 
expression in tumours was determined using an Armus-specific antibody against the 
Armus N-terminus region. 
Several other TBC/RabGAP proteins are found over-expressed in different 
cancer types and have been described as oncogenes (see section 1.6.3.2). It is 
conceivable that an upregulation of TBC/RabGAP proteins leads to an elevated amount 
of Rab-GDP and inhibition of vesicular trafficking. In some instances, the over- 
expressed GAP proteins could be malfunctioning (i. e. USP6/Tre2/Trel7; Papa et al., 
1993; Martinu et al., 2004; Bizimungu and Vandenbol, 2005). Alternatively, cycling of 
GTPases has been found important for their function. Thus, increased levels of a 
functional GAP can imbalance the regulation of cycling/localisation of active Rabs. 
1.9.3.5 Function of Armus 
Armus' closest homologous TBC1D2 protein differs with Armus by its lack of 
68 amino acids at the C-terminus and two polymorphisms at position 241 (Threonine -) 
Proline) and 253 (Serine -) Leucine). TBC1D2 function has not been identified nor its 
Rab substrate. However, TBC1D2 has previously been tested in large screens for 
identification of Rab substrates and their results can be summarised as follows. First, 
Itoh and colleagues (2006) tested interaction between 40 different mouse TBC/RabGAP 
domains and 60 GTP-bound Rab proteins. In this report, full-length TBC1D2 (called 
FLJ22456) did not show an interaction with any of the tested Rabs. Second, over- 
expression of wild-type T'BCID2 did not affect Golgi organisation in HeLa cells and 
telomerase-immortalised human retinal epithelial (hTERT-RPE1) cells. In addition, 
TBC1D2 did not affect the ER-Golgi intermediate compartment or anterograde 
transport of vesicular stomatitis virus G-protein (VSV G) from the ER to the cell surface 
(Haas et al., 2007). The TBC/RabGAP RN-Tre (substrate Rab43) together with 
TBC1D20 
(substrate Rab1) are found to control these transport routes. Thus, these results 
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Figure 1.11: Armus is over-expressed in tumours. 
Different human tumour samples were 
immunostained with a specific anti-Armus antibody 
and immunofluorescence levels were compared with 
normal tissues. The percentage of tumours showing 
increased levels of Armus staining is presented in the 
graph (D. Rimm, Yale University, unpublished data). 
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suggest that TBC1D2 (Armus) is not required for the transport events involving ER to 
Golgi and ER to plasma membrane. Third, TBC1D2 did not affect the uptake of EGF 
through early endosomes, a process dependent on Rab5 and RabGAP-5 signalling. 
Moreover, ectopic expression of the TBC/RabGAP proteins EVI5, RN-Tre, TBC1D1OB 
and TBC1D17 affected the uptake of Shiga toxins, but not over-expression of TBC1D2 
(Fuchs et al., 2007). Fourth, TBC1D2 did not participate in primary cilia formation in 
hTERT-RPE1 cells. Instead, essential signalling for this cellular process involves the 
TBC/RabGAP proteins EVI5-like, TBC1D7 and XM_037557 with their respective Rab 
substrate Rab23, Rab17 and Rab8a (Yoshimura et al., 2006). These results together 
suggests that TBC1D2 (Armus) does not function as a GAP protein for Rab1, Rab5, 
Rab8a, Rab17, Rab2l, Rab22a, Rab23, Rab3l, Rab35 and Rab43 as these are the 
substrates for above mentioned TBC/RabGAP family members. 
The distribution of Armus PH domain and C-terminal region to sites of E- 
cadherin-mediated cell-cell contacts suggests that Armus may have a regulatory role at 
those sites. Rac signalling has been implicated in the maintenance and disruption of 
adherens junctions, depending on the threshold of activation (see section 1.6.1.1). 
Armus interacts with Rac-GTP and could function as a Rac-specific effector, thereby 
regulating E-cadherin junctions. 
Furthermore, three other TBC/RabGAP family members have been linked to 
Arf6-dependent signalling by direct interaction with Arf6 or indirect association 
through the Arf6 effector protein GGA3 (Martinu et al., 2004; Hanono et al., 2006; 
Frittoli et al., 2008). Therefore, Armus could have a potential role on Arf6-dependent 
deregulation of E-cadherin cell-cell contacts. As Armus is over-expressed in different 
tumours, a possible participation of Armus in the perturbation of junctions induced by 
Arf6 or Rac may contribute to tumour progression. 
1.10 Aims 
Destabilisation of cell-cell junctions in keratinocytes can be induced by sustained 
activation of the small GTPases Rac and Arf6. The mechanism 
for junction 
perturbation by activated Rac requires PAK signalling. 
It remains to be tested whether 
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Arf6, like Rac, requires PAK function during junction disassembly. This will provide 
insight into a convergence or distinctiveness of signalling pathways that Arf6 and Rac 
use to promote junction disruption. 
Furthermore, Arf6-induced disassembly of adherens junctions is most likely 
dependent on Rac signalling downstream. Preliminary results show that GIT1, via 
interaction with the Rac GEF p-PIX, is a good candidate molecule to provide a link 
between Arf6 and Rac during keratinocyte junction perturbation. 
The cellular function of the novel Rac-binding protein Armus remains to be 
determined. A putative function for Armus in the regulation of adherens junctions 
together with a connection to Arf6 and Rac signalling will be investigated. 
Identification of the apparent Armusl-550-positive vesicles will help to identify the 
cellular function of Armus and the putative Rab substrate for Armus. Furthermore, 
functional analyses of the domains present in Armus remains to be done, in particular 
the Rab substrate and the ability to dimerise via the coiled-coil domains. 
The aims of my PhD project are to: 
1) Identify the molecular mechanisms by which Arf6 disrupts cell-cell contacts: 
1A Requirement of Rac and PAK signalling. 
1B Involvement of GIT1-(3-PIX to mediate Arf6-dependent Rac activation. 
2) Characterise Armus function: 
2A Ability to dimerise. 
2B Identification of GAP substrate. 
2C Characterisation of Armus-induced vesicular structures. 
2D Regulation of cell-cell contacts (Arf6- and Rac-dependent 
destabilisation). 
Chapter 2: Materials and Methods 
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2.1 Plasmid constructs 
Constitutively active Rac (RacQ61L), dominant-negative Rac (RacT171`') and PAK 
auto-inhibitory domain (PAKAID) all three in the pRK5-myc vector were a gift from 
Prof. A. Hall (Memorial Sloan-Kettering Cancer Center, New York, USA). pCS2-myc 
containing constitutively active Rac461L and Rac1b461- were previously prepared in the 
Braga laboratory by Dr. E. Lozano. pCMV-6myc-PAKT432E was a gift from Dr. J. 
Chernoff (Fox Chase Cancer Center, Philadelphia, USA) and the pGEX4T1-PAK-CRIB 
was provided by Dr. J. G. Collard (Netherlands Cancer Institute, Amsterdam, The 
Netherlands). 
The expression vector pCMV2-flag encoding full-length avian GIT1 and the 
truncation mutants GIT1-C, GIT1-C2 and GIT1-ASHD were kindly supplied by Dr. I. 
de Curtis (San Raffaele Scientific Institute, Milan, Italy; Di Cesare et al., 2000). The 
yeast originated pXJ40-flag-GIT1-M4D2941E295 mutant and rat pXJ40-HA-(3-PIX were a gift 
from Dr. E. Manser (Institute of Molecular and Cell Biology, Singapore; Manser et al., 
1998). 
Dr. P. Chavrier (Institute Curie, Paris, France) kindly provided the 
constitutively active Arf6 (Arf6Q671-) in the pLexA and pSRa vector, dominant-negative 
Arf6 (Arf6T17N) in the pSRa vector and pGAD-ARHGAP10-PH (Dubois et al., 2005). 
The Arf6 constructs were previously subcloned into pCS2-HA by Dr. E. Lozano in the 
Braga laboratory. The fast recycling HA-tagged Arf6 mutant (Arf6T157A) was a gift from 
J. Casanova (University of Virginia Health Sciences Center, Charlottesville, USA; Santy, 
2002). 
pEGFP-C2 and pGB-GAL4 encoding the constitutively active forms of Rab11a 
(Rabllaszov) and Rab25 (Rab25S21v) as well as dominant-negative Rabl1a (Rab11aS25N) in 
the pEGFP-C2 were provided by Dr. J. Goldenring (Vanderbilt University School of 
Medicine, Nashville, USA). Dr. M. Seabra (Imperial College London, UK) generously 
gave the pEGFP-C1 vectors containing the constitutively active forms of Rabla 
(Rab1a471L) and Rab5a (Rab5aQ79L) and the dominant-negative mutant Rabla 
(Rab1as25N); and in the pEGFP-C3 vector constitutively activated and 
dominant- 
negative Rab7 (Rab7Q67i- and Rab7T22N, respectively). RILP in the pEGFP-C1 vector was 
a kind gift from Dr. C. Bucci (Universitä del Salento, 
Lecce, Italy; Guignot et al., 2004). 
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Armus encoding residues 1 to 550 (Armus, _sso), residues 433 to 550 (Armus433_ 
550) and residues 547 to 928 (Armus547-928) in the pRK5-myc vector, and the residues 295 
to 433 (Armus295-433) and 547 to 928 (Armus547_928) in the pRK5-flag vector were 
previously cloned by R. Francis in the Braga laboratory. Full-length Armus was 
available in a Venus-tagged vector. 
All constructs were verified by the ABC Sequencing Service at Imperial College 
London. 
2.2 Cloning 
Armus547_928 was subcloned from the pRK5-flag into pGAD10 or pGEX-4T3 
using the BamH1 and EcoRl restriction sites of the. Armus residues 551 to 828 
(Armus551_828) using primers 1 and 2 and residues 828 to 928 (Armus828_928) using 
primers 3 and 4 were PCR amplified and cloned into pRK5-flag (see Table 2.1). 
Arf6Q67L was amplified with primers 5 and 6 and inserted into the EcoRI and BamHI 
cloning sites of pEGFP-C1 (see Table 2.1). Positive clones were selected by restriction 
enzyme digestion analysis and subsequently sequenced by ABC Sequencing Service at 
Imperial College London or Cogenics (Takeley). 
2.2.1 Polymerase chain reaction (PCR) 
The following procedure was performed for cloning of new constructs by PCR 
amplification. Sense and anti-sense primers with the appropriate restriction enzyme 
sites were manually designed to amplify the desired fragment by PCR (Table 2.1). 
Amplification was performed in a 5Oµl volume containing 1x Pfu buffer (Stratagene), 
10mM dNTPs, lpmol of each primer, 1U Pfu DNA polymerase (Stratagene) and 
-0.01µg DNA template. PCR reaction was carried out starting with a three minute 
denaturation step at 94°C, followed by 30 cycles including 45 seconds at 94°C, 45 
seconds at 5°C below the lowest melting temperature of the primers (Tn Table 2.1) and 
one minute at 72°C. Finally, an extension phase of 10 minutes at 72°C was performed. 
The PCR product was resolved on a 1% (w/v) agarose gel containing lng/ml ethidium 
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bromide and visualized under UV. PCR product was excised from the agarose gel and 
purified using QlAquick Gel Extraction Kit (Qiagen). 
2.2.2 Restriction enzyme digestion and ligation 
For subcloning, PCR product or plasmid was sequentially digested with 
restriction enzymes and the enzyme was heat-inactivated after each digest for 20 
minutes at 65°C. Alkaline phosphatase (10U) was added to the digested vector and 
incubated for 30 minutes at 37°C to prevent self-ligation in subsequent ligation 
reactions. Ligation reactions were set-up with 1U of Quick-Stick ligase (Bioline) and 
left for 15 minutes at room temperature. The subcloning efficient DH5a strain of 
Eschericia coli (E. coli) was transformed with 5. i1 of ligation reaction and plated on Luria 
Bertania agar (LB) containing 100µg/ml ampicillin or 50µg/ml kanamycin antibiotics 
depending on plasmid resistance. 
2.2.3 Site-directed mutagenesis 
The Stratagene's QuickChange® site-directed mutagenesis kit was used to 
generate point-mutations in pRK5-flag-Armus547-928. Mutagenic primers were designed 
with the PrimerX program (http: //bioinformatics. org/primerx/index. htm; Table 2.2). 
Site-directed mutagenesis reaction was prepared in a volume of 50µl containing 1x Pfu 
buffer (Stratagene), 40mM dNTPs, 5pmol of each primer, 1U PfuTurbo DNA 
polymerase (Stratagene), 2% dimethylsulfoxide (DMSO) and -0.01µg pRK5-flag- 
Armus547-928 template. The reaction was carried out starting with a three minute 
denaturation step at 95°C, followed by 16 cycles of 30 seconds at 95°C, one minute at 
55°C and 14 minutes at 68°C. To digest the parental DNA, 1OU of Dpnl was added to 
the sample and incubated for 1 hour at 37°C. PCR reaction (5p1) was resolved on a 1% 
(v/v) agarose gel and visualized under UV. Subsequently, 5µi of product was 
transformed into library-efficient DH5a bacteria and plated on LB agar containing 
100µg/ml ampicillin. 
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Table 2.1: Primers used for PCR amplification. 
Number Primer Sequence Tm (°C) 
1 Armus551 EcoRI, sense 5'GAAGGAATTCAGCATCGAGCTGAGC3' 65.6 
2 Armus828 Xbal, antisense 5'GAAGTCTAGAAATGGCCAAGGCATA3' 61.3 
3 Armus828 EcoRI, sense 5'GCGGAATTCATTTTCAAGTACAACGAG3' 63.7 
4 Armus928 Xbal, antisense 5'GAAGTCTAGATCAGGCTTCCCCCTC3' 66.3 
5 Arf6 EcoRI, sense 5'GAAGGAATTCTGATGGGGAAGGTGCTA3' 76.0 
6 Arf6 BgIII, antisense 5'GAAGACATCTGATTTGTAGTTAGAG3' 69.0 
Table 2.2: Mutagenic primers used for site-directed mutagenesis on ArmusS47.928. 
Mutagenic primer Sequence 
Q713A, sense 
Q713A, antisense 
G714A, sense 
G714A, antisense 
L794A, sense 
L794A, antisense 
W810A, sense 
W810A, antisense 
G714A on Q713A, sense 
G714A on Q713A, antisense 
5'CATCGGCTACTGCGCGGGCCTGAACAG3' 
5'CTGTTCAGGCCCGCGCAGTAGCCGATG3' 
5'GCTACTGCCAGGCCCTGAACAGGCTG3' 
5'CAGCCTGTTCAGGGCCTGGCAGTAGC3' 
5'CCTTCAACTGGTTCGCCGTGGTCTTTGCG3' 
5'CGCAAAGACCACGGCGAACCAGTTGAAGG3' 
5'CTCCTTCGGGTCGCGGATGCCTTCCTG3' 
5'CAGGAAGGCATCCGCGACCCGAAGGAG3' 
5'GCTACTGCGCGGCCCTGAACAGGCTG3' 
5'CAGCCTGTTCAGGGCCGCGCAGTAGC3' 
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2.3 Antibodies 
Primary mouse monoclonal antibodies used were anti-myc epitope (9E10; 
Upstate), anti-flag epitope (M2; Sigma), anti-GFP epitope (CRUK), anti-actin (C4, 
Sigma), anti-E-cadherin (HECD1, CRUK), anti-Rac (23A8, Upstate) and anti-Arf6 
(6ARF01, Lab Visions). Monoclonal rat anti-E-cadherin (ECCD2, Hirai et al., 1989) was 
purchased from, Zymed Laboratories and anti-HA epitope (3F10) from Roche Applied 
Science. Rabbit polyclonal antibodies used were anti-LAMP1 (Abcam), anti-HA 
epitope (SG77, Zymed), anti-flag epitope (F7425, Sigma), anti-a-catenin (VB1, Braga et 
al., 1995) and anti-GIT1 (H-170) and anti-PAK1 (N-20) were both purchased from Santa 
Cruz Biotechnology. Anti-(3-PIX antibody raised in rabbit was a gift from Dr. I. de 
Curtis (San Raffaele Scientific Institute, Milan, Italy). Anti-CD63 (IB5) was supplied by 
Dr. M. Marsh (MRC laboratory for Molecular Cell Biology, University College London, 
UK). Anti-Armus IC2 was produced in rabbit using peptide NH2- 
WRKVAEKEKALLTKCAYLQA-COOH and previously characterised on Western blots 
by R. Francis in the Braga laboratory. 
The following secondary antibodies were purchased from Jackson Immuno 
Research Laboratories: cyanine (Cy2)-conjugated goat anti-mouse IgG; 
indocarbocyanine (Cy3)-conjugated donkey anti-rabbit IgG; indodicarbocyanine (Cy5)- 
conjugated donkey anti-rat IgG. Horseradish peroxidase (HRP)-conjugated goat anti- 
mouse IgG and HRP-conjugated goat anti-rabbit IgG were bought from Pierce. 
2.4 Cell culture 
J2 mouse fibroblasts were grown in Dulbecco's modified Eagle medium 
(DMEM, Sigma) supplemented with 5% donor calf serum (DCS) at 37°C in 5% CO2. 
COS-7 cells were cultured in DMEM containing 10% fetal calf serum (FCS) and 5mM 
glutamine and maintained in 5% CO2 at 37°C. 
Normal human keratinocytes (strain SF, passages 3-7) were cultured on 
mitomycin C-treated 3T3-J2 fibroblasts at 37°C and 5% 
CO2 in standard FAD medium 
(BioWittaker) supplemented with 1.8mM CaCl2,100units/ml penicillin, 100µg/ml 
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streptavidin, 1.8x10-4M adenine, 5µg/ml insulin, 0.5µg/ml hydrocortisone, 0.1nM 
cholera toxin, 10% FCS, 5mM glutamine and 10ng/ml epidermal growth factor (EGF) 
(Rheinwald and Green, 1975). Keratinocytes were grown in the absence of calcium- 
dependent cell-cell contacts using low calcium medium. Low calcium medium 
contains the same as standard medium, but with 0.1mM CaC12 and FCS depleted of 
divalent ions by treatment with Chelex-100 resin (BioRad). The keratinocytes were 
seeded at 1x105 per 0 6cm culture dish or 3x105 per 0 9cm dish. For microinjection, 
keratinocytes were seeded at a density of 1-3x104 per 0 13mm glass coverslip and kept 
in standard calcium medium. For electron microscopy (EM) purposes, cells were 
plated on a coverslips with a grid (Cellocate Eppendorf). Keratinocytes were seeded at 
a density of 3x104 in standard medium and switched to low calcium medium after 3-5 
days for all short interference RNAs duplex oligonucleotide (siRNA) experiments. 
Subsequently, cells were cultured until confluent prior to siRNAs being added. 
2.5 Immunofluorescence 
After fixation in 3% paraformaldehyde for 10 minutes and three washes in 
phosphate-buffered saline (PBS, 10mM Na2PO4,2.7mM KCI, 137mM NaCl, pH7.4), the 
cells were stained in a dark humid chamber as follows. First, cells were permeabilised 
in 10% FCS in PBS containing 0.1% Triton X-100 for 10 minutes at room temperature. 
Next, immunolabeling was performed by individual and sequential incubation of 
primary and secondary antibodies. 
For double or triple labeling, care was taken to avoid cross-reaction of the 
antibodies. Therefore, labeling with anti-rat monoclonal antibodies 
followed by an 
anti-rat conjugate was carried out first. Subsequently, labeling with anti-mouse 
monoclonal and an anti-mouse secondary antibody and at 
last anti-rabbit polyclonal 
and anti-rabbit secondary antibody was performed. Antibodies were 
diluted in 10% 
FCS in PBS and incubated on the cells for 30 minutes, 
followed by nine washes in PBS. 
Finally, coverslips were washed three times in water 
before mounting in Mowiol 
(Sigma) on microglass slides. 
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Images were acquired with an Olympus Provis AX70 microscope coupled to a 
SPOT RT monochrome camera using SPOT Advanced Imaging software (Imsol). 
Alternatively, confocal images were obtained with a Leica DCS NT system using Leica 
LCS Lite software. To avoid leakage between the different filters on the confocal 
microscope, the laser was optimized for each fluorophore and images were collected 
separately. Pictures were processed using Adobe Photoshop® CS version 8.0 and 
WCIF Image) software. 
2.6 Electrophoresis and Western blotting 
Protein samples were separated by electrophoresis through sodium dodecyl 
sulfate-polyacrylamide gel electroforese (SDS-PAGE, running buffer containing 25mM 
Tris, 200mM glycine and 0.1% (w/v) SDS) and transferred onto a polyvinylidene 
difluoride membrane (PVDF) membrane (Millipore) using a standard wet transfer 
approach for proteins > 40kDa (transfer buffer 50mM Tris, 380mM glycine and 20% 
methanol) or semi-dry transfer approach for smaller proteins (48mM Tris, 40mM 
glycine and 0.037% SDS). 
For immunoblotting, non-specific binding sites on the membrane were blocked 
with 5% non-fat dry milk (Marvel) in PBS-Tween (PBS containing 0.05% Tween-20) for 
one hour with agitation. After blocking, the membrane was incubated with indicated 
antibodies and conjugates in blocking solution for one hour whilst shaking and then 
washed four times in PBS-Tween. For probing with rabbit polyclonal antibodies, a rich 
blocking solution consisting of 5% non-fat dry milk, 1% chicken egg albumin and 5% 
FCS was used for blocking and antibody dilutions. Precious primary antibodies which 
were reused were diluted in 3% bovine serum albumin (BSA) containing 0.01% azide. 
The blot was developed with SuperSignal West Dura Extended Duration Substrate 
(Pierce) and exposed to Hyperfilm ECL (Amersham Biosciences). For reprobing, 
membrane was stripped using 100mM glycine pH2.5 for 5 minutes followed by a brief 
wash in 100mM Tris-HC1 pH7.4 and extensive washes in PBS. For harsh stripping, the 
Restore Western blot stripping buffer (Pierce) was used for five minutes followed by 
extensive washes in PBS. 
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2.7 Microinjection 
Microinjections were performed using a phase contrast microscope (Axiovert 
135m Zeiss Inc., Thornwood, New York) attached to an Eppendorf Microinjection Unit 
(Microinjector model 5242; micromanipulator model 5170; CO2 Controller model 3700; 
Heat Controller model 3700). During microinjection, cells were maintained at 37°C and 
5% CO2 atmosphere (Braga et al., 1997). DNA concentrations were adjusted in sterile 
PBS to obtain optimal expression levels of each construct. For co-expression 
experiments, DNA concentrations diluted in PBS were titrated to achieve equal 
expression. Unless otherwise stated, Arf6Q67L was microinjected at 0.05µg/µl and other 
constructs at 0.1µg/µl in normal keratinocytes, and at 0.5µg/µl in siRNA experiments. 
Cells were allowed to express for indicated times at 37°C and 5% CO2 before fixing and 
staining as described in section 2.5. 
For EM studies of Armus1_55o expressing cells, a notation was made of the 
position of every injected keratinocyte grown on coverslips with a grid. After the 
desired expression time, cells were fixed in 0.1M cacodylate containing 2% 
paraformaldehyde and 2% glutaraldehyde for 30 minutes, washed three times in PBS 
and stored in PBS until further EM analysis performed by Dr. C. Futter (Institute of 
Ophthalmology, London, UK). 
2.8 Transfection of plasmid DNA 
For keratinocyte transfections, TranslT®-Keratinocyte transfection reagent 
(Mires) was incubated with serum-free medium for 15 minutes at room temperature. 
Next, plasmid DNA was added and incubated further for 15 minutes at room 
temperature. Coverslips (0 13mm) were transfected with a 1004l mixture of 2µg DNA 
with 8µl transfection reagent in a total volume of 400µl. Transfection on 0 9cm 
dishes 
was done with 1ml mixture of 20µg DNA with 20µl transfection reagent in a total 
volume of 2.5m1 serum-free medium. The mixture was added to the cells and 
incubated for 4 hours. The transfection medium was replaced with medium that was 
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removed from the same dish prior to the transfection. Keratinocytes were incubated 
for different time periods before washing in cold PBS and lysis. 
COS-7 cells were grown to 70-80% confluence on 0 6cm culture dishes. For 
transfection, 4µg of total plasmid DNA was diluted in 200µl of serum-free medium. 
Lipofectamine reagent (10pl, Invitrogen) was separately diluted in 300pl serum-free 
medium. Both dilutions were incubated for 15 minutes at room temperature. DNA 
and Lipofectamine solutions were mixed by pipeting and incubated for 15 minutes at 
room temperature. Cells were washed with serum-free medium and the 
DNA/Lipofectamine mix was diluted with 2m1 of serum-free medium before adding to 
the cells. After three hours post-transfection, 2.5m1 of standard medium was added to 
each dish and incubated for 48 hours. 
2.9 siRNA procedure 
All siRNAs were purchased from Dharmacon (listed in Table 2.3) and dissolved 
in 1x siRNA buffer (containing 100mM KCI, 30mM HEPES-pH 7.5,1. OmM MgC12) in 
RNAse-free diethylpyrocarbonate (DEPC)-treated water (Dharmacon). Different 
amounts of siRNA oligos and RNAiFect (Qiagen) were diluted in a total of 100µ1 low 
calcium medium and left for 15 minutes at room temperature to form complexes. For 
25nM, 50nM, 100nM and 200nM of oligos the amount of 1.5µl, 341,6µl and 1241 
transfection reagent was used, respectively. Cells grown on coverslips in low calcium 
medium were washed once in low calcium medium and transfection was done in a 
total volume of 4O0µl. After four hours incubation, the transfection mixture was 
replaced with fresh low calcium medium. At different time-points post-transfection, 
cells were washed twice with cold PBS and lysed by scraping in 60µl of cold lysis 
buffer (50mM Tris-HC1 pH7.5,1% Triton-X100,150mM NaCl, 0.1% SDS, and 1mM of 
each protease inhibitor PMSF, leupeptin, pepstatin and pefabloc). Lysates were 
centrifuged at 14,000rpm at 4°C and supernatant was removed from the cell pellet. 
Protein concentration of the samples was measured in triplicates using the BCA 
method (Pierce). Equal amounts of protein were calculated and samples were diluted 
in water with reducing loading buffer and boiled for 5 minutes at 100°C. 
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Subsequently, samples were run on SDS-PAGE and subjected to Western blotting (see 
section 2.6). Knockdown for the proteins was determined by comparison with the 
control sample treated with the non-targeting scrambled siRNA oligo. 
For microinjection purposes, after 42 or 66 hours post-transfection cell-cell 
contacts were induced by replacement with standard medium. This standard medium 
had been on cells for at least two days to avoid activation of other pathways by adding 
fresh. Subsequently, siRNA and control-treated cells were microinjected with 0.5µg/µl 
plasmid DNA and allowed to express for the indicated times. After staining with the 
appropriate antibodies, the presence of E-cadherin at junctions was analysed and 
quantified as below. To confirm knockdown, coverslips in parallel treated with the 
specific siRNA oligo and non-targeting scrambled siRNA oligo were lysed at the same 
time-point and analysed by Western Blotting. 
2.10 Quantification of microinjection experiments 
The accumulation of E-cadherin staining in the perinuclear area upon 
expression of Arf6a67L, Arf6T157A or RacQ61L was quantified by calculating the percentage 
of the cells showing this phenotype and expressed relative to the total number of 
expressing cells. 
The effect on E-cadherin junction stability by expression of Arf6Q67i- or Arf6Tl57 
per se and in combination with another protein (e. g. Arf6Q67f- + Rab7T22N) was quantified 
using the following criteria. Cells were stained for the appropriate epitope tags and 
E- 
cadherin, and images of the expressing cells were collected. In-between two 
expressing cells, an intact E-cadherin junction was scored as positive 
(arbitrarily set as 
1) and loss of junction was scored negative (arbitrarily set as 0). 
The total of positive 
scores was expressed as the percentage of the total number of cell-cell 
borders among 
expressing cells. At least three independent experiments were grouped 
together and 
statistical analysis was performed using the paired 
Student's t-test. 
Quantification of the percentage of intact cell-cell junctions in the presence of 
RacQ6 was carried out in the following way. 
The length of E-cadherin staining in- 
between two expressing cells was measured using the 
SPOT Advanced Imaging or 
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ImageJ software. Next, the predicted length for intact junctions was measured from 
corner to corner. The ratio between these two values was expressed for every cell-cell 
contact and control value was set to 100% (i. e. cadherin staining = cell-cell contact 
length). At least three independent experiments were grouped together and statistical 
analysis was performed using the paired Student's t-test. 
Junction disruption by active PAKT423E was performed by counting the number 
of expressing cells showing punctated E-cadherin junctions compared to surrounding 
non-injected cells. The percentage of expressing cells showing this phenotype was 
calculated and averaged from all experiments. 
The disruption of Armus, _sso-induced vesicular structures was quantified using 
the following criteria. Images of Armust-55, D, Armus295-433, Armus547-828, Armus547-928, 
Armus828_928, Arf6Q67L, Arf6T22N, Rac461L and RacT"I`I per se, or Armusl-550 co-expressed 
with these proteins were collected. Number of Armus, -55o-induced vesicles per cell was 
counted and grouped as the percentage of cells containing no Armus 1.550 vesicles, 0-20 
vesicles or more then 21 vesicles. Results are an average of three or more experiments. 
2.11 RT-PCR 
mRNA extraction from HNP-1 monocytes (a gift from Dr. E. Caron, Imperial 
College London) and keratinocytes grown in standard calcium media was carried out 
using the RNAzo1 B method (Biogenesis). Cells from a confluent 0 9cm dish were 
harvested in 1,5m1 RNAzo1 B reagent and 150µl chloroform on ice for five minutes, 
followed by spinning down at 14,000rpm for 15 minutes at 4°C. The clear upper 
aqueous phase was removed from the lower phenol: chloroform phase and an equal 
volume of isopropanol was added. Samples were incubated on ice for 15 minutes and 
centrifuged at 14,000rpm for 15 minutes at 4°C. The RNA pellet was washed once with 
1ml of 70% ethanol and centrifuged for eight minutes at 14,000rpm. 
Supernatant was 
removed and pellet was air dried and dissolved in RNAse-free water. 
A SuperScriptTM II Reverse Transcriptase reaction was performed to generate 
cDNA (Invitrogen). Briefly, 1µg RNA was heated with 
300µg random primers and 
5mM dNTP mix in a total of 12µl DEPC-treated water 
for 5 minutes at 65°C. First- 
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strand buffer (1x) and 0.1M dithiothreitol (DTT) was added and incubated for two 
minutes at 42°C. SuperScriptTM II Reverse Transcriptase (200U) was added and 
incubated for 10 minutes at 25°C, then 50 minutes at 42°C followed by heat inactivation 
for 15 minutes at 70°C. Removal of RNA was carried out by incubation with 
Ribonuclease H (2U) for 20 minutes at 37°C. 
Primers were designed for the human PAK1, PAK2, PAK3, GIT1 and GIT2 
proteins using the program Primer3 (Table 2.4; Rozen and Skaletsky, 2000). PCR 
reaction was carried out using 2 i1 template cDNA obtained above and lx Pfu buffer, 
5mM dNTP mix, 25pmol of each the sense and antisense primers and 2% DMSO and 
1U Pfu DNA polymerase (Stratagene) in a total volume of 50µl. PCR products (10µl) 
was resolved on a 1% (w/v) agarose gel containing 1ng/ml ethidium bromide and 
visualized under UV. 
2.12 Immunoprecipitation assay using COS-7 cells 
For Armus dimerisation, 2µg of either tagged-Armus fragments were 
transfected and expressed for 48 hours in COS-7 cells. Cells were harvested 48 hours 
post-transfection by washing once in ice cold PBS, followed by scrapping in 500µ1 of 
lysis buffer (20mM Tris-HC1 pH7.5,1% Triton-X100,150mM NaCI, 10mM NaF, 1mM 
Na-orthovanadate and 1mM of each protease inhibitor PMSF, leupeptin, pepstatin and 
pefabloc). 
For interaction of Rabs with Armus547.928, plasmids encoding 2µg flag-tagged 
Armus547 928 and 2µg of the activated forms of Rab1, Rab5, Rab7, Rab11a or Rab25 were 
transfected. Cells were lysed similarly to above but in lysis buffer containing 20mM 
Tris-HC1 pH7.5,0.5% Triton-X100,150mM NaCl, 10mM NaF, 1mM Na-orthovanadate, 
2mM MgC12,0.1mM DTT and 1mM of each protease inhibitor PMSF, leupeptin, 
pepstatin and pefabloc. 
Protein-A sepharose (Sigma) was prepared by hydrating in water for two 
hours, washing three times with PBS and resuspending in PBS to make a 1: 1 slur. 
Supernatant was incubated with 1Oµ1 of protein A slur and rabbit anti-flag antibody by 
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Table 2.3: siRNA oligonucleotides and their sequence used in this study. 
Target protein 
Oligo name (Dharmacon Sequence 
catalogue number) 
PAK1 PAK1#1 
PAK1 #2 (D-003521-01) 
PAK1#3 (D-003521-07) 
PAK1#4 (D-003521-03) 
PAK1#5 (D-003521-05) 
GIT1 GIT1#1 
GIT1#2 (D-020565-02) 
GIT1#3 (D-020565-03) 
GIT1#4 (D-020565-04) 
GIT1#5 (D-020565-05) 
ß-PIX ß-PIX#1(D-009616-01) 
ß-PIX#2 (D-009616-02) 
ß-PIX#3 (D-009616-03) 
ß-PIX#4 (D-009616-04) 
Non-targeting siRNA Control (D-001700-01) 
5'AAUCUGUAUACACACGGUCUG3' 
5' GAAGAAAUAUACACGG UU U3' 
5'AGAAAUACCAGCAC UAU GA3' 
5'CAUCAAAUAUCACUAAGUC3' 
5' CAACAAAGAACAA U CAC U A3' 
5'CGAG000CUUGUAGUGUAU3' 
5'GGACGACGCCA000AUUCAUU3' 
5'GCACACCCAUUGACUAUGCUU3' 
5'GGACGCCACA000CCAUUGUU3' 
5'CCGCACA000AUUGACUAUUU3' 
5'GGAAGAAGAUG000AGAUUUU3' 
5'GAAGAG000UCCCAAAGGAUU3' 
5'UCAAAGAG000GAGAGACAUU3' 
5'GGAGGGCGAUGACAU UAAAUU3' 
5'AUGAACGUGAAUUGCUCAA3' 
5'UAAGGCUAU GAAGAGAUAC3' 
5'AUGUAUUGGCCUGUAUUAG3' 
5'UAGCGACUAAACACAUCAA3' 
Table 2.4: Primers used for RT-PCR with expected PCR product size. 
Primer Sequence PCR product 
size bp 
PAM, sense 
PAM, antisense 
PAK2, sense 
PAK2, antisense 
PAK3, sense 
PAK3, antisense 
GIT1, sense 
GIT1, antisense 
5'ATACTGGATGGCACCAGAGG3' 788 
5'CTGGGCAGTTGAGTCACAGA3' 
5'AATTGACCCTGTTCCTGCAC3' 830 
5'CCCGAAATATTGGGGAAAGT3' 
5'CAAGGGGCATCAGGTACTGT3' 770 
5'ATCAGAGGAGTCAGGCTGGA3' 
5'AGTCCACCCCATCAAGTCAG3' 865 
5'CACGCTGTCGTAGTCGTGTT3' 
GIT2, sense 5'CATTCTCAGTGACGCCAAGA3' 813 
GIT2, antisense 5'CCTGGCCACACCATACTTCT3' 
CHAPTER 21 88 
rotating overnight at 4°C. Samples were washed three times with 5O0µ1 of lysis buffer 
(without Triton-X100 for Armus547 928 and Rab interaction) and separated in 10% SDS- 
PAGE followed by Western blotting. 
2.13 Immunoprecipitation assay using keratinocytes 
Keratinocytes cultured in 0 9cm dishes were washed in cold PBS and lysed in 
500µl lysis buffer (1% Triton X-100,15% Glycerol, 50mM Tris-HC1 pH 8,150mM NaCl, 
and 5mM EDTA, 1mM leupeptin, 1mM pefabloc, 1mM pepstatin, 1mM PMSF, 10mM 
NaF, 1mM Na-pyruvate, 1mM Na-orthovanadate and 4mM p-glycerol-phosphate). 
Protein-G beads were prepared by washing three times in an excess of PBS, and 
resuspended in an equal volume of PBS. After centrifugation of lysates at 14000 rpm at 
4°C for 5 minutes, samples were first pre-cleared using 40µ1 protein G slur for 30 
minutes. Lysates were centrifuged for 1 minute and supernatant was rotated with 40µl 
protein G slur and 5µl mouse anti-E-cadherin antibody (HECD1) for one hour at 4°C. 
An aliquot of the supernatant was kept aside as a loading control for Western blotting. 
Beads were washes three times in lysis buffer and loaded onto SDS-PAGE. 
2.14 GST-PAK-CRIB pull-down assay 
A GST-PAK-CRIB pull-down was performed to measure levels of activated 
GTP-bound Rac (Sander et al., 1998; Betson et al., 2000). GST-PAK-CRIB was produced 
in the BL21 strain of E. coli and isolated on glutathione sepharose-4B beads. Overnight 
culture (100ml) in LB medium (5g/l yeast extract, 10g/l Bacto-peptone, 5g/l NaCl and 
1mM NaOH containing 100µg/ml ampicillin) was 10x diluted into 1 liter and grown for 
two hours at 30°C. Protein production was induced with 0.5mM isopropyl-ß-d- 
galactopyranoside (IPTG) for three hours. Bacteria were pelleted at 6,000 rpm for 20 
minutes and resuspended in 3ml of lysis buffer (50mM Tris-HCl pH 7.5,100mM NaCl, 
1% Triton-X100 and 2mM PMSF). Sonication was performed with 20 second blasts for 
four times and lysate was centrifuged at 14,000 rpm for 20 minutes at 4°C. Supernatant 
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was removed and 5mM DTT was added. One ml of glutathione sepharose beads was 
incubated with the supernatant on a rotation wheel for 30 minutes at 4°C. Beads were 
collected at 4,000 rpm at 4°C and washed two times with lysis buffer containing 1mM 
DTT and two times with lysis buffer without Triton X-100 and with 1mM DTT. 
Keratinocytes grown to 70% confluency on a0 9cm dish were transfected with 
pCS2-HA-Arf6Q67L or pCS2-myc empty vector 24 hours prior to the PAK-CRIB pull- 
down assay (see 2.8 Transfection of plasmid DNA). As a positive control for Rac 
activation, cells were stimulated with 1OnM EGF for five minutes prior to pull-down 
(Betson et al., 2002). Cells were washed in cold PBS and lysed in 80041 pull-down 
buffer (50mM Tris-HCl pH7.5,1% Triton X-100,0.5% sodium deoxylate, 0.1% SDS, 
150mM NaCl, 10mM MgCl2 and 1mM of each protease inhibitor PMSF, leupeptin, 
pepstatin and pefabloc). Lysates were spun for two minutes at 14,000 rpm and 
supernatant was directly incubated with 10µl PAK-CRIB beads for 45 minutes on a 
rotation wheel at 4°C. Beads were washed three times with wash buffer (50mM Tris- 
HCl pH7.5,1% Triton X-100,150mM NaCl, 10mM MgCl2 and 1mM of each protease 
inhibitor PMSF, leupeptin, pepstatin and pefabloc). Samples (Rac - GTP) and 2.5% of 
the supernatant (total Rac) were separated by 15% SDS-PAGE, blotted and probed with 
anti-Racl and anti-HA antibodies. 
Quantification of Rac activation after EGF stimulation or Arf6Q67I- expression 
was performed with the Image) program. Rac activity level in each sample was 
measured by comparing the intensity of the bands obtained for total Rac in lysates (set 
as 100) and the active Rac pool that was precipitated with PAK-CRIB beads. The fold 
increase of Rac activation in the treated cells (EGF or Arf6Q67L) was calculated as over 
the value obtained for the negative control (no stimulation). 
2.15 Isolation of GST-ArmuS547-928 
Armus547_928 containing the predicted TBC/RabGAP domain was synthesized in 
E. coli (strain Rosetta DE3, Novagen) as a 66kDa N-terminally 
GST-tagged protein. For 
isolation, a 20m1 overnight bacterial culture in LB medium was 20x 
diluted into 4 liters 
and grown at room temperature until an OD600 - 
0.7 was reached. IPTG was added to 
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1mM and incubated overnight at room temperature. Culture was pelleted at 6,000rpm 
and stored at -80°C until use. For purification, bacterial cells were resuspended in 
100ml buffer (50mM NaPi, 0,5% Triton X-100,300mM NaCl, 5mM DTT, 5% CHAPS, 
1mM PMSF and a protein inhibitor cocktail), homogenised and disintegrated by 
passing three times through a microfluidiser (MicrofluidicsTM, model 110S). Lysate was 
centrifuged for one ho ur at 35,000rpm at 4°C and supernatant was adjusted to a 
100mM NaCI concentration (by diluting with buffer containing 50mM NaPi and 5mM 
DTT). Diluted supernatant was then incubated with 15m1 of equilibrated glutathione 
sepharose fast flow beads for one hour at 4°C on a rotation wheel. Beads were 
concentrated by centrifugation at 3,000rpm for five minutes, and transferred into a 
column and connected to a HPLC (Äkta prime plus, Amersham Biosciences). The 
beads were washed with buffer (100mM NaPi, 100mM NaCl and 5mM DTT) and by 
adding 10mM glutathione GST-ArmuS547-928 was eluted. For further purification, 
affinity purified GST-Armus547_928 was subjected to gel filtration using SuperdexTM 200 
(Pharmacia Biotech) equilibrated with 30mM Tris-HC1 pH8.0,50mM NaCl, 5mM 
MgC12 and 3mM DTT. This purification step separated a pool of oligomeric as well as 
dimeric/monomeric GST-Armus547-928. Both pools were each concentrated using 
centrifugal filters with a 30kDa cut off (Amicon® Ultra, Millipore) and protein 
concentrations were measured using a standard Bradford method. 
2.16 Production of nucleotide-free Rab GTPases 
GDP-bound Rab1, Rab7, Rab7CA22 and Rablla previously purified by N. 
Bleimling (Dr. A. Rak laboratory, MPI, Dortmund, Germany) were made in a 
nucleotide-free state as the following (Simon et al., 1996). GppCH2P (4504M) together 
with 5U alkaline phosphatase attached to beads (Sigma) were rotated with 1mg of Rab 
protein in exchange buffer (200mM (NH4)2SO4 and 0.1mM ZnC12) overnight at 4°C. 
Beads with alkaline phosphatase were removed from the proteins by centrifugation. 
Efficiency of the nucleotide exchange was confirmed by high pressure 
liquid 
chromatography (HPLC) on a C18 reversed-phase column using a 
Beckman Gold HPLC 
system equilibrated with buffer containing 50mM potassium phosphate at pH6.6, 
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10mM tetrabutylammonium bromide (TBA-Br) and 8% Acetonitrile (v/v) (Hemsath 
and Ahmadian, 2005). Guanine nucleotides were detected by their absorbance at 
252nm with a flow rate of 1,5m1/min. Calibration was performed with standard 
solutions of mGMP, mGDP and mGTP. To degrade the GppCH2P, the Rab proteins 
were incubated with 1-10-5U phosphodiesterase I (PDE, Sigma) attached to beads 
overnight at 4°C on a rotating wheel. Next day, beads with PDE were removed from 
the proteins by centrifugation. The absence of GppCH2P, GDP and GTP was tested 
using the HPLC system described above. If necessary, incubation step with alkaline 
phosphatase or PDE was prolonged to remove all GDP or GppCH2P, respectively. 
2.17 GAP activity assay 
Armus547_928 GAP activity was tested using a HPLC-based method (Hemsath 
and Ahmadian, 2005). Rab GTPase each 70pM and GST-Armus547.928 2µM were diluted 
in a total volume of 25µl in GAP reaction buffer (30mM Tris-HCI, pH7.5,10mM MgC12, 
3mM DTT and 10mM K2PO4) and incubated for two minutes at 25°C. GTP 25µM was 
added to form a 25µm GTP: Rab complex and incubated at 25°C. The reaction was 
stopped after 10 minutes by shock-freezing in liquid nitrogen. To measure the intrinsic 
GTP-hydrolysis of each Rab protein, the same reaction was performed without 
Armus547-928" To determine the GTP/GDP ratio, the frozen samples were thawed at 
95°C for 10 seconds and immediately subjected to HPLC as described above. 
By 
loading GDP or GTP alone, the typical elution time of GDP was 
determined -7.2 
minutes and of GTP at -13.3 minutes. From the GDP and GTP peak areas, the relative 
amount of GTP was calculated according to: GTP/(GDP+GTP) and presented 
in a bar 
graph. Experiments were at least performed twice. 
2.18 Yeast two-hybrid assay 
The Saccharomyces cerevisiae reporter strain L40 (genotype MATa trpl 
leu2 his3 
LYS2:: lexA-HIS3 URA3:: lexA-lacZ) was used in the yeast two-hybrid assay 
to test a 
CHAPTER 21 92 
putative interaction of Arf6Q67L with Armus547_928. Yeast strains were grown in medium 
(1% yeast extract, 2% bacto-peptone, and 2% glucose) at 30°C. Yeast transformation 
was performed using the lithium acetate (LiAc) procedure according to Schiestl and 
Gietz (1989). L40 overnight culture (5ml) was spun down and resuspended in 1ml of 
100mM LiAc and incubated for five minutes at 30°C. The yeast pellet was resuspended 
in a 350µl volume containing 35% polyethylene glycol (PEG), 0.1M LiAc, 2mg/ml 
ssDNA (boiled for 10 minutes) and 1µg of each plasmid DNA. The samples were 
mixed by vortexing for 20 seconds and incubated for 20 minutes at 42°C. Yeast was 
peletted by centrifugation for 30 seconds and resuspended in sterile water. Each cell 
suspension was plated on yeast peptone dextrose (YPD) minus trypsin and leucine 
which selects for the presence of the plasmids, and incubated for three-four days at 
30°C. Colonies were streaked out in patches on YPD minus trypsin, leucine and 
histidine to screen for interaction. 
2.19 In vitro translation of Armus proteins 
In vitro transcription and translation of myc- and flag-labelled Armus fragments 
was performed using a TNT® SP6 Coupled Rabbit Reticulocyte Lysate system or TNT® 
SP6 Coupled Wheat Germ Extract system (Promega), according to the manufacturers' 
protocol. The Reticulocyte Lysate system gives a high yield of most transcripted and 
translated proteins, but it is not useful for the production of smaller proteins 
(approximately less than 25kDa). In the Reticulocyte Lysate system smaller proteins 
can be degraded by the presence of the proteosomal machinery. Therefore, the Wheat 
Germ Extract system which has a lower production yield but does not contain the 
proteosomal machinery was used for smaller molecular weight proteins. 
Binding of in vitro translated Armusl-550, Armus433-550 and Armus547_928 proteins 
was tested by incubation of 1-5µl of each protein without or with different 
concentrations of bis(sulphosuccinimidyl) suberate (BS3) cross-linker (Pierce; Salhany et 
al., 1990) in 20mM Hepes pH 7.5 for 30 minutes at 30°C. The reactions were quenched 
by adding to 10mM TrisHCl pH 7.5. Samples were analysed in 10% SDS-PAGE and 
immunoblotted as indicated. 
Chapter 3 
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3.1 Introduction 
More than 80% of human tumours are of epithelial origin. A hallmark of 
tumour progression is loss of E-cadherin-dependent cell-cell adhesion which facilitates 
detachment from neighbouring cells and increases cell motility resulting in metastasis 
potential (Thiery, 2002). Tumour cells fail to acquire this phenotype when the 
perturbation of E-cadherin junctions is reversed (Vleminckx et al., 1991; Frixen et al., 
1991; Perl et al., 1998). Therefore, there is much interest in identifying the key events 
regulating adherens junction destabilisation. 
Over-expression of a non-hydrolysable mutant of Arf6 (Arf6Q67L) triggers 
adherens junction dissociation in MDCK cells (Palacios et al., 2001,2002) and 
keratinocytes (E. Lozano, unpublished observations). As a consequence, Arf6 
signalling could support tumour progression by disrupting E-cadherin cell-cell 
junctions. Indeed, an aberrant elevation of Arf6 protein levels is found in highly 
invasive breast cancer cells (Tague et al., 2004; Hashimoto et al., 2004). Furthermore, 
the Arf6 exchange factor GEProo/BRAG2 is activated downstream of EGF-induced 
invasion of breast cancer cells (Morishige et al., 2007). Consistent with a role for Arf6 in 
tumour progression, Arf6 signalling is required downstream of HGF/SF-induced 
scattering of polarised MDCK cells (Palacios et al., 2003; Santy and Casanova, 2001). 
Studies have shown that constitutive activation of Rac per se (Rac467-) perturbs 
E-cadherin-based cell-cell contacts (Braga et al., 2000b; Akhtar and Hotchin, 2001; 
Quinlan, 1999). The disruptive potential of Rac461L suggests that Rac could contribute 
to tumorigenesis through down-regulation of E-cadherin junctions. In support with 
this, over-expression of Rac proteins in different tumours from epithelial origin, as well 
as upregulation of the Rac GEF proteins Tiam1 and (3-PIX has been reported (Lozano et 
al., 2003; Sahai and Marshall, 2002). Moreover, participation of Rac signalling induced 
by oncogenic Ras or growth factors has been well established (Zohn et al., 1998). Of 
interest regarding E-cadherin junctions, is the fact that inhibition of Rac activity blocks 
Ras-induced junction disassembly in keratinocytes (Braga et al., 2000b). 
Furthermore, the involvement of PAK in Rac461L-induced E-cadherin junction 
disassembly has been investigated in our laboratory. Preliminary experiments showed 
that co-expression of different inactive mutants of PAK can block Rac461L-mediated 
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junction destabilisation (Lozano et al., 2008). Increased PAK activity contributes to 
survival advantage and tumour cell invasiveness by regulating cell proliferation, 
apoptosis, mitosis, cytoskeletal reorganisation and cell motility. In addition, 
upregulated protein levels and activity of PAK1 and its substrates are often observed 
in various cancer types, especially breast tumours (Kumar et al., 2006). 
Thus, expression of Arf6a671- or RacQ61L can induce E-cadherin junction 
disassembly in keratinocytes. A link between these GTPases during cell-cell contact 
destabilisation has been observed in MDCK cells. Most importantly, Palacios and 
colleagues (2003) showed that, during v-Src-induced junction disassembly in MDCK 
cells, a transient decrease in Arf6-dependent Rac activation is required to dissociate 
cell-cell junctions. Thereafter, an increase of Rac activation promotes cell migration. 
In contrast, preliminary results showed that Arf6Q67- signalling requires active 
Rac in order to perturb keratinocyte junctions (E. Lozano, unpublished data). 
However, the precise mechanism via which Arf6 cross-talks to Rac or to downstream 
targets involved has not been elucidated. In this chapter, I will verify the functional 
relationship between Arf6 and Rac during adherens junction disruption in 
keratinocytes. First, the destabilisation pattern of E-cadherin-mediated junctions by 
Arf6467L and RacQ61L will be compared. Thereafter, a possible role for PAK in junction 
perturbation by dominant-active Arf6 will be explored. siRNA experiments to 
downregulate PAK1 proteins will be used to further establish the role of PAK1 during 
adherens junction disruption induced by Arf6Q67I- and Rac461L. 
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3.2 Results 
3.2.1 Pattern of keratinocyte junction destabilisation by active Arf6 and Rac 
As demonstrated previously, inappropriate over-expression of Arf6Q67- and 
Rac461L in keratinocytes leads to E-cadherin junction disassembly (E. Lozano, 
unpublished data; Braga et al., 2000b; Akthar and Hotchin, 2001). HA-Arf6Q67- and 
flag-Rac461L were allowed to express for three and six hours (respectively), fixed and 
stained for the appropriate tags and E-cadherin. Interestingly, the pattern of junction 
disruption induced by these GTPases was remarkably different. Injection of 
constitutively active Arf6 potently disrupted E-cadherin junctions, which was 
accompanied with cell detachment and rounding up (Figure 3.1a A rf6Q67J, arrow). 
Quantification of the number of intact adherens junctions in between two Arf6Q67L- 
over-expressing cells showed only 10% intact junctions (Figure 3.1b). Besides junction 
perturbation, accumulation of E-cadherin receptors in a perinuclear area of the 
Arf6a671--expressing cells was observed (Figure 3.1a Arf6Q671--, arrowhead). The 
percentage of cells that showed this clear phenotype was 77% (Figure 3.1d). 
Intracellular accumulation of junctional components by dominant-active Arf6 has been 
reported in MDCK cells (Palacios et al., 2001) and MCF-7 cells (Paterson et al., 2003), or 
via Arf6 activation induced by v-Src in MDCK cells (Palacios et al., 2003,2005). 
In contrast, over-expression of Rac461L showed a partial loss of E-cadherin 
junctions that initiated from the corners between two expressing cells and was often 
accompanied by thickening of cadherin staining in the middle of cell-cell contacts 
(Figure 3.1a Raca61L, arrows). Moreover, RacQ61L-expressing cells did not round up as 
observed following Arf6Q67Lexpression but often showed a larger cell area, suggestive 
of spreading. Because of the complete disruption of adherens junctions induced by 
Arf6Q67L compared with the partial loss of junctions by RacQ61L, a different criterion of 
quantification was considered. The E-cadherin-positive staining 
between two 
expressing cells was measured followed by the length of junctions (corner-to-corner). 
The ratio of E-cadherin staining over junction length was 
determined for each injected 
patch and averaged per experiment, where controls were predicted 
to be 100% 
(cadherin staining/junction length). Typically, expression of 
Rac461L showed 40% ratio 
(Figure 3.1c). Contrary to Arf6467L, Rac461L did not show intracellular accumulation of 
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Figure 3.1: Comparison adherens junction disassembly by Arf6Q67L and RacQ61'- 
expression. 
(a) Plasmids encoding Arf667L and RacQ61- were microinjected into the nucleus of 
keratinocytes, and allowed to express for three and six hours, respectively. Labelling for 
HA-Arf6, flag-Rac and E-cadherin was performed and pictures of over-expressing cells 
were taken. Arrows point to disrupted cell-cell junctions, arrowhead indicates intracellular 
E-cadherin accumulation. Scale bar = 50µm. (b) Quantification of the number of intact 
junctions counted in between two Arf6Q67--expressing cells (+) or in control cells (-). (c) 
Quantification of the ratio of E-cadherin staining along cell-cell junctions over junction 
length (corner to corner) in RacQ61L-expressing cells (+) and non-injected cells (-). (d) 
Percentage of the number of Arf6Q67L- and Races"--expressing cells showing clear 
accumulation of E-cadherin receptors at a perinuclear area. Error bars show standard error 
of the means (S. E. M. ). n >: 3. 
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E-cadherin receptors at a perinuclear area (Figure 3.1d) although small intracellular 
vesicles labelled for RacQ61L and E-cadherin were clearly visible (E. Lozano, 
unpublished observations). 
3.2.2 Cell-cell contact perturbation by constitutively active Arf6 can be mimicked by 
a fast cycling variant of Arf6 
Next, I investigated whether a fast cycling mutant of Arf6 could induce a 
similar phenotype as observed with Arf6Q67I-. This fast cycling mutant, Arf6T157A, can 
undergo spontaneous GTP-GDP exchange and has the ability to bind and hydrolyse 
GTP at a faster rate than wild-type Arf6 (Santy, 2002). It is predicted that fast cycling 
mutants behave more similar to wild-type GTPases with respect to regulation of 
signalling and their localisation. I expected that this mutant was able to disrupt 
adherens junctions, but with slower kinetics than the constitutively active Arf6 mutant. 
Cells were allowed to express Arf6T157A for three and six hours, followed by fixation 
and staining of HA-tagged Arf6T157A and E-cadherin. After three hours expressing, 
Arf6T157A destabilised E-cadherin junctions albeit less efficiently than Arf6Q671- (Figure 
3.2a, Arf6T157A 3h, arrow): Arf6T157A showed 49% intact junctions against 10% for Arf6Q67L 
(Figure 3.2b). The amount of intact junctions after six hours expression was decreased 
to 33% (Figure 3.2a and 3.2b, Arf6T157A 6h). Furthermore, after three and six hours of 
Arf6T157A expression, the percentage of cells showing accumulation of junctional 
components in the perinuclear region was 24% and 35%, respectively (Figure 3.2c). 
This amount was significantly lower when compared to 83% of cells with accumulated 
E-cadherin observed in Arf6Q67L-expressing keratinocytes (p<0.0002). 
In conclusion, both dominant-active and fast cycling Arf6 mutants were able to 
perturb junctions, but Arf6T157A signalling occurred with slower kinetics. 
Similarly, the 
intracellular accumulation of E-cadherin receptors induced by Arf6T157A was 
significantly slower. 
3.2.3 Rac is an essential downstream component of the Arf6-induced pathway of 
junction disassembly 
Although the pattern of cell-cell contact destabilisation induced by Arf6a67Land 
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Figure 3.2: Comparison of E-cadherin-mediated junction destabilisation by Arf6Q67L 
and Arf6h1571 . 
(a) Cells were injected and allowed to express Arf6Q67L for three hours (3h) or Arf6T157A 
for three or six hours (3h, 6h), followed by fixation and staining for HA-tag and E- 
cadherin. Arrows point to disrupted E-cadherin cell-cell contacts, arrowheads show 
intact junctions. Scale bar = 50µm. (b) Proportion of cells showing intact junctions (*, 
p<0.008) or (c) intracellular accumulation of E-cadherin receptors (*, p<0.0002). Error 
bars are S. E. M. n=3. 
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Raca61L were different (Figure 3.1), preliminary data by E. Lozano suggested that these 
GTPases are linked during E-cadherin junction disruption. Here I verified whether 
Arf6 requires Rac signalling during this event. 
Involvement of Rac signalling downstream of Arf6Q67---driven junction 
perturbation in keratinocytes was investigated by microinjection. In contrast to 
Arf6Q67L, independent expression of a dominant-negative mutant of Rac, RacT' , did 
not affect the stability of mature junctions (Figure 3.3a, Arf6Q67L arrow and RacT17N 
arrowhead). Interestingly, RacT"N efficiently blocked Arf6Q671--induced cell-cell contact 
perturbation when co-expressed. Essentially, similar keratinocyte junctions were 
observed as in non-injected control cells (Figure 3.3a, Arf6Q671- + RacT17Narrowheads). 
Quantification of these experiments showed a significant increase of intact cell-cell 
contacts from 10% to 85% (Figure 3.3b, p<0.002), in accordance with our preliminary 
results (E. Lozano). In contrast, Arf6 signalling was not required for Rac461L to perturb 
junctions (E. Lozano, unpublished data). Thus, Arf6a67f- requires Rac signalling in 
order to disrupt E-cadherin junctions in keratinocytes (and not vice versa). 
To further substantiate these results, endogenous Rac activity levels were 
measured after Arf6Q67L expression in keratinocytes. Active GTPases can be separated 
from inactive GTPases by using the ability of the GTP-bound GTPase to specifically 
interact with an effector protein. For Rac, this has previously been demonstrated by a 
PAK-CRIB pull-down assay (Sander et al., 1998). PAK is a well-characterised effector 
of Rac that facilitates binding with this GTPase via its CRIB domain (Bokoch, 2003) and 
was produced in a GST-bound form (Figure 3.4a). 
The optimal concentration of GST-PAK-CRIB to detect specific binding of Rac- 
GTP and Arf6Q67L transfections first needed to be determined. To accomplish this, 
endogenous Rac was activated by adding EGF for five minutes (Betson et al., 2002). As 
controls, lysate from normal, untreated keratinocytes was taken. After Western 
blotting with an anti-Rac antibody, the observed bands in Figure 3.4b clearly showed 
the specific pull-down of active Rac with 10µl PAK-CRIB in EGF-stimulated cells (PD, 
EGF), opposed to non-treated cells (PD, -). When 20µ1 of bead slur was used in this 
assay, non-specific binding of Rac was observed due to the larger amount of PAK- 
CRIB fusion proteins. Equal levels of Rac were observed in lysates of both stimulated 
and non-stimulated cells (Figure 3.4b, 20µl - and EGF). Therefore, 10µl of 
PAK-CRIB 
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Figure 3.3: Inhibition of Rac signalling blocks junction perturbation induced 
by constitutively active Arf6. 
(a) Constitutively active Arf6 (Arf6Q61L), dominant-negative Rac (RacT"") or a 
combination of both proteins was microinjected in keratinocytes. 
Arrow point to 
disrupted E-cadherin junctions, arrowheads show intact cell-cell junctions. Scale 
bar = 50µm. (b) The percentage of intact junctions calculated 
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beads was chosen to be used subsequently. Optimisation of active Arf6 transfection in 
keratinocytes cultured in standard calcium was found by using 20µg plasmid DNA 
and an overnight expression time (circa 18 hours). 
Next, Rac activity levels after Arf6Q67L expression was measured in two 
independent experiments (Figure 3.4c). During the procedure, care was taken to avoid 
Rac activation by serum stimulation (see section 2.8) and fold stimulation of Rac-GTP 
levels was compared to empty vector. As a positive control, EGF treatment showed an 
extensive stimulation of Rac activation in one experiment but less in the other (Figure 
3.4c left and right respectively; PD, EGF). However, in both experiments an increase 
for Rac activation was observed in the Arf6Q67L-expressing cells, albeit to different 
extent (PD, Arf6Q671-). Compared to the negative control, Rac activation after over- 
expression of Arf6Q67L was quantified as a six fold and a three fold increase (Figure 3.4c, 
left and right respectively). Taken together, activation of Rac by Arf6Q67f- was observed 
in keratinocytes and Rac signalling downstream of Arf6Q671-- is necessary to disrupt the 
stability of E-cadherin junctions. 
3.2.4 Inhibition of endogenous PAK does not interfere with Arf6-dependent E- 
cadherin junction dissociation 
Recently, PAK has been shown to be downstream essential for Rac-induced 
junction perturbation (Lozano et al., 2008). Inhibition of endogenous PAK activity by 
expression of the PAK auto-inhibitory domain (PAK amino acids 83-149 hereafter 
called AID; Zhao et al., 1998), a kinase-dead mutant of PAK, or a kinase-dead unable to 
bind Rac and Cdc42 (Tang et al., 1997) all prevented active Rac from inducing junction 
disassembly. Because Rac functions downstream of Arf6Q67L, I investigated whether 
PAKMD blocks Arf6Q67L-induced junction disruption. Keratinocytes were co- 
microinjected with Arf6467L and 0.3µg/µl of the construct encoding PAKAID. 
After three 
hours expressing, constitutively activated Arf6 alone disrupted 
E-cadherin junctions 
(Figure 3.5a, Arf6a67L arrow) while PAKA11D did not affect junction stability (Figure 
3.5a, 
PAKAID arrowhead). Upon co-expression, PAKAID was not able 
to block Arf6Q67L- 
induced E-cadherin junction disassembly (Figure 3.5a, Arf6a67L+. PAKAID, arrows and 
Figure 3.5b). These results suggest that PAK did not function 
downstream of Arf6Q67L- 
induced junction disassembly, although PAK effectively inhibited Raca61L 
in previous 
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Figure 3.4: Dominant-active Arf6 activates Rac in a PAK-CRIB pull-down assay. 
(a) GST-PAK-CRIB proteins were produced in bacteria and purified by attaching to GSH 
beads. P, pellet; L, lysates; W, wash; B, beads. (b) Testing of PAK-CRIB beads activity in 
non-treated (-) or EGF-treated (EGF) cells by using 10µl or 20µl of bead slur. PD, pull-down; 
lys, lysate. (c) PAK-CRIB pull-down experiments with keratinocytes grown in standard 
conditions transfected with pCS2 (vector) or Arf667L 18 hours prior to pull-down. As 
control, EGF stimulation was performed for five minutes prior to pull-down. Two different 
experiments are shown. Western blot analysis shows GTP-Rac in pull-down (PD), total Rac 
levels in lysates (lys) and detection of HA-tagged Arf6Q67L. Quantification of fold increase of 
Rac activation is shown. n=2. 
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experiments. Our data imply that Arf6a67- and RacQ61L induce distinct signalling 
pathways to perturb keratinocyte junctions. 
3.2.5 Optimisation PAK1 siRNA 
To substantiate the above unexpected results I asked whether endogenous PAK 
was required for Arf6Q67L function on junctions. As PAKAID is known to block the 
activation of class I PAKs (PAK1, PAK2 and PAK3; Bokoch, 2003), I determined which 
class I family members were expressed in keratinocytes. RT-PCR products were 
obtained for PAK1, indicating that only this protein was expressed in keratinocytes but 
not PAK2 or PAK3 (Figure 3.6a, keratinocytes). PAK3 expression is reported to be 
enriched in brain tissue, consistent with our results (Knaus and Bokoch, 1998). 
However, lack of PAK2 expression was surprising as this ubiquitously expressed 
protein (Knaus and Bokoch, 1998) has previously been detected in mouse epidermis by 
immunostaining (Benitah et al., 2005). A reason for the absence of a band for PAK2 
could lie in malfunctioning of the primers designed. As PAK2 has been shown to 
express in cells present in the blood (Chu et al., 2003), cDNA from HNP-1 monocytes 
was used to check the functionality of the PAK2 primers. Visualisation of the samples 
showed that PAK1 as well as PAK2 were expressed in monocytes, but PAK3 was not 
detected (Figure 3.6a). Thus, the lack of PAK2 in keratinocytes was not due to faulty 
primers. The discrepancy between our results (Figure 3.6a) and published data 
(Benitah et al., 2005) may lie in the PAK2 antibodies used in the latter study. For 
example, it is not specified which anti-PAK2 antibodies (PAK2 and phosphorylation- 
specific PAK2) were used. Thus, recognition of the highly homologous PAKT could 
have occurred. 
Next, PAK1 siRNA conditions were optimised in keratinocytes. To begin with, 
a new PAK1 specific antibody was optimised for Western blot analysis (Figure 3.6b). 
A specific target silencing RNA (siRNA) oligonucleotide sequence (hereafter 
abbreviated as oligo) to deplete endogenous PAK1 was designed using the siGENOME 
design tool of the company Dharmacon (PAK1#1). A time-course was performed using 
PAK1#1 at a concentration of 50nM (24,48 or 72 hours; Figure 3.6c) or non-targeting 
control oligos at each time-point. Keratinocytes were lysed and protein concentration 
of each sample was measured for equal loading of the proteins 
for comparison on SDS- 
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PAGE analysis. A consistent knockdown of PAK#1 was observed with 50nM after 48 
and 72 hours incubation (Figure 3.6c). Changes in oligo concentration (25 and 100mM) 
did not show a knockdown (data not shown). Additional siRNA oligos (PAK1#2 and 
PAK1#3) were ordered and two oligos showed a consistent depletion of PAM 48 hours 
post-transfection using a concentration of 50nM oligo, which was more efficient than 
using 25nM or 100nM (Figure 3.6d and 3.6e). 
The above RNA interfering (RNAi) conditions were previously set-up in the lab 
using keratinocytes cultured in the absence of calcium, which are not able to form E- 
cadherin junctions (Watt et al., 1984; Green et al., 1987; O'Keefe et al., 1987). For 
purpose of this work (disassemble mature E-cadherin junctions), the experiments 
ideally should be performed in cells grown in standard calcium (1.8mM calcium). 
Hence, PAK1#1-mediated knockdown was re-optimised in standard calcium cells. 
Several attempts were made to knockdown PAK1 after 24,48 and 72 hours post- 
transfection at a concentration of 50nM. However, no consistent result was produced. 
Possible explanations are: (i) lower transfection efficiency in keratinocytes containing 
cell-cell contacts and (ii) higher levels of proliferation observed in standard medium. 
The latter meant that cultures were confluent within four days, with the complication 
of stratification that prevent appropriate visualisation by immunofluorescence. 
To overcome this problem, siRNA was performed in keratinocytes cultured in 
low calcium medium and cell-cell contacts were induced prior to expression of Arf6467f- 
or Raca61L. Within fifteen minutes after adding calcium to physiological conditions, 
keratinocytes form complete adherens-like junctions (O`Keefe et al., 1987). However, 
care should be taken to minimise stratification of the keratinocytes that normally starts 
four to six hours post-induction of cell-cell contacts (Magee et al., 1987). 
As control, it is important to determine whether PAK1 depletion interferes with 
E-cadherin protein levels or junction formation. As shown in Figure 3.6f, no obvious 
effect on the levels of E-cadherin or actin were detected by Western blots after siRNA 
with PAK1-specific oligos. Moreover, no changes in the formation of 
E-cadherin 
junctions were observed upon PAK1 siRNA treatment compared to the non-targeting 
control (Figure 3.6g). Typically, no E-cadherin junctions were 
formed in the absence of 
calcium (time is 0) and complete junctions were observed 
30 and 60 minutes after 
addition of calcium ions to physiological 
levels in all siRNA-treated cells (Figure 3.6g). 
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In summary, of the class I PAK family members only PAK1 is expressed in 
keratinocytes (Figure 3.6a) and specific knockdown conditions for PAK1 were 
optimised. This technique will be used to further investigate junction destabilisation 
by Arf6Q671- and Rac461L in the absence of endogenous PAK1. 
3.2.6 PAK1 is specifically required for dominant-active Rac, but not for Arf6, to 
induce cell-cell contact dissociation 
After optimisation of the PAK1 siRNA conditions, the ability of constitutively 
active Rac to perturb E-cadherin junctions in PAK1-depleted cells was tested. 
Expression of flag-tagged Rac461- in low calcium keratinocytes was substantially lower 
in comparison to standard calcium cells. A concentration of 0.5µg/µl DNA and 
expression time of seven hours was optimised in order to observe sufficient cell-cell 
contact disruption in low calcium culture. To ascertain knockdown in each 
experiment, samples treated in parallel were checked by subjection to Western blotting. 
Figure 3.7a shows that Rac461L could not perturb adherens junctions in PAKT 
knockdown cells (arrowheads) as potent as in control cells (arrows). In PAK1-depleted 
cells, apparent more E-cadherin staining along junctions was observed in between two 
Rac461L-expressing cells. Quantifications of these results was performed as described 
above, and showed that in control cells the ratio of E-cadherin staining over junction 
length was averaged at 27%. In contrast, a value of 61%, 61% and 63% was calculated 
for cells treated with PAK1#1, PAK1#2 and PAK1#3 oligos, respectively (Figure 3.7b). 
These values were significantly different from control cells (p<0.04, p<0.04 and p<0.03 
respectively). 
To assess disruption by dominant-active Arf6, Arf6a67L was injected at 0.5µg/µl 
and expressed for six hours in low calcium keratinocytes opposed to three hours in 
standard cultured cells. Under these conditions, about 29% of intact E-cadherin 
junctions were observed (Figure 3.8a, control). Following PAKT siRNA, Arf6a67L 
disrupted E-cadherin-based cell-cell contacts as efficiently as control cells (Figure 3.8a). 
In PAK1#2-treated cells 24% of junctions remained intact, which was comparable to 
levels observed in PAK1#3-treated cells (25%; Figure 3.8b). 
Taken together, constitutive activation of Rac disrupted cell-cell contacts less 
efficiently in cells depleted of endogenous PAKT (Figure 3.7). This result is supported 
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Figure 3.6: Optimisation of PAK1 siRNA. 
(a) RT-PCR analysis of PAK1, PAK2 and PAK3 expression in keratinocytes and monocytes. (b) 
Optimisation of PAK1 antibody for Western blotting with keratinocyte lysates. (c) Knockdown in 
keratinocytes grown in low calcium medium tested with 50nM PAK1#1 and non-targeting oligos (control), 
lysed at 24,48 or 72 hours post-transfection and loaded on SDS-PAGE. (d) Transfection of 25,50 or 100nM 
of PAK1#2 or (e) PAK1#3 oligos followed by Western blot analysis 48 hours post-transfection. (f) Protein 
levels of actin and E-cadherin in cells treated with PAK1#1, PAKT#2 and PAK1#3 oligos. (g) Comparison of 
induction of cell-cell contacts by addition of calcium to physiological levels in PAK1#2, PAK1#3 and control 
treated cells. Scale bar = 50µm. n>2. 
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by the experiments showing a blockage of RacQ61L-driven junction perturbation by 
dominant-negative PAK constructs (Lozano et at., 2008). Furthermore, PAK1 siRNA 
did not influence the ability of Arf6 to disrupt adherens junctions (Figure 3.8), 
consistent with inhibition of endogenous PAK with a dominant-negative approach 
(PAKAID; Figure 3.5). Although Arf6Q67L requires Rac signalling during junction 
destabilisation (Figure 3.3), PAK1 is not necessary downstream of constitutively active 
Arf6. The data indicate that different molecular mechanisms are induced by 
constitutive activation of Rac or Arf6 to perturb cadherin junctions. 
3.2.7 PAK disturbs the stability of mature E-cadherin cell-cell contacts 
Because RacQ6IL requires PAK1 signalling to disrupt E-cadherin junctions, I 
investigated whether activation of PAK1 by itself was also able to induce this 
phenotype. For this, a kinase-active mutant of PAK1 (PAKT423E) was expressed in 
keratinocytes. Expression time of PAKT423E was set on 18 hours as no expression was 
found at earlier time-points (data not shown). Compared to non-injected control cells 
(Figure 3.9a, zoom top, arrowhead), PAKT423E could slightly affect E-cadherin junction 
stability as E-cadherin staining was observed as a punctate, non-continuous between 
two expressing cells (Figure 3.9a, PAKT423E zoom bottom, arrow). Moreover, the 
pattern of junction disruption induced by Rac461L and PAKT423E was very different 
(compare E-cadherin staining of Rac461L- and PAKT423E-expressing cells). Quantification 
of these injections was performed by counting the number of loosened junctions in 
between two PAKT423E-expressing cells. The described effect of PAKT423E on junctions 
was seen in 71% of the injected cells (Figure 3.9b). 
Thus, PAKT423E can affect stable E-cadherin junctions but it did not reproduce 
the pattern on E-cadherin cell-cell contacts induced by constitutively active Rac. 
Moreover, longer expression of active PAK1 was necessary to induce this phenotype. 
The different kinetics and pattern induced by PAK1 activation suggests that additional 
signalling pathways activated by Rac461L may cooperate with PAK1 to induce the 
typical RacQ61L-disruptive pattern of cell-cell contacts (Figure 3.1a and 3.9a). 
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Figure 3.7: PAK1 siRNA cells prevent dominant-active Rac to disrupt junctions. 
(a) After 40 hours post-transfection of PAM-specific (PAK#1, PAK#2 and PAK#3) and non- 
targeting oligos (control) in keratinocytes, E-cadherin-mediated cell-cell contacts were induced 
and cells were microinjected with 0.5µg/pl RacQ61L. After seven hours expression, cells were 
fixed and stained for the flag-tag and E-cadherin. Arrows point to severely perturbed E- 
cadherin junctions, whereas arrowheads indicate partially rescued junctions. Scale bar = 50µm. 
(b) Quantification of cell-cell contact disruption. The length of E-cadherin staining and 
junctions (corner to corner) were measured with ImageJ and the ratio calculated (cadherin 
staining/junction length). *, p<0.04; *'; p<0.04; ***, p<0.03. Error bars are S. E. M. n=3. 
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Figure 3.8: junction perturbation driven by Arf6Q67- is not affected by PAK1 
depletion. 
(a) PAK1#2, PAK1#3 and control oligos were transfected into keratinocytes and 
incubated for 40 hours. E-cadherin-mediated junctions were induced and cells 
were injected with Arf6Q6'L and expressed for six hours before fixing and staining. 
Arrowheads point to disrupted E-cadherin cell-cell contacts. Scale bar = 50µm. 
(b) The percentage of cells with intact junctions was quantified for each condition. 
Error bars represent S. E. M. n=3. 
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Figure 3.9: Constitutive activation of PAK disturbs the stability of E-cadherin 
junctions. 
(a) Expression of activated Rac (RacQ61L) was performed for six hours and an 
active PAK mutant (PAKT423E) for 18 hours, and cells were immunolabelled for 
E-cadherin and flag- or myc-tag. Zoomed images show a detailed view of 
junctional staining in control cells (top) or PAKT423E-expressing cells (bottom). 
Arrow points to disturbed stability of E-cadherin junctions, arrowheads 
indicate stable cell-cell contacts. Note the distinct pattern of junction disruption 
induced by RacQ6"- and PAKT423E. Scale bar = 50µm, scale bar zoom = 325µm. 
(b) Quantification of the proportion of PAKT423E-expressing keratinocytes with 
clear disturbed cadherin staining. Error bar is S. E. M. n=4. 
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3.3 Conclusion 
In this chapter E-cadherin-mediated cell-cell contact disassembly induced by 
constitutively active Arf6 and Rac were compared. Arf6Q67L, as well as the fast cycling 
variant Arf6T157A, disrupted adherens junctions that was accompanied by accumulation 
of E-cadherin receptors intracellularly. Such pattern of junction disruption was not 
observed with Rac461L over-expression where only a partial loss of E-cadherin staining 
along cell-cell contacts was observed. Though Arf6Q67t- needed active Rac signalling to 
disrupt junctions, the discrepancy in the pattern could he in the ability of Arf6Q67L to 
activate additional pathways than RacQ61L can. This is supported with data showing 
that PAKT is essential during Raca61L-induced adherens junction disassembly, but not 
downstream of Arf6Q67Linduced cell-cell dissociation. siRNA experiments for PAK1 
were set-up and the role of PAKT signalling during RacQ611-- but not Arf6Q67--induced 
junction destabilisation was confirmed using this tool. 
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3.4 Discussion 
3.4.1 Participation of Rac signalling during junction disassembly driven by Arf6Q67L 
Arf6 can clearly activate Rac in different cell types to promote actin 
reorganisation at the plasma membrane (Franco et al., 1999; Brown et al., 2001) and cell 
motility (Santy and Casanova, 2001). While activation of Rac by Arf6 is well- 
established, the role of Rac in junction disruption is controversial. Arf6Q67Linduces Rac 
activation in keratinocytes (Figure 3.4c) and Rac signalling is required to induce 
junction disassembly (Figure 3.3). In contrast, in MDCK cells Arf6 activation (via 
HGF/SF or v-Src) requires Rac inactivation to disrupt cell-cell contacts (Palacios et al., 
2002). Inhibition of Rac function by Arf6 is indirect via activation of Nm23-H1 
(Palacios et al., 2002). Nm23-H1 is a nucleoside diphosphate kinase involved in 
dynamin-mediated endocytosis and can bind the Rac GEF Tiam1. Activation of Nm23- 
H1 sequesters Tiam1 protein by direct association, thereby reducing the amount of 
GTP-Rac in the cell (Otsuki et al., 2001). To initially facilitate cell-cell contact 
dissociation, Arf6 activates Nm23-H1, which in turn sequesters Tiam1 and inactivates 
Rac. Subsequently, Rac activation is important to promote cell migration (Palacios et 
al., 2002,2003). 
An explanation for the discrepancy regarding the role of Rac in cell-cell contact 
disruption in MDCK cells and keratinocytes might be the various pathways that are 
activated by the different stimuli used to drive junction disassembly, i. e. the addition of 
HGF/SF or over-expression of v-Src and Arf6Q67L. Another explanation could be the 
possibility of cell-type specific regulatory mechanisms in keratinocytes and MDCK 
cells, which have been shown in the context of Rac signalling and junction stability. 
Inactivation of Rac induces destabilisation of E-cadherin junctions in immortalised 
MDCK cells (Hordijk et al., 1997; Sander et al., 1999; Zondag et al., 2000; Kamei et al., 
1999). In contrast, similar results are obtained by sustained Rac activation in normal, 
non-transformed keratinocytes (Braga et al., 2000b; Akthar and Hotchin, 2001). 
Potential mechanisms will be further explored in chapter 5 and 6 to shed light on to 
how Arf6 and Rac promote adherens junction disassembly in keratinocytes. 
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3.4.2 Depletion mechanisms of E-cadherin receptors from the cell surface by Arf6Q67L, 
Arf6T157A and RacQ61L 
The pattern of adherens junction disruption by inappropriate activation of Arf6 
or Rac is very distinct. Expression of Arf6a67- and Arf6T157A induce rapid cell-cell 
junction disruption accompanied by complete loss of E-cadherin staining at sites of 
cell-cell contacts, clear intracellular accumulation of E-cadherin receptors and 
rounding-up of keratinocytes (Figure 3.1a and 3.2). In contrast, RacQ61- induces loss of 
E-cadherin junctions with slower kinetics that initiates from the corners between two 
over-expressing cells (Figure 3.1a). 
Palacios and colleagues (2001,2005) demonstrated that Arf6 induces junction 
disassembly in MDCK cells by increased endocytosis of E-cadherin receptors. During 
RacQ61L-driven E-cadherin receptor internalisation in keratinocytes, it has been shown 
that the receptors accumulate in enlarged Rab5-positive endocytic vesicles (Akthar and 
Hotchin, 2001). In support of this data, co-localisation of RacQ61L and E-cadherin is 
observed in small vesicular structures during adherens junction perturbation in normal 
keratinocytes (E. Lozano, unpublished data). Endocytosis of many transmembrane 
receptors including E-cadherin occurs in homeostasis and is believed to have a 
regulatory role (see section 1.2.3). Recycling of E-cadherin can contribute to 
remodelling of cadherin junctions and lysosomal degradation together with delivery of 
newly synthesised receptors to renewal of adherens junctions (Bryant and Stow, 2004). 
However, increased internalisation of E-cadherin by activated Arf6 and Rac suggests 
that depletion of E-cadherin receptors from the cell surface occurs in order to induce 
cell-cell dissociation. 
The fate of these receptors by activation of both GTPases might be differently 
regulated, depending on whether Arf6 or Rac are activated. The intracellular E- 
cadherin accumulation at a perinuclear region upon Arf6Q67L over-expression (Figure 
3.1a) suggests that these receptors are targeted to a lysosomal compartment destined 
for degradation. This has previously been described during adherens junction 
disassembly in MDCK cells induced by v-Src-mediated tyrosine phosphorylation of E- 
cadherin and its binding proteins through downstream activation of Arf6 (Palacios et 
al., 2005). In addition, tyrosine phosphorylation of the E-cadherin complex by growth 
factor receptors induces the recruitment of the E3-ubiquitin ligase Hakai. As a result 
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the E-cadherin complex is then ubiquinated, internalised and sorted into lysosomes for 
protein degradation (Fujita et al., 2002). Whether keratinocyte junction disruption 
induced by Arf6Q67L and Arf6T157A also result in the degradation of E-cadherin in 
lysosomes via the proteasome pathway remains to be investigated. 
No such intracellular E-cadherin accumulation as for Arf6Q671- or Arf6T157A was 
observed in RacQ61L-expressing cells (Figure 3. la and 3.2). A potential reason for this 
difference is the rapid and complete junction disruption observed by Arf6Q67- or 
Arf6T157A over-expression, compared to the slower disruption induced by Rac461L. In 
the case of constitutive active Arf6 during the process of junction break-down, 
cadherins might accumulate as a consequence of the large amount of receptors 
delivered in a short period. The removal of E-cadherin from the cell surface in RacQ61L- 
over-expressing cells is clearly less rapid, which might allow more efficient 
degradation of these receptors without intracellular accumulation. Whether RacQ61L 
internalises E-cadherin receptors and transport them to the proteosomal machinery, 
but at a slower rate than Arf6Q671-, can be clarified experimentally. 
However, RacQ61L could have a different mechanism to downregulate E- 
cadherin-receptors than Arf6a67L/Arf6T157A. Further characterisation of the RacQ61L- 
induced vesicles by Akthar and Hotchin (2001) revealed that these vesicles positive for 
E-cadherin-catenin complex proteins are not labelled with markers for late endosomes 
or lysosomes. This suggests that E-cadherin molecules are maintained in endosomal 
structures, but are prevented from targeting back to the plasma membrane. In support 
of this possibility, preliminary observations in our laboratory shows that active Rac 
accelerates E-cadherin internalisation from the membrane and could delay its recycling 
(K. Smolarczyk, unpublished observations). 
3.4.3 Potential roles of PAK1 during E-cadherin-mediated junction destabilisation 
Our data suggest that constitutively activated Rac and Arf6 can signal through 
different pathways to induce a similar outcome i. e. E-cadherin-mediated cell-cell 
contact disassembly. This interpretation is supported by (i) the distinct patterns of 
junction disruption induced by RacQ61L and Arf6Q67L (Figure 3.1) and (ii) requirement of 
Rac (Figures 3.3 and 3.4) but not PAK1 signalling (Figure 3.5) for Arf6-induced 
junction destabilisation. 
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Based on previous reported functions of PAK, we envisage that PAK may 
contribute to junction disassembly on the following processes: (i) serine/threonine 
phosphorylation of the E-cadherin-catenin complex, (ii) E-cadherin transcriptional 
repression via Snail or (iii) increased E-cadherin endocytosis. 
The functional integrity of adherens junctions is regulated via phosphorylation 
events on the E-cadherin/catenin complex (Gumbiner, 2005; see section 1.3). Many 
reports describe tyrosine phosphorylation events that cause increased internalisation of 
adherens junction components followed by cell-cell dissociation. However, serine or 
threonine phosphorylation can also destabilise E-cadherin complexes. Prevention of 
the serine phosphorylation sites on the E-cadherin tail region that mediates binding to 
ß-catenin results in reduced cell-cell adhesion (Stappert and Kamler, 1994). Casein 
kinase I (CK1), CK2 and protein kinase D1 (PLD1) are all serine/threonine kinases that 
can phosphorylate the E-cadherin cytoplasmic tail directly (Dupre-Crochet et al., 2007; 
Lickert et al., 2000; Jaggi et al., 2005). In addition, serine/threonine phosphorylation 
occurs especially on p120 and (3-catenin (Alemä and Salvator, 2007; Brembeck et al., 
2006). Phosphorylation events by these kinases can either positively or negatively 
regulate the stability of cell-cell contacts. 
Interestingly, PAK1 has been shown to phosphorylate serine or threonine 
residues on proteins that associate with adherens junctions. For example, 
phosphorylation of filamin A that probably regulates cross-linking of actin at sites of 
vascular endothelial cell-cell junctions (Feng et al., 2006), phosphorylation of LIM 
kinase (LIMK) that controls adherens junction dynamics in Sertoli-germ cells in the 
testis (Lui et al., 2003) and phosphorylation of myosin VI that plays a role in maturation 
of cell-cell junctions via the a-catenin-binding protein vinculin (Breshears and Titus, 
2007). It would be interesting to investigate whether PAK1-mediated serine/threonine 
phosphorylation of one of these proteins and/or of components of the E-cadherin- 
catenin complex could signal to induce internalisation. 
Alternatively, it is possible that Rac461L via PAK1 could affect E-cadherin 
transcription regulation via Snail. The transcription factor Snail has been found to 
repress E-cadherin gene expression by binding directly to regions in the E-cadherin 
promoter (Battle et al., 2000). A correlation between increased Snail expression and 
reduction of E-cadherin proteins in different epithelial tumour cell lines and tumours 
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has been detected (Cheng et al., 2001; Blanco et al., 2002; Battle et al., 2000). 
Phosphorylation events on Snail can trigger export and subsequent activity in the 
nucleus (Dominguez et al., 2003), which is found to occur by PAK1 in MCF-7 cells 
(Yang et al., 2005b). Thus, Rac might induce signalling via PAK1 activation, Snail 
phosphorylation and subsequent repression of E-cadherin protein transcription during 
junction disassembly. Whether this event occurs during keratinocyte junction 
disruption by expression of RacQ61- remains to be determined. 
RacQ61L-induced cell-cell contact dissociation is accompanied by increased 
endocytosis of E-cadherin receptors (Akthar and Hotchin, 2001; E. Lozano, 
unpublished observations). PAK plays a regulatory role in the process of normal 
growth factor-induced macropinocytosis, a process that involves its kinase activity and 
cytoskeletal rearrangements (Dharmawardhane et al., 2000). In addition, 
phosphorylation of PAK on myosin VI on serine 371 stimulates membrane endocytosis 
(Yamashita and May, 1998). Therefore, PAK1 could cooperate with RacQ61L in E- 
cadherin internalisation. 
Rac signalling is required during oncogenic Ras-induced keratinocyte junction 
disassembly (Braga et al., 2000b) and PAK signalling has been shown to be essential 
downstream of Ras-induced transformation of Rat-1 fibroblasts (Tang et al., 1997). It 
would be interesting to implicate PAK1 signalling downstream of Ras transformation 
in keratinocytes as well and to identify more components of this pathway resulting in 
disruption of E-cadherin-mediated junctions. 
PAK activation via expression of its constitutively active kinase domain 
(PAKT423E) was not able to disrupt adherens junctions in a similar pattern as RacQ61L 
(Figure 3.9). The differences observed by PAKT423E and RacQ61- over-expression 
suggests that besides PAK1 activation, other signalling events stimulated by Rac might 
be important to induce the Rac-specific phenotype. Experiments performed in our 
laboratory exclude that Rac-dependent E-cadherin junction destabilisation occurs by 
lamellae protrusion (Braga et al., 2000b) or increased contractility via ROCK (Lozano et 
al., 2008). Moreover, the Rac1 effector molecules JNK1 and CrkII are also not involved 
during this event (Lozano et al., 2008). It remains to be determined which other 
downstream effectors of Rac might be involved during junction perturbation. 
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3.5 Future experiments 
3.5.1 RacQ61L-induced breakdown of adherens junctions 
Constitutive activation of Rac induces junction destabilisation in keratinocytes 
whereby E-cadherin receptors are internalised via endocytic vesicles that do not 
contain markers of late endosomal or lysosomal compartments (E. Lozano, 
unpublished data; Akthar and Hotchin, 2001). It will be interesting to investigate 
whether RacQ61L downregulates keratinocyte junctions by modulating the trafficking 
route of E-cadherin. 
Firstly, Rac may modulate E-cadherin transport by preventing recycling and 
maintaining the receptors in endosomes (Le et al., 1999). Following RacQ61- expression, 
internalisation and recycling rate of biotinylated cell surface receptors will be 
investigated over a time-course. 
Secondly, upon longer incubation time after RacQ61L expression, E-cadherin may 
eventually be targeted to lysosomes for digestion. During v-Src-induced junction 
disassembly in MDCK cells, the degradation of E-cadherin has previously been 
demonstrated to require the ubiquitin-proteasome pathway for Rac downregulation 
(Palacios et al., 2005; Fujita et al., 2002). Whether this degradation pathway is also 
activated in keratinocytes following over-expression of Raca61- merits further 
investigation. After a similar biotinylation procedure as described above, 
ubiquitination of the recovered E-cadherin will be determined using anti-ubiquitin 
antibodies on Western blots. In addition, degradation of E-cadherin receptors will be 
investigated using E-cadherin-specific antibodies on Western blots. 
Because the transfection efficiency of plasmids in primary keratinocytes is 
currently only about 30%, higher transfection efficiency for above suggested 
experiments is desirable and could be obtained using RacQ611- fused to a TAT sequence. 
Cell permeability is close to 100% for the protein transduction domain of the HIV 
(human immunodeficiency virus) transactivator protein, called TAT (Frankel et al., 
1988; Mann and Frankel, 1991; Gustafsson et al., 2005). Treatment of keratinocytes with 
TAT-RacQ61L essentially mimics the destabilisation of cell-cell adhesion observed 
by 
transfection or microinjection of activated Rac. 
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3.5.2 Potential mechanisms of PAK1 to mediate Rac-induced junction perturbation 
Constitutive activation of PAK1 by itself can disturb the stability of cell-cell 
junctions, although not as potently as Rac461L per se can. It may be possible that Rac461L 
induces PAK1-mediated serine/threonine phosphorylation on junctional proteins and 
as a result disassemble keratinocyte junctions. The ability of constitutively activated 
PAK1 to phosphorylate E-cadherin and catenins has not yet been tested and will first 
be determined in vitro. Once substrates have been identified, non-phosphorylatable 
mutant proteins can be tested for their ability to block Rac-induced dissociation of cell- 
cell contacts. Alternatively, in case that none of the cadherin-catenin complex proteins 
are PAK1 targets, other PAM-substrates known to associate with E-cadherin junctions 
like filamin A (Feng et al., 2006), myosin VI (Breshears and Titus, 2007) and LIMK (Lui 
et al., 2003) could be tested for their participation during Rac-mediated junction 
disassembly. 
Co-localisation studies will show whether wild-type or endogenous PAK1 is 
also present on endosomal structures containing E-cadherin when Rac461L is over- 
expressed. Interestingly, it may be possible that PAK1 regulates increased turnover of 
E-cadherin receptors upon RacQ61L expression by phosphorylating proteins that can 
rearrange actin filaments necessary for endosomes. Both myosin VI and Eilamin A 
comprise actin-motor activity properties and have been shown to participate in 
endocytosis (Yamashita and May, 1998; Swiatecka-Urban, 2004; Liu et al., 1997). Co- 
microinjection experiments of RacQ61-- and dominant-negative forms of myosin VI 
(Swiatecka-Urban, 2004) and filamin A (Lin et al., 2002) that are unable to interact with 
actin, could reveal participation of these PAK1-targets in the trafficking of E-cadherin 
upon adherens junction disruption. Alternatively, a siRNA approach could 
demonstrate the participation of these target proteins during keratinocyte junction 
disruption driven by over-expression of constitutively active Rac. 
A mechanism for Rac461L to interfere with de novo formation of E-cadherin 
receptors could be phosphorylation of Snail by PAK (Battle et al., 2000; Dominquez et 
al., 2003). Phosphorylation-specific Snail antibodies will verify whether PAK 
phosphorylates and activates Snail in cells expressing RacQ61L. Snail activation will be 
determined by a shift of Snail immunostaining towards the nucleus compared to 
control cells (Yang et al., 2005b). Moreover, analysis of E-cadherin mRNA levels by 
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Northern blotting will further indicate whether Raca61L modulates the transcription of 
E-cadherin gene. 
3.5.3 Involvement of other Rac effectors downstream of cell-cell contact dissociation 
Although participation of JNK1, CrkII and ROCK during RacQ61L-induced 
keratinocyte junction disassembly has previously been excluded (Lozano et al., 2008), it 
will be worth testing a potential role of IQGAP. IQGAP has been implicated in 
deregulating E-cadherin-mediated cell-cell contacts by direct interaction with ß-catenin 
and a region in the E-cadherin tail that overlaps with the a-catenin binding site (Li et 
al., 1999b; Kuroda et al., 1996,1998). Inhibiting IQGAP signalling by siRNA and 
expression of RacQ61L will show participation of IQGAP during cell-cell junction 
destabilisation. Furthermore, co-expression of an IQGAP mutant unable to interact 
with active Rac (to rule out direct binding and titration) will be tested for its essential 
signalling during Rac-induced junction perturbation. Expression of IQGAP alone will 
demonstrate whether this protein is sufficient to disrupt adherens junctions in 
keratinocytes. If only a partial effect will be observed, co-expression of activated PAK1 
with IQGAP will show whether these proteins cooperate to induce a greater effect on 
keratinocyte junction stability. 
3.5.4 Breakdown of E-cadherin during Arf6-induced junction disruption 
It would be interesting to investigate whether ubiquitination of E-cadherin 
occurs following Arf6Q67- over-expression in keratinocytes. This will provide insights 
into trafficking of E-cadherin and the identity of the compartment in which receptors 
accumulate. LTbiquitination of E-cadherin receptors will be assessed 
by studying the 
involvement of Hakai (Fujita et al., 2002) and Hrs (Palacios et al., 2005). 
The E3 
ubiquitin-ligase Hakai has been identified in a complex with E-cadherin 
following v- 
Src activation (Fujita et al., 2002). Similar association between 
Hakai and cadherin 
following Arf6Q67L over-expression will be determined by co-immunoprecipitation and 
co-localisation. Further involvement of Hakai 
during Arf6-induced junction 
disassembly will be investigated by co-expressing a 
dominant-negative mutant of 
Hakai (HakaiC109A, Fujita et al., 2002). 
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Recent studies have shown that Hrs functions during v-Src-induced cell-cell 
dissociation by binding to ubiquitinated E-cadherin receptors and regulating its 
trafficking from endosomes to lysosomes (Palacios et al., 2005). Immunolabelling with 
Hrs will indicate whether E-cadherin internalisation induced by Arf6Q67- is 
accompanied by Hrs. Moreover, a Hrs mutant that lacks the ubiquitin-interacting 
motif (HrsS27OE) could show whether Hrs is essential for Arf6-induced keratinocyte 
junction disruption. 
Chapter 4 
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4.1 Introduction 
The function of the novel protein Armus is unknown, but its ability to bind to 
Rac and potentially being a RabGAP protein predicts that this protein may be a 
signalling molecule. In chapter 4 and 5, the cellular function of the novel protein 
Armus will be investigated. Insights into Armus function were provided by 
localisation studies and the ability of Armus to induce the perturbation of enlarged 
vesicles. First, the cellular distribution of different Armus truncation mutants (Figure 
4.1) is distinct. Armus mutant containing the predicted PH domain (Armus1_169) 
localised at the plasma membrane and at E-cadherin-based cell-cell contacts in 74% of 
expressing cells. Interestingly, the construct including the Armus TBC/RabGAP 
domain and coiled-coil (Armus547_928) was distributed throughout the cytosol and at 
adherens junctions in 38% of expressing cells. In contrast, an Armus mutant containing 
the PH domain and central coiled-coil domains (Armus, _sso) was not present at cell-cell 
junctions, but instead induced the formation of vesicluar structures (R. Francis, 
unpublished data). 
The identity of these vesicles is currently unknown. However, no overlap was 
observed between Armusl_550 vesicles and vesicles induced by the active form of Rab5 
(Roberts et al., 1999; Mc Bride et al., 1999), indicating that both proteins form 
independent vesicular populations. In addition, no localisation of Armus, _550-induced 
vesicles was observed with Transferrin, LAMP1 or CD63 (M. Finelli, unpublished 
data). A partial localisation of endogenous Rab11a and Rab25 in Armusl-55o-positive 
vesicles was observed previously and the activated form of Rab25 completely 
abolished vesicles formed by Armus, _55o. 
Together, these results suggest that Armus 
may play a role where Rab11 proteins function: at apical recycling endosomes 
(Casanova et al., 1999) or transport of molecules from the trans-Golgi network (TGN) 
towards the endosomal system or vice versa (Chen et al., 1998). 
The vesicular phenotype induced by the PH domain and central coiled-coils 
(Armus1_550) and the potential connection with Rabs via Armus TBC/RabGAP supports 
a putative involvement of Armus in vesicular trafficking. 
The mechanism of the 
formation of vesicles by Armus could lie in the potential 
dimerisation capability of the 
three predicted coiled-coil domains and the 
localisation at the plasma membrane 
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provided by Armus PH domain (Figure 4.1). This is supported by different reports 
showing that for many coiled-coil proteins that participate in cellular trafficking, their 
restricted intracellular distribution depends on a coiled-coil domain with or without an 
additional membrane associated domain (Gillingham and Munro, 2003). For example, 
the Snxl protein has three coiled-coil domains in its C-terminus and contains a Phox 
domain in its N-terminus that recognizes specific Ptdlns present in cell membranes. 
Zhong and co-workers (2002) showed that when Snxl is over-expressed, it localises to 
tubulo-vesiclar endosomal structures. Using a mutational approach, proper Snx1 
localisation was disrupted when either the Phox domain or the second coil domain was 
deleted. Other examples are the Golgi proteins Giantin, Golgin-84 and Syntaxin-5 that 
all consist of a similar protein topology. Although these proteins contain a C-terminal 
membrane-anchoring domain (CMD), only their coiled-coil domains were found to be 
essential for Golgi localisation (Misumi et al., 2000). 
There are two possibilities on how Armus may form dimers (Figure 4.2). Inter- 
molecular association could be achieved by interaction of coiled-coil domains of two 
different Armus proteins in a parallel or anti-parallel conformation. For example, the 
Rho effector ROCK consists of a parallel diner mediated by its coiled-coil domain 
(Yamaguchi et al., 2006). On the other hand, intra-molecular association could also 
occur. For example, by binding of a central coil to the C-terminal coil domain within a 
single Armus molecule. This latter potential configuration of Armus could constitute 
an auto-inhibition mechanism. Auto-inhibition is a potent regulatoE of protein activity 
by intra-molecular interaction of separable domains resulting in an inactive protein 
(Pufall and Graves, 2002). This mechanism of regulation is frequently found in Rho 
effectors such as PAK (Bokoch, 2003), WASP (Pufall and Graves, 2002) and mDia 
(Copeland et al., 2007). 
Identification of the vesicular structures induced by Armus N-terminal 
fragment (Armusl-550) will provide clues about the potential Rab substrate for the 
Armus TBC/RabGAP domain and will therefore be informative about Armus function. 
In this chapter, I will gain insight into the mechanism of vesicle 
formation induced by 
Armüsl_sso by studying: 
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1) The nature of the particular compartment induced by Armusl_55o by electron 
microscopy (EM). 
2) Localisation of exogenous and endogenous Armus in keratinocytes to verify 
whether full-length Armus is able to show a similar distribution pattern as observed 
with truncation mutants. 
3) A potential role for Rac and Arf6 in vesicle formation induced by Armus, _550. 
4) Evaluate the ability of the coiled-coil domains to interact with each other by 
expression studies (in vivo) and binding assays (in vitro). 
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Figure 4.1: Overview of Ariuus constructs. 
Outline of the different Armus construct used in this study. The amino 
acids stretching the shorter truncation mutants are indicated as subscript. 
PH, Pleckstrin Homology; C, coiled-coil; RabGAP, TBC/RabGAP domain. 
Figure 4.2: Dimerisation possibilities of Armus. 
Armus consists of three predicted coiled-coil domains, of which two lay adjacent to 
each other in the middle of the protein and one coiled-coil at the very end. The 
three coiled-coil domains on Armus could interact in an intra-molecular or inter- 
molecular fashion. Inter-molecular interaction can occur between two Armus 
proteins in a parallel or anti-parallel manner. Binding of different regions within 
one Armus molecule is called intra-molecular interaction and could for example 
occur with binding of the C-terminal coil domain to one of the central coil domains. 
PH, Pleckstrin Homology; C, coiled-coil; RabGAP, TBC/RabGAP domain. 
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4.2 Results 
4.2.1 Armus j. 550-induced vesicles are autophagosomes 
The formation of vesicles by an Armus-derived mutant containing the PH 
domain and central coiled-coils (Armus, _550) seems to 
initiate in the cytoplasm at 
random places, followed by targeting towards a perinuclear area. When longer 
expression time is allowed, large vesicles are observed around the nucleus suggesting 
that these vesicles are fusing together over time. No other changes in cell morphology 
like cell size and adherens junction stability were observed upon Armus, _sso expression 
(R. Francis, unpublished data). The observed pattern of vesicle formation suggests that 
vesicles induced by Armus, _sso are not a component of the secretory pathway 
for 
transport towards the plasma membrane. Instead, Armus, _sso-positive vesicles could 
be part of the secretory pathway in transport from the TGN to endosomes or vice 
versa, transport from cytoplasmic components to the lysosomes (autophagy) or 
trafficking in the endocytic pathway (Stehmark and Olkkonen, 2002; Van Vliet et al., 
2003). 
In collaboration with Dr. C. Futter (Institute of Ophthalmology, London), the 
abundant vesicles produced by the PH domain and central coiled-coils of Armus 
(Armusl-550) were visualised by EM in order to identify the type of vesicle that Armus, _ 
Ss induces. Keratinocytes were seeded on gridded coverslips and microinjected with 
Armus1550 followed by expression for three hours. Injected and non-injected cells 
showed that the keratinocytes contained small vesicle-like structures which were quite 
dense in appearance (Figure 4.3a and 4.3b, arrows). However, enlarged vesicular 
compartments were observed in the injected cells which seem to contain MVBs, 
lysosomes and in some cases organelles (Figure 4.3b, asterisks). The findings are 
consistent with the appearance of autophagosomes (Ueno et al., 1991; Eskelinen 2005). 
4.2.2 Full-length Armus co-localises at E-cadherin-mediated cell-cell junctions and 
induces the formation of vesicles 
To explore whether full-length Armus also generates the distribution patterns 
observed with Armus truncation mutants, its intracellular localisation was analysed. 
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Figure 4.3: Armusl_550-dependent vesicles are autophagosomes. 
EM study of (a) non-injected and (b) Armus1_s5o-injected cells 
performed by Dr. C. Futter (Institute of Ophthalmology, London). 
Arrows point to small vesicle-like structures observed in injected 
and non-injected cells and asterisks indicate autophagosomes. 
Scale bar = 2µm. 
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Venus-tagged Armus was microinjected into keratinocytes, allowed to express and 
stained for E-cadherin. After three hours of expression, a proportion of cells showed 
Armus distribution in the cytoplasm and 62% co-localised with E-cadherin junctions 
(Figure 4.4a, 3hrs arrowheads). However, 22% of the cells induced a vesicular 
phenotype as observed previously with the shorter truncation mutant containing the 
PH domain and central coiled-coils (Armus, _sso; 
Figure 4.4a, 3h arrows). When 
keratinocytes were allowed to express Armus for five hours, a smaller number of cells 
showed co-localisation with E-cadherin staining at sites of cell-cell contacts, namely 
11% (Figure 4.4b). On the contrary, an increased percentage of the cells induced 
vesicle-like structures at this time-point, which were larger and localised in a 
perinuclear area (85%, Figure 4.4a, 5h arrow and Figure 4.4c). These results indicate 
that Armus formation of vesicles occurs with slower kinetics when compared to 
expression of the Armus-derived construct containing the PH domain and central 
coiled-coils (Armus, _sso)" 
Interestingly, there is an inverse correlation between junction 
localisation and vesicle formation. Yet, E-cadherin adhesion is not perturbed and 
cadherin receptors did not localise at Armus-induced vesicles. 
Endogenous Armus localisation was investigated in keratinocytes using a 
specific antibody raised against Armus that was characterised previously by Western 
blots (R. Francis, unpublished data). Endogenous Armus localised in the cytoplasm 
and distinctively along the cell membrane at sites of cell-cell contacts (Figure 4.4d, 
arrowheads). The observed Armus staining at cell-cell contacts and cytoplasm was 
specific as such staining could not be observed with the conjugate only (Figure 4.4d, 
conjugate). 
In conclusion, endogenous and full-length Armus localisation coincides with all 
shorter Armus truncation mutants: cell-cell contacts, vesicles and cytoplasm. These 
results indicated that no spurious localisation was observed due to the use of 
truncation mutants. However, endogenous Armus was not detected at vesicular 
structures, indicating that formation of large vesicles by exogenous full-length Armus 
and the smaller Armus construct containing the PH and two central coiled-coil 
domains (Armus, 
_sso) might 
be due to over-expression of these constructs and its 
j 
y, 
Q 
consequence to vesicular trafficking. 
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Figure 4.4: Armus distribution in keratinocytes. 
(a) Venus-tagged Armus was microinjected in keratinocytes, expressed for three or five hours, 
fixed and permeabilised followed by immunostaining for E-cadherin. Images were taken on a 
confocal microscope and the panels at the bottom show a merge of the two fluorescence images 
above. Coincident staining appears yellow in the merge image. Arrows point to Armus- 
positive vesicular structures and arrowheads show co-localisation of Armus with E-cadherin 
junctions. Scale bar =16µm. (b) Quantification of the proportion of Armus over-expressing cells 
co-localising with E-cadherin or (c) the proportion of cells with a vesicular phenotype. Data is 
the mean of three individual experiments ± S. E. M. *, p<0.06 and **, p<0.006. (d) Keratinocytes 
staining of endogenous E-cadherin and Armus. Third panel shows a merged image. Conjugate 
indicates staining using only the secondary antibody used to detect Armus. Arrowheads point 
to co-localisation of Armus with E-cadherin. Scale bar =16µm. 
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4.2.3 Active Rac blocks vesicle formation driven by Armusl_550 
Rac binding to the central coiled-coil domains of Armus may influence Armus 
function and be involved in the formation of autophagosomes. Rac has not been 
implicated in autophagosome formation, but it was shown to be involved in endocytic 
trafficking (Qualmann and Mellor, 2003). Hence, I decided to test the influence of 
dominant-active Rac (Rac461L) on the formation of vesicles induced by Armus N- 
terminus Armus, 
_sso" 
Active Rac localised in the cytoplasm and at E-cadherin junctions; 
the latter were already slightly affected at this time point as shown before (Lozano et 
al., 2008; Figure 4.5, RacQ61L arrowhead). Interestingly, Armus1_550was not able to form 
vesicles in the presence of active Rac (Figure 4.5, Armus, _sso + 
Rac461L). Moreover, 
when Armus, _sso and 
Rac461L were co-expressed, less E-cadherin junction disruption 
was observed. This may suggest that active Rac was titrated out by binding to the 
central coiled-coil domains present in Armus, _550. 
Vesicle formation by Armusl_sso in the 
presence of active Rac was quantified from three independent microinjection 
experiments as described previously (Figure 4.5b). 
If Rac activation is essential for Armus to induce vesicles, then over-expression 
of dominant-negative Rac (RacT"I`1) may interfere with this phenotype. Rac-GDP 
cannot interact with Armus (R. Francis, unpublished data) and therefore RacT17N should 
not disturb vesicle formation induced by Armus PH and central coiled-coil domains 
(Armusl-550) by direct binding. RacTl'I`1 showed a cytoplasmic distribution when 
expressed in keratinocytes (Figure 4.5a, RacT11`l). When Armusl-550 was co-expressed 
with dominant-negative Rac, vesicles were still observed (Figure 4.5a, Armusl_550 + 
RacT"N arrow). Taken together, these results showed that active Rac prevents 
formation of vesicles induced by the PH and central coiled-coil domains of Armus 
(Armusl-550) but not inactive Rac (Figure 4.5b). However, the data cannot distinguish 
whether this effect is due to in vivo binding of active Rac to Armusl-55o, hereby titrating 
it out. In addition, a potential caveat is that the expression levels of dominant-negative 
Rac may not be enough to block a potential activation of endogenous Rac. 
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Figure 4.5: Expression of active Rac interferes with Armusl_55o-driven vesicle 
formation, but not dominant-inactive Rac. 
(a) Analysis of vesicle formation by Armusl_550 when co-expressed with RacQIlL 
and RacTl'^'. After three hours expression time, keratinocytes were fixed and 
immunolabelled for the indicated tags and E-cadherin. Arrowheads point to 
vesicular structures, arrow to perturbed E-cadherin junctions. Scale bar = 
50µm.. (b) Quantification of the proportion of cells containing 0,1-20 or >20 
vesicles. Error bars represent the S. E. M. n=3. 
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4.2.4 Arf6 is not involved in the formation of vesicles by Armusl_sso 
Arf6 has a well-established function in the formation of vesicles at the plasma 
membrane (D'Souza-Schorey and Chavrier, 2006). A possible involvement of Arf6 on 
formation of vesicular structures by Armus N-terminal fragment (Armusl_550) was 
tested. Optimal co-expression of different plasmids was found at a concentration of 
0.025µg/µl for active Arf6 (Arf6Q67L), 0.3µg/µl for inactive Arf6 (Arf6T27N) and 0.1µg/µl 
for Armus 1.550. As expected, expression of Armus 1.550 by itself induced vesicular 
structures while Arf6Q67Lby itself perturbed adherens junctions (Figure 4.6a). No 
changes were observed in these two different phenotypes when the proteins were co- 
expressed: Armusl-550 formed vesicles and Arf6Q67L still rapidly disrupted adherens 
junctions (Figure 4.6a, Armus1550 + Arf6Q67-). Similarly, vesicle formation by Armus1_550 
did not change to a great extent when Arf6 activation was inhibited (Figures 4.6a and 
4.6b, Armusl-550 + Arf6 T27N). Quantification of these results illustrates that Arf6Q67L or 
Arf6T27Ndid not alter the amount of vesicular structures formed by Armusl-550 (Figure 
4.6b). All together, these results indicate that (i) Armus l-550 over-expression does not 
block Arf6-induced junction disassembly, and (ii) vesicle formation by Armus1.550 is 
independent of Arf6 function. 
4.2.5 In vivo interaction of Armus mutants 
Both full-length Armus and the Armus-derived construct including the PH 
domain and central coiled-coils (Armusl_sso) are able to form vesicular structures. The 
fact that expression of Armus, _55o 
induces these vesicles without the C-terminal 
TBC/RabGAP can be explained as (i) Armus, _sso might 
interact with endogenous 
Armus in vivo and therefore mimics the phenotype induced by full-length Armus, or 
(ii) the predicted central coiled-coils and PH domain present on Armus, _sso 
(and 
Armus) could be sufficient to induce vesicular structures, by sequestering regulators in 
a dominant-negative fashion. To address whether dimerisation may play a role in 
formation of vesicles, I tested whether different Armus fragments were able to affect 
vesicle formation by Armusl_550. The mechanism of vesicle formation was explored 
in 
vivo by co-expression followed by quantification of vesicle formation. Additionally, co- 
localisation of Armus1.55o and Armus truncation mutants was determined to 
investigate 
a potential direct association. 
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Figure 4.6: Arf6 signalling does not interfere with Armusl_55o-dependent vesicle 
formation. 
(a) The ability of Armusl_sso to induce vesicle formation in the presence of 
dominant-active Arf6 (Arf6Q67L; 0.025µg/µ1) and inactive Arf6 (Arf6T27N; 0.3µg/µ1). 
Arrowheads point to vesicular structures, arrows to perturbed E-cadherin 
junctions. Scale bar = 50µm. (b) Percentage of expressing cells with 0,1-20 or >20 
vesicles. Error bars represent the S. E. M. of three independent experiments. 
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I determined whether Armus C-terminus fragment containing the 
TBC/RabGAP domain and last coiled-coil domain (ArmuS547-928) can interfere with 
vesicle formation induced by Armus N-terminal fragment (Armus 1.550; Figure 4.1). As 
expected, Armus 1550 per se induced vesicular structures and Armus547 928 was 
concentrated in the cytoplasm and at sites of cell-cell contacts (Figure 4.7a, Armus547-928 
arrow). Surprisingly, co-expression of Armus547-928 and Armus, -550 could not mimic 
the 
vesicular phenotype observed for full-length Armus (Figure 4.4a). Under these 
conditions, vesicle formation by Armus, -550 was efficiently 
inhibited and the two 
proteins co-localised in the cytoplasm (Figures 4.7a and 4.7c, Armusl_550 + Armus547.928)" 
These results suggest that Armus547-928 can interfere with Armusl-550-induced vesicles. 
As Armus C-terminal domain efficiently blocked vesicle formation by Armusl_ 
550, I mapped the relevant domains required for this effect. First, the role of the 
TBC/RabGAP domain was addressed. Co-expression of the TBC/RabGAP domain 
only , without the 
C-terminal coiled-coil domain (Armus55 -828; 
Figure 4.1) with Armus, 
550 abolished the formation of vesicular compartments (Figures 4.7a and 4.7c, Armus, _ 
550 + Armus551-828). Co-localisation of these proteins in the cytoplasm was observed 
similarly to Armusi-550 and Armus547_928 (arrow). Taken together, the results in Figure 
4.7a indicate that (i) association of the TBC/RabGAP domain of Armus may occur with 
the PH domain or central coiled-coils on Armusl_550, which could inhibit the formation 
of vesicles, or (ii) the construct encoding the PH and central coiled-coil domains 
(Armusi-550) cannot induce the formation of vesicles due to GAP activity of the 
TBC/RabGAP domain on Armus547 928 and Armus551.828. The latter possibility infers that 
inactivation of a specific Rab protein is essential for the induction of these vesicular 
structures. 
Second, the ability of the Armus C-terminal coiled-coil domain to interfere with 
vesicle formation induced by Armus, _sso was 
tested. An Armus mutant stretching 
amino acid 828 to 928 (Armus828_928; Figure 4.1) was generated using PCR and i is 
expression optimised at a concentration of 0.2µg/4l. This C-terminal coiled-coil 
domain (Armus828_928) by itself localised in the nucleus, together with some diffuse 
staining in the cytoplasm and at plasma membrane (Figure 4.7b, Armus828_928 arrow). 
When this mutant was co-expressed with Armus1550, the latter still induced vesicles 
albeit less potently (Figure 4.7b, Armusl-550 + Armus828_928). No 
localisation of Armus828_ 
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928 at Armus 155o-positive vesicles was observed, indicating that these mutant proteins 
did not associate in vivo (arrowhead). The partial inhibition effect observed in this 
experiment could be due to a slightly lower expression level of Armus, _sso 
in the 
presence of Armus828_928. On the other hand, the C-terminal coiled-coil domain may 
dimerise with and sequester endogenous Armus which latter could be required for 
Armusl_550 to induce vesicles. Together with this hypothesis, the detected localisation 
of the C-terminal coil domain (Armus828_928) at the plasma membrane was unexpected 
and may also be explained by interaction of this last coiled-coil with endogenous 
Armus that localises at the plasma membrane. ' 
Third, the role of the central coiled-coil domains was investigated (Figure 4.7). 
Expression of the central coiled-coil domains (Armus295-433) by itself showed a diffuse 
pattern over the cytoplasm and was not able to induce similar vesicle structures 
(Figure 4.7a, Armus295-433)" Although somewhat less potently, Armus, -550 was able to 
form vesicles in the presence of Armus295433 (Figure 4.7a, Armus, 
-550 
+ Armus295-433)" In 
many co-expressing cells, Armus295433 localisation on Armus, -55o-induced vesicles could 
be observed (arrowhead). Quantification of the number of vesicles per cell indicated 
that Armusl_55o-dependent induction of vesicles is slightly disturbed upon expression 
with Armus295433 (Figure 4.7c). The observed co-staining of Armus295-433 at Armus, -550- 
positive vesicles suggested a possible interaction of the two coiled-coil domains on 
both proteins. Moreover, the cytoplasmic distribution of Armus295-433 is distinct from 
Armus, 
_55o and 
indicates that additional domains other than the central coiled-coil 
domains are required to form vesicles. Most likely the PH domain may play a role as it 
specifically localises Armus to cell-cell contacts and it may interact with lipids at these 
membranes (Maffucci and Falasca, 2001). 
Finally, M. Finelli (unpublished data) checked whether the interference on 
vesicle formation by the Armus-derived construct containing the PH and central 
coiled-coil domains (Armus, _sso) was not a consequence of non-specific 
inhibition due 
to the over-expression of different proteins. The PH domain of PLC61 binds PI(4,5)P2 
lipids (phosphatidylinositol (4,5) bisphosphate) and is constitutively localised at the 
plasma membrane (Värnai and Balla, 1998; Värnai et al., 2002). Cells expressing 
Armus, 
_sso and 
PLC61 showed induction of vesicles similarly to expression of Armusl_ 
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550 alone (Figure 4.7d). The observed effects on Armus, _sso-vesicle 
formation by 
different Armus mutants were therefore considered specific. 
In conclusion, the required regions of Armusl-550 to form vesicles are both the 
central coiled-coils and the PH domain as deletion of the PH domain (Armus295_433) or 
central coiled-coil domains (Armus1_169) abolishes vesicle formation. Furthermore, a 
partial inhibition of vesicle formation by Armus1.550 was seen by expression of the 
central coiled-coils or the C-terminal coiled-coil domain but not expression of the 
PLC61 PH domain. Armus central coiled-coil domains might interact with similar 
coiled-coils as observed by co-localisation. In addition, vesicle formation by Armusl_550 
is efficiently perturbed by co-expression of Armus TBC/RabGAP domain with or 
without the C-terminal coiled-coil. 
4.2.6 In vitro interaction of Armus mutants 
Armus N-terminal fragment (Armusl_550) can induce vesicular structures and 
different Armus domains interfere with the formation of vesicles most likely by direct 
binding. Potential interaction between different Armus domains was investigated by 
cross-linking and co-immunoprecipitations. 
A cross-linker has the potential to link two molecules in close proximity 
together, i. e. when there is a protein: protein interaction. The bis(sulfosuccinimidyl) 
substrate (BS3) cross-linker was chosen (Salhany et al., 1990): it is reactive towards 
amino groups, water-soluble and among the shortest cross-linkers with a spacer arm of 
0 
11.4A. If Armus interacts with itself, BS3 should keep this complex together and show 
a shift in molecular weight by Western blot analysis. 
The Armus-derived constructs containing the PH and central coiled-coil 
domains (Armus, 
-550), 
the TBC/RabGAP and last coiled-coil domains (Armus547-928) and 
as a negative control a region without predicted coiled-coil domains (Armus433-55o; 
Figure 4.1) were tested for cross-linking. In vitro translated tagged-Armus proteins 
were incubated with different concentrations of BS3 and analysed by Western blotting. 
Monomeric Armus, 
-550, 
Armus547-928 and Armus433-550 were detected at their expected 
sizes of 70kDa, 45kDa and 14kDa, respectively (Figure 4.8). In the presence of 3mM 
BS3, all tested constructs showed a shift from their monomeric size, including the 
negative control Armus433-550 (Figure 4.8). Altogether, these results indicated that BS3 
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Figure 4.7: Disruption of Armusl_sso vesicles by expression of different Armus constructs. 
(a) The amount of vesicles induced by myc-Armus, _sso was analysed when co-expressed with 
flag- 
tagged Armus547 928 or Armus551-828 or with (b) flag-tagged Armus828_928 or Armus295-433. Cells were 
injected, fixed and stained for myc- and flag-tag. Arrowheads indicate vesicular structures and 
arrow shows concentration of the injected protein at a specific location. Merged pictures are in 
colour, and zoomed pictures are from the area marked with a white square. Coincident staining 
appears yellow. Scale bar = 50µm, scale bar zoom = 325µm. (c) Quantification of the number of 
Armusl-550-positive vesicles per expressing cell divided in the group representing 0,1-20 or >20 
vesicles. (d) Quantification performed as under (c) of the microinjection experiments of Armusl_ 
550 and PH-PLCS1 performed 
by M. Finelli (unpublished data). Shown data represents the 
average of three independent experiments and error bars are S. E. M. 
PH-PLCS1 
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probably cross-links the Armus proteins non-specifically and may not be appropriate 
to use in this assay. 
Co-immunoprecipitation assays to test dimerisation of proteins have previously 
been shown for GIT1, Snxl and MTK1/MEKK4 for example (Paris et al., 2003; Zhong et 
al., 2002; Miyake et al., 2007). COS-7 cells were transfected with full-length Venus- 
Armus and Armus N-terminal fragment (myc-Armus, _sso) or the 
C-terminal fragment 
(myc-ArmuS547_928). Subsequently, an immunoprecipitation of Venus-Armus was 
performed. Western blotting of myc-tagged proteins detected interaction of full-length 
Armus with both Armus, _sso and 
Armus547_928 (Figure 4.9a). This indicates that both N- 
and C-terminal fragments are able to interact with the full-length Armus molecule. 
As control, each tagged Armus construct was transfected independently and 
were not co-precipitated with anti-flag-coated beads (Figure 4.9b). Transfections were 
performed with the flag-tagged Armus construct stretching the PH domain and central 
coiled-coils (Armusl-55o) and the myc-tagged mutants containing the central coiled-coils 
(ArmuS295433), the PH domain and central coiled-coils (Armus, -550) or 
the TBC/RabGAP 
and last coiled-coil domains (Armus547-928)" Armus1_550was able to bind all different 
constructs tested: Armus, -55o, 
Armus547-928 and a small amount of Armus295.433 (Figure 
4.9c). These results indicate that the following interactions may occur: Armus, _ 
550: Armus1-55o, Armusl_550: Armus295-433 and Armust-550: Armus547-928" 
To substantiate these binding properties, the TBC/RabGAP domain and last 
coiled-coil (Armus547_928) was tested for interaction with itself, with the central coiled- 
coil domains (Armus295.433) and with the PH and central coiled-coil domains Armus1.550. 
Immunoprecipitation showed that Armus547_928 could interact with itself and with 
Armusi_sso and Armus295-433 (Figure 4.9d). Furthermore, the mutant containing only the 
central coiled-coil domains (Armus29s_433) was tested for an interaction with itself, with 
Armusi_550 or with Armus547.928. Dimerisation of the central coiled-coils with identical 
coiled-coil domains was detected (Figure 4.9e). In addition, interaction of these central 
coiled-coil domains with Armus, _sso and 
Armus547_928 was confirmed with this reverse 
immunoprecipitation assay (Figure 4.9e). Above results were repeated by M. Finelli. 
The PH domain of PLC81 was used as a negative control in these experiments 
and did not show interaction with any of the Armus constructs used 
(M. Finelli, Figure 
4.9f). This indicates that the described interactions of Armus truncation mutants are 
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Figure 4.8: BY concentration curve with Armus constructs. 
The Armus constructs Armusl-550, ArmUS547-928 and ArmnUS433-550 were in vitro translated using a 
Rabbit Reticulocyte Lysate system or a Wheat Germ System. Dimerisation of the individual 
constructs was tested with different concentrations of the cross-linker BS3. Monomeric sizes of the 
different Armus translated proteins are indicated with one asterisk, and a shift in size is indicated 
with two asterisks. n=3. 
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specific and not a consequence of over-expression in COS-7 cells. 
Taken together, the results in Figure 4.9 show that the central coiled-coil 
domains on Armus can dimerise with another set of similar coiled-coil domains 
(Armus295-433: Armus295-433, ArmuS295-433: Armusi-550). Similarly, the C-terminal coiled-coil 
domain is likely to mediate the binding of Armus547-928 with itself. Furthermore, the 
binding of the TBC/RabGAP domain and last coiled-coil with the central coiled-coils on 
Armus (Armus547-928: Armus295-433) suggests that association of either the C-terminal 
TBC/RabGAP or coiled-coil may exhibit an auto-inhibitory mechanism regulation of 
Armus function. These interactions may inhibit vesicle formation by Armus1.550. 
However, the importance of GAP activity of the TBC/RabGAP on Armus547-928 in the 
disruption of vesicles induced by Armus, -550 can not 
be excluded (Figure 4.7a). 
Additionally, Armus547-928 interacted with itself, which is likely to occur via the 
predicted last coiled-coil domain on this construct. Unfortunately, the experiments 
exploring Armus homodimerisation was not completed during my PhD project due to 
time constraints. 
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Figure 4.9: Specific in vivo interaction of Armus truncation mutants, but not with PH-PLC81. 
(a) COS-7 cells were transfected with Venus-Armus and the myc-tagged Armus constructs containing the 
PH domain and central coiled-coils (Armusi-550) or TBC/RabGAP and last coiled-coil domain (Armus547-928)" 
Immunoprecipitation with anti-GFP antibody was performed that recognises the Venus tag. (b) As a 
negative control the plasmids encoding myc-tagged central coiled-coil domains (Armus295-433), Armus, -550 
or Armus547-928 were subjected to an immunoprecipitation assay using anti-flag antibody. (c) The flag- 
tagged constructs Armusl_550, (d) Armus547-928 or (e) Armus295-433 were co-precipitated with myc-tagged 
ArmUS295-433, Armus1.55o and Armus547-928. (f) As a negative control for binding, GFP-PH-PLC81 was 
incubated with Armus295.433, Armusl-55o and ArmUS547-928. Data in figures (a) and (f) was obtained 
by M. 
Finelli (unpublished data). Blots are representative of at least three independent experiments. 
CHAPTER 41 148 
4.3 Conclusion 
In this chapter, EM studies showed that the induced vesicles by the PH 
domain and central coiled-coils (Armus1_55o) are potentially autophagosomes (Figure 
4.3). Furthermore, dimerisation as a potential mechanism of the formation of vesicles 
by Armus was investigated. In order to produce vesicles, the central coiled-coils as 
well as the presence of the PH domain (on Armus, _sso) 
is necessary. First, no shorter 
truncation mutants of Armus, _sso can 
induce vesicle formation. Second, the central 
coiled-coil domains of Armus can dimerise with similar coiled-coil domains of 
another Armus molecule (Armus295.433: Armus295.433, Table 4.1). Third, binding of 
ArmUS295433, active Rac or the C-terminal domain of Armus (ArmuS547-928) with the 
central coiled-coil domain on Armus295.433 was detected (Table 4.1). These 
interactions may interfere with dimerisation status of Armus central coiled-coil 
domains and potentially regulate vesicle formation. 
The experiments in this chapter support an auto-inhibition mechanism for 
Armus as the mutant containing the C-terminal fragment (Armus547.928) can interact 
with central coiled-coil domains (Armus295.433; Table 4.1). This association can 
potentially be mediated via dimerisation of the last coiled-coil with the central coiled- 
coils or via binding of the TBC/RabGAP domain towards the central coiled-coils. The 
interaction of Armus C-terminal fragment with the central coiled-coil domain occurs 
as both constructs co-precipitate with each other and could disrupt the vesicular 
phenotype of Armus1_550 (Table 4.1). Yet, the last coiled-coil domain (Armus828 928) 
could not produce a similar blockage on vesicle formation (Figure 4.1). However, the 
role of GAP activity in vivo still needs to be excluded. Overall, more experiments are 
necessary to verify the conformation of Armus with respect to intra-molecular and 
inter-molecular binding. 
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Table 4.1: Summary of results using Armus fragments. 
Co-expressing Armus1_550 In vitro binding with Cellular 
Protein localisation Armusl-550- induced Localisation Armus295 -433 Armus1-550 Ar mus-a7-928 by itself 
vesicles protein 
Armus PM, V ND ND ND + + 
ArmUS295-433 C +/- C, V + + + 
ArmUS1-550 V +1 V1 + + + 
Armus547_928 PM, C - C + + + 
Armus551-828 PM, C - PM, C ND ND ND 
Armus828-928 PM, C +/- C ND ND ND 
RacQ6 PM, C - PM, C +2 +2 -2 RacT"" PM, C + PM, C ND ND ND 
Rac. GDP ND ND ND +Is Z_ . +-3 
Z 
-12 
Arf6Q67L C + C ND ND -43 
Arf6T27N PM, C + PM, C ND ND ND 
Note that only full-length Armus and Armusl_55o are able to induce vesicles. PM, plasma membrane; V, 
vesicles; C, cytoplasm; +, present; -, absent; ND, not determined; 
1, d ata obtained by M. Finelli 
3 (unpublished observations); , data obtained by R. Francis using pull-down assay (unpublished data); , data shown in chapter 5 using yeast two-hybrid. 
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4.4 Discussion 
4.4.1 Function of Armus at autophagosomes 
Our data suggest that the induced vesicular structures mediated by the 
Armus N-terminal fragment (Armus, 
_sso) may 
be autophagosomes. Autophagy is a 
normal degradative pathway, in which autophagosomes need to mature into 
autolysosomes to degrade their contents by fusing with endosomes and subsequently 
lysosomes (Mizushima et al., 2002). Whether Armus has a function at 
autophagosomes requires further investigation. Hence, the regulation of 
autophagosomes could be mediated by specific Rab(s) that can be inactivated by 
Armus. Possible Rab candidates shown to be involved in autophagy are Rab7 
(Gutierrez et al., 2004) and Rab24 (Munafö and Colombo, 2002). Once the Rab target 
of Armus has been identified, immunoreactivity of this Rab and the specific Rab 
effector proteins on Armus1_55o-positive vesicles could reinforce the identification of 
these vesicles as autophagososmes. This has previously been shown for Rab5Q67L- 
induced early endosomes, where co-staining of endogenous Rab5 (Roberts et al., 
1999), early endosome marker 1 (EEA1) and Rabaptin-5 on these endosomes was 
observed (McBride et al., 1999). 
Although MVBs and lysosomes were observed in the Armus, _sso-induced 
autophagosomes by EM (Figure 4.3), the lack of co-staining with LAMP1 or CD63 
was surprising (M. Finelli, unpublished data). An explanation for this observation 
may be the inability of these autophagosomes to mature into autolysosomes 
(Mizushima et al., 2002) due to the extensive over-expression of Armus1.550. 
Therefore, additional staining with autophagosomal markers could strengthen the 
EM findings. 
On the other hand, Rabli has not been implicated in autophagy. The finding 
that active Rabil is able to disrupt Armus1_550-induced vesicles is difficult to interpret. 
Armus could hydrolyse GTP-bound Rabil that would result in inactive Rabll and as 
a consequence induce enlarged vesicles. However, localisation of a Rab and its GAP 
protein has never been demonstrated previously (Haas et al., 2005), indicating that 
Armus might not be a GAP protein for Rabll. Moreover, the active form of a Rab 
protein is necessary for vesicle budding from an adaptor membrane, transportation, 
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docking and eventually fusion with the donor compartment (Segev, 2001). Therefore, 
activation of Rab11 should in principle stimulate Armus-dependent vesicle formation 
but the opposite (i. e. disruption of vesicle formation) was observed. In addition, 
dominant-negative Rab11 did not interfere with Armus vesicle formation (R. Francis, 
unpublished data). 
Another possible reason for Rabl1 interference could be by direct binding of 
this protein to Armus1_550 or to endogenous Armus. This is supported by the co- 
localisation of active Rab25 with Armusl_55o as well as Armus547 928 on tubular 
structures (R. Francis, unpublished data) and the weak yeast two-hybrid binding of 
Rablla with Armus547-928 (M. Frasa, unpublished observations). However, staining of 
endogenous Rablla and Rab25 showed a punctated concentration inside the vesicles, 
rather than on the vesicle edge where fluorescence of Armus, -550 was observed 
suggesting that a direct association between Rabll and Armus, -550 
does not occur. A 
different reason for the interference of active Rab25 might be indirect, by inhibition of 
specific effector proteins necessary for Armus to induce vesicles. 
A role for Rac or Arf6 in autophagy has not been reported in the literature. 
Both dominant-negative Rac as well as Arf6 did not interfere with vesicle formation 
induced by the PH and two central coiled-coil domains on Armus1-550 (Figures 4.5 
and 4.6) indicating that activation of these GTPases are not required in this event. 
Active Rac blocked vesicle formation, but this is likely due to direct binding to 
Armusl-550" However, this explanation does not rule out that active Rac per se can 
influence Armus-dependent vesicle formation. Although active Arf6 can trigger Rac 
signalling during adherens junction disruption in keratinocytes (Figure 3.3), it was 
surprising that Arf6 did not interfere with vesicle formation like active Rac. This 
phenomenon might be explained by the possible spatial and temporal activation of 
Rac by Arf6. 
4.4.2 Potential mechanisms for vesicle formation by Armus 
Our data demonstrate that only full-length Armus and the N-terminal 
truncation mutant (Armust_sso) can induce vesicles (Figures 4.10a and 4.10b). None of 
the Armus domains when expressed by themselves can form enlarged vesicles. Thus, 
vesicle formation by Armus1550 and full-length Armus requires the PH 
domain and 
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central coiled-coils of this protein as removal of either domain from N-terminal 
Armus (Armus, 
_550) abolishes the ability to 
form vesicular structures (Table 4.1). 
Dimerisation of the central coiled-coil domains of Armus is required for 
r 
vesicle formation. This is supported by the fact that (i) the two central coiled-coil 
domains can interact with themselves in vitro (Figure 4.10b) and (ii) co-localisation of 
the central coiled-coil domains (Figure 4.7b). Conversely, binding of active Rac to the 
central coiled-coil domains on Armus, -550 
(Figure 4.5), binding of the TBC/RabGAP 
domain towards this region (Figures 4.7a and 4.10e) or expression of central coiled- 
coils (Armus295-433) disrupt Armusl-55o-induced vesicle formation, possibly by 
interfering with dimerisation. A higher expression level of the Armus295-433 construct 
compared to the Armus 1.550 mutant should in principle be more effective. Indeed, an 
increase in Armus295-433 concentration resulted in progressively less vesicles when co- 
expressed with Armus, -550 
(M. Finelli, unpublished data). 
When Armus dimers form, vesicles might only be induced if Armus is 
localised at appropriate sites via the PH domain. The inefficient blockage effect of 
vesicle formation by the central coiled-coils (Armus295.433; Figure 4.10c) further shows 
the requirement of the PH domain in this process. The PH domain is predicted to 
bind membrane lipids and therefore can contribute to the specific localisation at cell 
membranes where the protein functions (Maffucci and Falasca, 2001). However, 
preliminary results showed that Armus PH domain (Armus1_169) did not bind lipids in 
vitro (R. Francis, unpublished data). Many PH domains (about 66%) are not capable 
of targeting to membranes via Ptdlns but require secondary membrane-associated 
factors (Lemmon, 2004). For example, the Snxl protein localises to tubulovesicular 
endosomal membranes that is mediated via the Ptdlns-interacting Phox box and a 
helical coiled-coil domain. Both an intact Phox region and coiled-coil 
domain are 
necessary for Snxl localisation with neither alone being sufficient (thong et al., 
2002). 
Armus PH and two central coiled-coil domains are, in a similar 
fashion as the Phox 
and coiled-coil domain on Snx1, both necessary for localisation of 
Armus to vesicular 
structures. 
Small Arf GTPases have been shown to play a role in defining the specific 
localisation of PH domains to membranes (Lemmon, 
2004). However, it is unlikely 
that Arf6 may regulate Armus localisation to membranes 
because no obvious co- 
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Figure 4.10: Summary of possible mechanisms of vesicle formation and disruption by Armus and 
Armusl_550. 
(a-b) Full-length Armus and Armusl-55o induce vesicles mediated by the PH domain and dimerisation via 
the central coiled-coil domains. For sake of simplicity, only a parallel type of inter-molecular dimerisation 
is represented. Shorter truncation mutants do not show a vesicular phenotype (PH domain only (Armusl- 
169) or central coiled-coils (ArMUS295-433))" Dimerisation of the C-terminal coil domain in full-length Armus 
is likely, as suggested by the ability of Armus C-terminal fragment to dimerise. (c) Less vesicles are 
observed when Armusl-55o is co-expressed with the central coiled-coil domain lacking the PH domain 
(Armus295-433) and (d) no vesicular structures are detected by co-expression with active Rac. (e) Blockage of 
Armusl-550-dependent vesicles by the C-terminal region (Armus547-928 or Armus551-828) may result from 
direct binding or (f) by GAP activity of the predicted TBC/RabGAP on a Rab GTPase involved in vesicle 
formation. Potential interactions with endogenous Armus are not depicted here. 
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localisation between Arf6 and Armus 1-55o-induced vesicles was observed. In addition, 
Arf6 function is not required for vesicle formation (Table 4.1). How Armus PH 
domain is targeted to the membrane requires further investigation. 
4.4.3 Dimerisation and auto-inhibition mechanism of Armus 
Armus full-length induces vesicles with slower kinetics than the N-terminal 
fragment Armus1.550 (Figure 4.4). This result can be explained by a difference in the 
activation and conformational state of full-length Armus as compared to the N- 
terminal fragments. For example, it is possible that full-length Armus exists in an 
auto-inhibited conformation. Such mechanisms of regulation by auto-inhibition are 
frequently observed in Rho effector proteins. For example, PAK proteins form 
homodimers via the CRIB region and intra-molecular interaction of the inhibitory 
switch (IS) domain occurs with the kinase domain. Binding of active Rac or Cdc42 
towards the CRIB releases the dimerisation and auto-inhibition upon monomeric 
PAK, subsequently becoming auto-phosphorylated in its kinase domain and 
activated (Zhao et al., 1998; Lei et al., 2000; Buchwald et al., 2001). The activity of 
mDia is inhibited via an auto-inhibition mechanism by interaction of the DID 
(diaphanous inhibitory domain) with DAD (diaphanous auto-regulatory domain). 
Active Rho can activate mDia by binding towards the GBD (GTPase binding domain) 
that releases the auto-inhibition restraint of mDia (Lammers et al., 2005; Nezami et al., 
2006). mDia also forms dimeric or higher order structures in its auto-inhibited form 
possibly via its N-terminal DD (dimerisation domain) and C-terminal FH2 (Formin 
homology 2; Copeland et al., 2007). Another example is WASP that exists in a 
monomeric intra-molecular auto-inhibited form whereby the GBD and VCA domains 
(verprolin homology region (VHR), cofilin homology region (CHR) and acidic region 
(AR)) interact. These intra-molecular contacts that inactivate WASP can be relieved 
through binding of active Cdc42 to the GBD domain (Kim et al., 2000). Thus, the 
auto-inhibition states of PAK, mDia and WASP can be counteracted by binding of an 
active GTPase which leads to activation. 
It is therefore possible that binding of Rac could activate Armus in a similar 
way as the PAK or mDia activation mechanism described above, because both these 
proteins exist in a dimeric form when auto-inhibited. The data shown in Figure 4.5 
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suggests that the mutant containing the PH domain and central coiled-coils (Armus, _ 
550) could not induce vesicles upon binding of active Rac to the central coiled-coil 
domains. Potentially, full-length Armus undergoes a similar mechanism (see Figure 
4.10a). Upon Rac binding, full-length Armus dimerisation could be disrupted and 
the TBC/RabGAP domain of the protein could become activated. A GAP activity 
assay using full-length Armus is necessary to demonstrate whether Armus requires 
Rac binding to stimulate its GAP activity. Moreover, it remains to be determined 
whether Rac binding can also disrupt Armus-induced vesicle formation by binding to 
the central coiled-coil domains. 
An auto-inhibition mechanism for regulation of endogenous Armus function 
is consistent with the interaction of the TBC/RabGAP domain with the central coiled- 
coil domains (Table 4.1). An intra-molecular binding of different domains could 
occur in Armus similarly to what observed with WASP and mDia (Kim et al., 2000; 
Copeland et al., 2007). Folding of the TBC/RabGAP domain onto the central coiled- 
coil domains could then provide an auto-inhibitory mechanism. In this state, binding 
of a Rab to the TBC/RabGAP could be difficult and Armus activation would involve 
opening up the folded conformation. Future work is required to determine what the 
inactive and active state is of Armus with respect to dimerisation of the central coiled- 
coil as well as Rac binding and TBC/RabGAP domain binding to this region. 
Because Armus central coiled-coils are likely to dimerise, it is possible that this 
region of exogenous Armusl-550 interacts with endogenous Armus as well as with 
itself. As a result, GAP activity of endogenous Armus could be inhibited whereby 
overriding regulatory circuits. Alternatively, Armus, _550 may act as a 
dominant- 
negative protein thereby competing out for localisation of endogenous Armus at the 
right place at the membrane and therefore inhibiting spatial regulation of GAP 
activity. However, this latter thought is unlikely as (i) full-length Armus can induce 
vesicular structures like the shorter truncation mutant Armus1.550 and (ii) 
both Armus 
and Armus1.550 Can potentially dimerise with endogenous Armus. 
Although not directly tested here, it is unlikely that the C-terminal coiled-coil 
domain of Armus (region 828-928) can interact with the Armus central coiled-coil 
domains because (i) in vivo co-localisation between Armus1_55o-induced vesicles and 
the C-terminal coiled-coil (Armus828_928) was not observed and (ii) expression of 
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Armus828-928 only had a minor disruptive effect on vesicle formation by Armus, _550 
(Table 4.1). Consistent with this, the expression of TBC/RabGAP domain (Armus551- 
828) could mimic the interference of the C-terminal fragment (Armus547 928) on vesicle 
formation, suggesting that the C-terminal coiled-coil is not essential for inhibition. 
Co-precipitation of Armus547-928 with itself indicates that the last coiled-coil domain 
could mediate dimerisation of the C-terminal region. This indirectly supports a 
parallel dimer conformation of Armus, where dimerisation of the central and last 
coiled-coils with the respective coiled-coils in a distinct Armus molecule is facilitated 
(Figure 4.10a). 
In summary, Armus most likely dimerises via its N-terminal central coiled- 
coil domains. Armus last coiled-coil may mediate dimerisation of the C-terminal 
region although a possible binding to the central coiled-coils cannot be excluded. 
Besides dimerisation, Armus is potentially regulated by auto-inhibition via folding of 
the C-terminal domain towards the central coiled-coils whereby active Rac binding to 
the same region may regulate its activity. However, whether the C-terminal coiled- 
coil domain or the TBC/RabGAP domain binds the central coiled-coils remains to be 
investigated. 
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4.5 Future experiments 
4.5.1 Identifying the Armusl_550-induced vesicles as autophagosomes 
To substantiate the possibility that Armus to induce the formation of 
autophagosomes, co-staining of the autophagic-specific markers LC3 or 
monodansylcadaverine will be used (Kabeya et al., 2000; Biederbick et al., 1995). The 
agent vinblastine induces the formation of large autophagic vesicles in cells (Munafo 
and Colombo, 2001). Co-localisation of vinblastine and vesicles induced by Armus will 
be tested. Furthermore, 3-methyladenine is a widely used inhibitor of autophagy as it 
can block the activity of phosphatidylinositol 3-kinase (P13K) which is required for 
autophagosome formation (Seglen and Gordon, 1982). Pre-treatment of cells with 3- 
methyladenine followed by Armus or Armus1_550 expression will in principle inhibit 
autophagosomal structures induced by this construct. 
4.5.2 Armus formation of vesicles 
Both full-length Armus and Armus 1.550 induce the formation of vesicle-like 
structures. The mechanism for the formation of these structures is not known and may 
comprise inter-molecular and/or intra-molecular interactions of Armus proteins. An 
important step forward will be to investigate (i) Armus dimerisation, (ii) the role of Rac 
and (iii) Armus TBC/RabGAP domain binding to the central coiled-coil domains, (iv) 
participation of Armus PH domain and (v) additional molecules in the formation of 
vesicles induced by Armus. 
4.5.2.1 Armus dimerisation 
Further investigation is required to define which of the three coiled-coil 
domains on Armus has the ability to dimerise. Point-mutations on essential residues 
(often important leucine residues) can change the coiled-coil conformation and might 
influence dimerisation abilities. In the case of Armus, different point-mutations in its 
central coiled-coil domains could be made. Ectopic expression of the point-mutants 
can be investigated on their ability to induce vesicles as observed with wild-type 
Armus. Subsequently, dimerisation of these mutant constructs can be tested by 
immunoprecipitation in COS-7 cells and alternatively by gel filtration. Similar studies 
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could be performed with deletion mutants, such as Armus without the first coil or 
second coil domain. 
If vesicle formation by Armus1.550 occurs by dimerisation with endogenous 
Armus, co-staining of endogenous Armus will be present on Armus, _sso-induced 
vesicles. Although endogenous Armus may dimerise with Armusl_sso, this does not 
provide evidence whether endogenous Armus is required for vesicle formation. 
siRNA of Armus and injection of tagged-Armus, _sso 
in these Armus depleted cells will 
indicate whether participation of endogenous Armus in vesicle formation by Armus, _ 
550 is essential. 
Additional experiments are necessary to confirm dimerisation of the last coiled- 
coil domain with itself and with the central coiled-coil domains. For example, similar 
immunoprecipitation experiments presented in Figure 4.9 or a yeast two-hybrid assay 
(Tu and Wigler, 1999) could be performed with only the C-terminal coiled-coil domain 
(Armus828_928) as well as the TBC/RabGAP domain (Armus547_828). In addition, binding 
of the central coiled-coils (Armus295.433) with the last coiled-coil (Armus828_928) will be 
tested by immunoprecipitation. Moreover, other biochemical methods should be 
performed to reinforce the results in vivo. Interaction of bacterially-produced Armus 
coiled-coil domains could be tested for interaction with each other using pull-down 
assays or gel filtration experiments. 
4.5.2.2 Binding of Rac and TBCIRabGAP domain to Armus central coiled-coils 
It is important to map the minimal region on the central coiled-coils responsible 
for Rac binding as well as Armus TBC/RabGAP binding. Subsequently, it should be 
tested whether these interactions with the central coiled-coil region are mutually 
exclusive. The point-mutants on the central coiled-coil domains outlined above 
(section 4.5.2.1) can also be tested for association with Rac and TBC/RabGAP 
domain. 
Next, future experiments should clarify whether the GAP activity of the 
TBCRabGAP domain or direct binding of this domain to the central coiled-coil 
domain in Armusl_550 perturbs vesicle formation. Therefore, it would 
be important to 
determine what the activation status of Armus is and 
how this is achieved. Armus 
activation might potentially be induced via Rac binding. 
To gain some insight into this 
ý. 
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issue, it should be tested whether full-length Armus GAP activity requires active Rac 
to disrupt the auto-inhibited state. 
4.5.2.3 Further characterisation of Armus PH domain 
Testing binding of the Armus PH-domain only (Armus1_169) towards different 
lipids will be performed with in vitro assays. Mutations on essential motifs in the PH 
domain can abolish its interaction with specific lipids and thus its localisation. Such 
mutations can be generated on Armus to provide additional evidence that the 
interaction with membrane lipids is essential for Armus x_550 to induce vesicular 
structures. 
If Armus PH domain does not bind to lipids, other unidentified Armus- 
interacting proteins may recruit Armus to the plasma membrane. Mass spectrometry 
and yeast two-hybrid screening using Armus as bait can identify novel interacting 
partners. 
4.5.2.4 Novel Armus-associated proteins 
Besides inter- and/or intra-molecular interactions of Armus, participation of 
Armus-associated proteins like its potential Rab target could be involved in vesicle 
formation. Identifying these proteins will gain insight into the cellular function of 
Armus and will be investigated by a yeast-two hybrid assay using a 
keratinocyte 
cDNA library and Armus as bait. Hereafter, co-localisation of these novel interacting 
proteins on Armusl_550-positive vesicles will be performed. 
Alternatively, 
immunoprecipitation of tagged-Armus l . 55o 
followed by silver staining and mass 
spectrometry will gain insight into novel proteins that regulate or are required 
for 
Armus function. 
Chapter 5 
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5.1 Introduction 
Until now, the cellular function of Armus remains elusive but clues for its 
function can be surveyed from previous expression studies. Interestingly, endogenous 
Armus as well as the constructs encoding full-length Armus, the PH domain (Armusl_ 
169) and the C-terminal TBC/RabGAP and coiled-coil domains (Armus547_928) were able 
to co-localise with adherens junctions (Figure 4.4 and R. Francis, unpublished data). 
This observed distribution at E-cadherin cell-cell contacts implies that Armus might be 
involved in the regulation of junctions. 
Thus far, many identified GAP and GEF proteins contain a PH domain (Bos et 
al., 2007). Consequently, the putative PH domain on Armus could be involved in 
concentrating Armus at the plasma membrane. However, the ability of Armus547 928 to 
localise to E-cadherin junctions was unexpected as this fragment does not contain the 
PH domain. One possibility is that Armus547-928 might dimerise in vivo with 
endogenous Armus and then can be connected with the plasma membrane via the PH 
domain or Rac binding (as discussed in Chapter 4). 
To date, the specific Rab substrates of 22 RabGAP proteins are identified of 
which 19 RabGAP proteins contain a TBC/RabGAP domain (Table 1.1 and Figure 
1.11 In principle, each TBC/RabGAP protein can inactivate a particular Rab. 
Recently, several papers have published a large screening with TBC/RabGAP proteins 
to detect the regulation of different cellular events by Rab GTPases. Haas and co- 
workers (2007) performed a screening to identify the Rab GTPases important for Golgi 
function: over-expression of all predicted proteins containing a TBC/RabGAP domain 
was performed and their effect on Golgi function was analysed. Using this approach, 
RN-Tre and its substrate Rab43 were found important for regulating retrograde 
transport into the Golgi from the endocytic pathway. In addition, the TBC/RabGAP 
protein TBC1D20 and its substrate Rab1 were found to control the organisation of the 
Golgi complex and delivery of cargo from the ER to the cell surface. 
Another screen 
using a similar approach identified Rab27 as substrate 
for EP164 important for 
melanosome aggregation (Itoh and Fukuda, 2006). In these screenings and others, 
screening of TBC1D2 (the closest homologue of Armus) was 
included but no 
involvement in cellular events like Golgi transport, EGFR uptake, 
Shiga toxin uptake, 
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primary cilium formation and melanososme aggregation was observed (Haas et al., 
2007; Fuchs et al., 2007; Yoshimura et al., 2006; Itoh and Fukuda, 2006). Furthermore, a 
large yeast two-hybrid screen to identify the Rab substrate of all predicted mouse 
TBC/RabGAP-containing proteins was also performed (Itoh et al., 2006). In this 
screening, TBC1D2 was tested but no binding to a specific Rab substrate was found. 
Thus, although Armus-related proteins have been tested in some assays, its specific 
Rab target as well as its cellular function is unknown. 
In this chapter I will investigate a potential role for Armus in the regulation of 
E-cadherin-mediated junctions. First, in vivo association of Armus with the E-cadherin 
complex will be tested. Results from R. Francis (unpublished data) showed that Armus 
depletion using siRNAs did not affect de novo formation of junctions. However, a 
potential function for Armus in the maintenance or destabilisation of mature junctions 
has not yet been investigated. I focus on a role for Armus in the disassembly of mature 
E-cadherin junctions driven by over-expression of dominant-active small GTPases Arf6 
and Rac. I investigated the ability of Armus to modulate the GTPase activity of 
candidate Rabs, including Rabl1a and Rab25, which I showed interact with Armus. I 
used an in vivo binding assay to investigate interaction between Armus547 928 and 
different Rabs (Pei et al., 2002), an HPLC-based GAP assay (Hemsath and Ahmadian, 
2005) and in vivo localisation studies ( Haas et al., 2005) to define the specific Rab 
substrate for Armus. Furthermore, I tried to characterise the nature of the perinuclear 
region where E-cadherin receptors accumulate after Arf6a67L expression and 
investigated the participation of Rab proteins in the trafficking route of these receptors 
during junction disassembly driven by Arf6Q671-. 
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5.2 Results 
5.2.1 Armus associates with E-cadherin receptors in vivo 
Armus localises at the plasma membrane at sites of E-cadherin-based cell-cell 
contacts (Figure 4.4). This suggests a possible involvement of Armus in the regulation 
of these adherens junctions. In an attempt to address Armus function at adherens 
junctions, I tested a potential association of Armus with E-cadherin receptors in vivo 
using an immunoprecipitation assay. Endogenous E-cadherin receptors were obtained 
from keratinocytes grown in standard conditions and lysates were 
immunoprecipitated using an anti-E-cadherin antibody and Western blotted for Armus 
and E-cadherin. Under these conditions, Armus was able to specifically co-precipitate 
with E-cadherin receptors (Figure 5.1a). No background binding was found in the 
control sample without antibody added. As control loading, 5% input was run in 
parallel to show the presence of endogenous Armus and E-cadherin in both samples 
(Figure 5.1a, lysates). As negative control, the Arf6 GAP protein GIT1 was tested in 
parallel but did not associate with endogenous E-cadherin receptors (Figure 5.1b) 
whereas the Rac GEF p-PIX co-immunoprecipitated non-specifically with beads 
(Figure 5.1c). 
Thus, Armus associates with E-cadherin receptors in vivo and this is consistent 
with the immunofluorescence study shown in Figure 4.4. These results together 
suggest that Armus has a function at keratinocyte adherens junctions. The mechanism 
of Armus to localise at junctions is not known but could be facilitated 
by its PH 
domain. 
5.2.2 Armus is not involved in E-cadherin junction disassembly induced 
by RacQ61L 
Previous data showed that over-expression of Armus, Armus1-550 and Armus547. 
928 for up to five hours did not affect 
junction stability. The constitutively activated 
GTPases Rac and Arf6 perturb keratinocytes junctions, 
but the signalling pathway 
during junction disassembly is different (see chapter 3). I investigated whether 
Armus 
could participate in keratinocyte junction 
destabilisation. E-cadherin-mediated 
junction stability was analysed when the 
N-terminal truncation mutant of Armus 
(Armusl-550) was over-expressed with active Rac. 
Active Rac binds the two central 
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Figure 5.1: Armus associates with E-cadherin. 
Lysates from keratinocytes grown in standard calcium conditions were immunoprecipitated with an 
anti-E-cadherin antibody or without antibody as a negative control. Western blotting was performed of 
E-cadherin and (a) Armus, (b) GIT1 and (c) ß-PIX. IP, immunoprecipitation. n=3. 
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coiled-coil domains on Armus (residues 295 to 433) and displayed less perturbed 
junctions when expressed with Armus1.550 for three hours (Figure 4.7). These results 
were quantified by measuring the actual length of E-cadherin staining at cell-cell 
contacts and the expected junction length from corner to corner between two 
expressing cells. Thereafter, the ratio between these two values was calculated. RaCQ61L 
expression by itself shows 58% E-cadherin ratio, which is significantly higher at 85% 
when Armus1.550 is co-expressed (p<0.009, Figure 5.2a). The interference of Armus1.550 
with Rac-induced junction disassembly is most likely caused by direct binding and 
titration of Rac. Alternatively, Armus1_550 could alter the activity of endogenous Armus 
that in turn could modulate the activity of a specific endogenous Rab protein essential 
during RacQ61L-induced disruption of junctions. 
Active Rac does not bind Armus547-928 (R. Francis, unpublished data) and was 
tested for a role during Rac-induced junction perturbation. To assess possible 
involvement of Armus during junction disassembly induced by RacQ61L, differently 
tagged Armus547 928 and RaCQ61L constructs and concentrations were tested to achieve 
optimal co-expression levels. In this experiment, expression of constitutively active 
Rac for a period of six hours removed E-cadherin receptors from the corners between 
three cells, resulting in E-cadherin staining only in the middle of cell-cell contacts 
(Figure 5.2a, RaCQ61L arrow). However, co-expression of Armus547 928 had no effect on 
the destabilisation efficiency on E-cadherin junctions by RaCQ61L (Figure 5.2a, RaCQ61L + 
Armus547-928 arrow). Qualitatively, Raca61L by itself and in combination with Armus547- 
928 showed respectively a 38% and 41% length of E-cadherin staining at junctions 
(Figure 5.2b). This result provide evidence that Armus does not function downstream 
of Rac during adherens junction disruption. 
5.2.3 Armus TBCIRabGAP domain can block Arf6-driven junction disassembly 
Although Armus547 928 did not affect Rac-induced junction 
disruption, potential 
implication of Armus during E-cadherin junction disruption driven by the small 
GTPase Arf6 was investigated. Arf6Q6 potently disassembled E-cadherin junctions 
often followed by accumulation of E-cadherin staining in a perinuclear area 
(Figure 
5.3a, Arf6Q67L arrow). This result is similar to what observed in 
MDCK (Palacios et al., 
2001,2002,2005) and MCF-7 breast cancer cell line (Paterson et al., 2003). 
Co- 
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Figure 5.2: Armus TBC/RabGAP domain cannot block junction perturbation induced 
by over-expression of constitutively active Rac. 
(a) Quantification of E-cadherin-positive staining at cell-cell contacts between cells 
expressing Armusl_550, RacQ61L or a combination of both proteins shown in Figure 4.7. 
Values were normalised to the predicted length of each cell-cell contact. *, p<0.009. (b) 
Keratinocytes were injected with active Rac (RacQML), Armus547 928 or a combination of 
both plasmids and expressed for six hours. Immunolabelling was performed for flag- 
Rac, myc-Armus547-92s and E-cadherin and images were taken on a fluorescence 
microscope. Arrows indicate disrupted cell-cell contacts, arrowheads show intact 
adherens junctions. Scale bar = 50pm. (c) Quantification of Armus547-92g and RacQ61L co- 
microinjections as performed under (a). Higher calculated ratio for RacQ61L in (a) 
comvared to (c) is caused by difference of three and six hour expression time, 1` 
respectively. Error bars represent the S. E. M. n=3. 
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expression of Arf6Q67L with Armus547-928 plasmids was optimised for an expression time 
presence of Armus547-928 : over-expressing cells showed stable E-cadherin junctions 
accompanied with a normal epithelial cell morphology as observed in surrounding 
non-injected control cells (Figure 5.3a, Arf6Q67i- + Armus547-928 arrowhead). The number 
of intact E-cadherin junctions between two expressing cells was counted and values 
were expressed as the percentage of predicted number of junctions. After active Arf6 
expression, only 10% of total junctions were intact (Figure 5.3b). In contrast, a 
significant rescue of the proportion of intact junctions was observed when Arf6Q67- was 
co-expressed with Armus547_928 (68% intact junctions, p<0.008; Figure 5.3b). 
The C-terminal construct of Armus (Armus547 928) inhibited cell-cell contact 
perturbation driven by sustained Arf6 activation. I investigated the role of full-length 
Armus on Arf6-dependent junction disruption. For these injections, Armus 
concentration had to be reduced to 0.05µg/µl and Arf6Q67- increased to 0.1µg/µl as 
Armus otherwise blocked the expression, and thus the phenotype, induced by Arf6467L . 
Remarkably, full-length Armus did not inhibit the Arf6-driven junction perturbation. 
Instead, it co-localised with the internalised E-cadherin receptors caused by sustained 
Arf6 activation (Figure 5.4a, Arf6Q67L + Armus arrowheads). Qualitatively, no change 
in the number of intact junctions was observed (Figure 5.4b). 
In summary, dominant-active Arf6 requires Armus (Figure 5.4 and 5.5) as well 
as Rac activation (Figure 3.3) to perturb E-cadherin junctions. Armus547-92g rescued E- 
cadherin junction disassembly induced by inappropriate activation of Arf6, but not 
full-length Armus. Instead, Armus localised at sites of perinuclear E-cadherin 
accumulation induced by Arf6Q67L. Thus, Armus associates with E-cadherin receptors 
at steady state (Figures 4.4 and 5.1) and remains associated with E-cadherin when Arf6 
causes rapid internalisation and subsequent intracellular accumulation of these 
receptors (Figure 5.4). The discrepancy observed between blockage of Armus547-928 
versus non-blockage of full-length Armus during Arf6-induced junction disassembly is 
not known but could lay in a difference of activation status of each protein. 
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Figure 5.3: Loss of E-cadherin junctions by expression of constitutively 
activated Arf6 is inhibited by Armus547-928. 
(a) Arf6Q67L and Armus547-928 were co-expressed for three hours before cells 
were fixed and stained with the HA-tag, flag-tag and E-cadherin. Arrow point 
to disrupted cell-cell contact, arrowhead indicates stable adherens junction. 
Scale bar = 50µm. (b) Quantification was performed by counting the number 
of intact junctions between cells expressing Arf6Q67L, Armus547-928 or both 
proteins. The obtained values were expressed as the percentage of the 
predicted intact cell-cell contacts. Error bars represent the S. E. M. from four 
independent experiments. *, p<0.006. 
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Figure 5.4: Armus localises at Arf6-induced E-cadherin accumulation at perinuclear region. 
(a) HA-Arf6Q67L and Venus-Armus were microinjected into keratinocytes and the cellular 
localisation of Arf6Q67L, Armus and E-cadherin was visualised by confocal microscopy. 
Arrowheads show co-localisation of immunolabelled Armus and E-cadherin when dominant- 
active Arf6 causes junction disassembly. Scale bar = 16µm, insert scale bar = 64µm. (b) 
Quantification of the percentage of intact junctions following expression of Arf6Q6? L. Armus or 
both. Error bars represent the S. E. M. n=3. 
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5.2.4 Active Arf6 does not interact with Armus547-928 
The mechanism via which Armus547_928 is able to block Arf6-induced junction 
perturbation (Figure 5.3) is not known. Three TBC/RabGAP proteins have previously 
been linked to Arf6 GTPases. USP6/Tre2/Trel7 interacts with Arf6-GDP (Martinu et al. 
2004), EP164 binds Arf6-GTP (Hanono et al., 2006) and TBC1D3/PRC17 interacts with 
the Arf6 effector GGA3 (Frittoli et al., 2008). Thus, it is possible that stable E-cadherin 
junctions were observed after expression of Arf6Q67L with Armus547_928 by direct binding 
and thus titration of active Arf6 out. 
I addressed this possibility by two means: intracellular localisation and binding 
assays. The distribution patterns of endogenous and exogenous Armus were 
investigated when active Arf6 was expressed in keratinocytes. In Figure 5.4, 
exogenous full-length Armus is clearly co-distributed with E-cadherin receptors at 
junctions and perinuclear compartment and does not localise with Arf6 staining. 
Endogenous Armus in the non-injected control cells localised at cell-cell contacts as 
shown in Figure 4.2d. However, in many Arf6Q671--expressing cells endogenous Armus 
was distributed to the typical E-cadherin accumulation at perinuclear region and did 
not show obvious association with HA-Arf6Q67L immunostaining (Figure 5.5a, merge, 
arrowhead). Together, the similar localisation of exogenous (Figure 5.4) and 
endogenous Armus (Figure 5.5a) upon Arf6-induced junction perturbation indicated 
that Armus and Arf6 do not co-localise in vivo. 
Next, a possible direct binding of Armus547_928 with Arf6Q67Lwas studied using 
the yeast two-hybrid technique. This technique is the most common method used to 
investigate binding of a protein to Arf GTPases (Palacios et al., 2002; Takatsu et al., 
2002; Dubois et al., 2005; Fielding et al., 2005). The Armus truncation mutant Armus547. 
928 was cloned in the pGAD10 vector which contains a GAL4 activation 
domain. 
Arf6a67L was available in the pLexA vector and empty vector pGAD10 was used as a 
negative control. As a positive control ARHGAP10 was used, which is a GAP protein 
for Cdc42 but its PH domain has been shown to bind active Arf6 (Dubois et al., 2005). 
In each experiment, growth was observed with the transformed yeast cells containing 
Arf6Q67L and ARHGAP10-PH indicating a functional yeast two-hybrid technique 
(Figure 5.5b). Yeast transformants carrying Arf6Q67L in combination with Armus547_928 
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showed no growth, similarly observed with the negative control Arf6Q67Land pGAD10 
vector. This implies that Armus did not bind Arf6Q67L under these conditions. 
Altogether, Armus localised at a compartment where E-cadherin receptors 
accumulated upon active Arf6 expression, but did not show localisation with Arf6Q67L 
per se. Moreover, Armus547-928 did not interact with Arf6Q67L in a yeast two-hybrid 
(Figures 5.4 and 5.5). These results indicated that Armus547 928 cannot inhibit Arf6- 
induced junction disruption by titrating out Arf6. Taken together, the data argue that 
another molecular mechanism may be responsible for Armus-dependent stabilisation 
of E-cadherin-mediated junctions in the presence of active Arf6. 
5.2.5 Armus547_928 binds Rablia and Rab25 
Since over 70 Rab proteins together with 52 TBC/RabGAP proteins have been 
predicted in the human genome (Bernards, 2003), it is likely that each TBC/RabGAP 
domain has specific GAP activity towards one or two Rabs. Until now, 22 active 
human RabGAP proteins have been identified of which p85a, p120GAP and Rab3GAP 
do not contain a classical TBC/RabGAP domain (Table 1.1 and Figure 1.10). Because of 
the large number of Rabs and putative GAPs in mammals, it is not a trivial task to find 
the specific GAP protein for each Rab. 
Techniques that helped to identify the Rab substrate of previously described 
GAP proteins can be used in this study to determine the Rab substrate for Armus, i. e. 
in vitro GAP assays using specific Rab proteins as substrates. In a few studies, 
additional methods are used to determine the binding of Rabs with a GAP, such as the 
yeast two-hybrid, immunoprecipitation and pull-down method (Cuff et al., 1999; Haas 
et al., 2005; Dabbeekeh et al., 2007; Itoh et al., 2006; Pei et al., 2002; Lanzetti et al., 2000). 
Alternatively, if the GAP protein displays GAP activity towards a Rab, then over- 
expression of the GAP protein should result in redistribution of an effector protein of 
the particular Rab as shown by Haas et al. (2005). 
Using the above techniques, I addressed whether the inhibition of Arf6- 
dependent adherens junction destabilisation by Armus547 928 might involve the 
inactivation of an essential Rab GTPase by its putative Armus TBC/RabGAP domain. 
An immunoprecipitation assay using COS-7 cells was set-up to investigate the ability 
of Armus547.928 to bind different Rabs. COS-7 cells were transfected with Armus547 928 in 
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Figure 5.5: Armus does not localise or associate with active Arf6. 
(a) Endogenous Armus and E-cadherin staining was performed following expression of 
Arf6Q67- for three hours. Arrows indicate localisation at junctions, arrowheads indicate 
accumulated Armus and E-cadherin at perinudear compartment. Coincident staining appears 
yellow in merge image. Inserts of images are shown below and the white boxes mark the 
original area. Scale bar = 16µm, insert scale bar = 64µm. (b) Yeast two-hybrid assay to test 
interaction of Armus547.928 with Arf6Q . pGAD10 was used as a negative control and 
ArfGAP10-PH as a positive control (Dubois et al., 2005). Yeast transformants were streaked on 
agar containing histidine (HIS+) or without histidine (HIS-) to screen for interaction. Data 
representative of three independent experiments. 
Arf6Q67'- 
HIS6 HIS 
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combination with the dominant-active form of Rabla, Rab5a, Rab7, Rab11a and Rab25. 
Rabla has been reported to play a role in vesicular trafficking at the Golgi, which is an 
organelle that functions in intracellular trafficking of secretory material synthesised by 
the ER (Stenmark and Olkkonen, 2001). Endocytic trafficking is regulated by Rab5 
(Bucci et al., 1992). Rab7 is the main regulator of transport from late endosomes to 
lysosomes and has been shown to be important for autophagosome formation (Feng et 
al., 1995; Meresse et al., 1995; Press et al., 1998; Bucci et al., 2000). Rab11a and Rab25 
share 63% amino acid homology and belong to the Rab11 subfamily of GTPases 
(Goldenring et al., 1993). These Rabs regulate trafficking in the recycling endosome 
compartment (Ullrich et al., 1996). Equal expression levels of Armus547-928 and Rabs 
were optimised as shown in Figure 5.6a (lysates). After immunoprecipitation of flag- 
tagged Armus547_928 followed by Western blot analysis, ArmuS547-928 was able to co- 
precipitate specifically with Rabl1a and Rab25 and not the other Rabs tested (Figure 
5.6a, IP). Surprisingly, Rab11a was able to precipitate non-specifically with the protein 
A beads coated with anti-flag antibody (Figure 5.6b, IP). However, this binding was 
weaker than that observed between Rabl1a and Armus547-928, indicating that latter is 
more specific in this assay. 
A yeast-two-hybrid screen carried out previously using Armus547 928 as a bait 
showed a weak interaction of Armus with active Rab11a and Rab25 and not with the 
activated forms of Rab3a, Rab5a, Rab8, Rab13, Rab27a and Rab38a (M. Frasa, 
unpublished data). Although the interaction of Rab11a and Rab25 with Armus was 
very weak in the yeast two-hybrid assay, a possible functional link was strengthened 
by the fact that co-expression of Armus547 928 with active Rab25 or Rab11a lead to co- 
localisation of Armus547 928 on active Rab25- or Rab11a-induced tubular structures 
in 
keratinocytes (R. Francis, unpublished data). The immunoprecipitation and yeast two- 
hybrid results together suggest that Armus547-928 interacts with Rablla-GTP and Rab25- 
GTP most likely by the predicted Armus TBC/RabGAP domain. 
However, co-localisation of a wild-type GAP with its substrate has never been 
shown before which can be explained by the transient interaction of a GAP with 
its Rab 
substrate (Haas et al., 2005). Therefore, the previous data showing co-localisation of 
Rab11a and Rab25 on tubular vesicles (R. Francis, unpublished 
data) may imply that 
Rab11 is not Armus' substrate, but perhaps an effector molecule. 
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Figure 5.6: Active Rabila and Rab25 co-immunoprecipitate with Armus547-928" 
(a) Cell lysates expressing flag-Armus547_928 and the activated forms of GFP-tagged 
Rabia, Rab5a, Rab7, Rab11a or Rab25 were incubated with an anti-flag antibody 
bound to beads. Beads were washed followed by separation on a SDS-PAGE gel 
and Western blotting for anti-GFP and anti-flag. (b) Control experiment to show 
specificity of interaction. Immunoprecipitation with anti-flag antibody bound to 
beads incubated with lysates over-expressing flag-Armus547 928 together with GFP- 
Rab11as2ov, or GFP-Rab11as2ov only. IP, immunoprecipitation. n=3. 
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5.2.6 Armus is a novel GAP protein for Rab7 
Most TBC/RabGAP domain containing proteins have been shown to comprise 
GAP activity towards one or two specific Rab substrates in vitro. While above results 
describe binding of Rablla with Armus, it remains to be determined whether Armus 
acts as a GAP on Rabl1. Therefore, a GAP activity assay was performed in 
collaboration with A. Rak and M. R. Ahmadian at the Max Planck Institute for 
Molecular Physiology (MPI) in Dortmund, Germany. For the GAP activity assay, 
Armus547_928 was cloned into the pGEX-4T3 vector, produced as a GST-tagged protein 
and purified using glutathione sepharose beads followed by anion exchange (Figure 
5.7a) and gel filtration chromatography (Figure 5.7b). GAP activity of GST-Armus547-928 
towards Rab1, Rab7 and Rablla was tested with a standard HPLC-based method 
(Hemsath and Ahmadian, 2005). At this stage, only these Rab proteins were available 
(Figure 5.7c, previously produced by N. Bleimling, MPI in Dortmund) and made in a 
nucleotide-free state. 
For the GAP activity assay, GTP-loaded Rabs (25µM) were incubated with or 
without the presence of GST-Armus547-928 (24M) for 10 minutes at 25°C. Samples were 
snap-frozen in liquid nitrogen and boiled for 10 seconds before subjection to HPLC 
that allowed separation of the nucleotides. Under these conditions, GDP eluted 
around 7.1 minutes and GTP around 13.2 minutes. GST- Armus547-928 did not show any 
activity towards Rab1 nor Rab11a, as a similar GTP content was observed with or 
without the incubation of Armus547-928 (Figure 5.8a and 5.8b, Rab1 and Rab11a). 
Instead, ArmuS547-928 accelerated Rab7-GTP hydrolysis very efficiently (Figure 5.8c, 
Rab7). From the chromatograms observed, the GDP and GTP peak areas were 
assessed and the relative amount of GTP was calculated (Figure 5.8e). Qualitatively, 
Armus547-928 significantly hydrolysed the GTP on Rab7. This result conclusively shows 
that Rab7 is the preferred substrate for Armus547-928 and not Rabl1a. 
In addition, a Rab7 mutant lacking the last 22 C-terminal amino acids 
(Rab7CA22) was also tested for an accelerated GTP hydrolysis induced by GST- 
Armus547_928. There are some controversial reports on the importance of these amino 
acids regarding GAP activity. The last C-terminal amino acids, are important 
for 
prenylation events on the Rab protein, which is necessary to target the Rab towards the 
plasma membrane (Walworth et al., 1989). Fukui and co-workers 
(1997) discovered a 
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Figure 5.7: Production and purification of GST- Armus547 928. 
(a) GST-Armus547 928 was produced in E. coii, purified on GSA beads and eluted using 10mM 
glutathione followed by size separation on anion exchange chromatography. Fractions were 
collected (number 4 to 10) and loaded on a gel to check protein content. GST-Armus547-928 was 
detected at the expected size of 67kDa. TL, total lysate; SN, supernatant; P, bacterial cell pellet; 
FT, flow through; W, wash. (b) Gel filtration of GST-Armus547-928. Fractions 4 to 8 under (a) 
were loaded on a Superdex-200 column. Fractions 7 to 12 and 13 to 20 were pooled separately 
and concentrated. (c) Rabla, Rab11a, Rab7 and Rab7CA22 proteins used in the GAP activity 
assay were previously purified by N. Bleiming (MPI Dortmund, Germany). 
CHAPTER 51 177 
GAP for Rab3 (Rab3GAP) which was only able to hydrolyse GTP from prenylated 
Rab3, as no activity was found towards non-prenylated Rab3. However, for any other 
published RabGAP protein there is no discrepancy between prenylated and non- 
prenylated Rabs. Because of these dissimilar results, Armus547_928 GAP activity towards 
a C-terminal deletion mutant of Rab7 was tested in this report. GST-ArmuS547-928 
seemed to act identically towards Rab7CA22 as towards Rab7, by significantly reducing 
the relative amount of GTP from 90% to 19% (Figure 5.8d and 5.8e, Rab7CA22). In 
conclusion, C-terminal modifications at the last 22 amino acids do not seem to affect 
the ability of Armus to facilitate GTP hydrolysis of Rab7. 
It has been published before that re-distribution of a GAP and an effector 
protein of the GAP's specific Rab substrate can occur by an over-expression approach 
(Haas et al., 2005). The REST/NRSF-interacting LIM domain protein (RILP) is a well- 
studied effector of Rab7 required for transport from late endosomes to lysosomes and 
can be used as a read-out for localisation of active Rab7 (Cantalupo et al., 2001). RILP 
over-expression has been reported to localise at late endosomal and lysosomal 
membranes, where proteins such as Lysosomal Associated Membrane Protein 1 
(LAMP1), LAMP2 and the protease CathepsinD can be found. In keratinocytes, RILP 
localised at similar perinuclear structures as published before by Cantalupo and 
colleagues (2001; Figure 5.9). As shown previously, concentration of Armus547 928 per se 
only occurs at the cell membrane and additionally has an equal distribution 
throughout the cytoplasm (Figure 5.3). Interestingly, co-expression of RILP caused 
recruitment of Armus547-928 to RILP-positive structures. Clearly not all cells showed 
this phenotype, as the expression of ArmuS547-928 had to be above certain threshold. 
This is demonstrated in Figure 5.9a, where the co-injected cell marked with an 
arrowhead shows a RILP-positive compartment but expression of Armus547 928 is weak 
and is not recruited to this compartment. However, when Armus547 928 is expressed at 
similar levels as RILP it co-localised with RILP-positive structures (Figure 5.9, arrow). 
Quantification of these results in Figure 5.9b demonstrated that the distinct 
localisation 
of Armus547.928 at RILP-positive structures is present in 51% of the 
Armus547 928- 
expressing cells. 
A co-expression study was set-up to investigate the subcellular 
distribution of 
Armus547 928 with Rab7, as no obvious co-localisation 
between a GAP and its Rab 
CHAPTER 51 178 
a 
C 
u 
C 
i 
C 
C C' M C' 
C 
C V. 
C C 
f 
C a 1 
h 
. uqw 
E 
N 
N 
N 
la 
V 
C 
(0 
O 
0 
Rab7C022 Armus 547. M 
Eý Ir 
C 
N 
It) 
N 
v 
.0 I- O 
2 d 
10 12 14 8 10 12 14 
time (min) time (min) 
KaP91 a+ Armus 47 
a 
t 
o 
S" 
W 
NJ 
h. 
10 12 14 8 10 12 14 
time (min) time (min) 
e 
IL 100 I- w 80 
0 
60 
0 
40 
ý-, 
20 
Q- Armusr. 
47-92s 
®+Armus547,2, 
Rabi Rabl1a Rab7 Rab7Ci22 
Figure 5.8: Armus547-928 is a novel GAP protein for Rab7. 
(a) Analysis of GAP activity of Armus TBC/RabGAP by HPLC. Rabla, (b) Rab11a, (c) Rab7 and 
(d) Rab7CA22 were incubated with or without 2µM GST-Armus547_92$ for 10 minutes at 25°C. 
Samples were injected into the HPLC apparatus which detected GDP after -7.1 minutes and 
GTP after 13.2 minutes. (e) The ratio between the GDP and GTP peak areas was calculated 
and expressed as relative amount of GTP (%). * p<0.00002, ** p<0.007. n >_ 2. 
Rabl a 
LL 
a cu 
Cn 
Rabla + Armus347,. &2 
cu 
ti 
Rab11a 
a iu iz 14 B 10 12 14 8 10 12 14 8 10 12 14 time (min) time (min) time (min) time (min) 
d 
Rab7CA22 + Rab7 
a 
II'ý 
CO 
CHAPTER 51 179 
a 
IF Injection 
RILP 
a J_ 
CL L 0 
y 
E 
d 2' 
C) 
E 
b 
100 
80 
IIi 
60 
0 
40 
20 
* 
Arm usr547_928 ++ 
I 
RILP -+ 
+ RILP 
Figure 5.9: RILP-positive vesicular structures recruit Armus547 928. 
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Armus547_928. Images were taken using confocal microscopy and panel at 
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structures following expression of Armus547-928 alone or in combination 
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substrate has been predicted previously because of their transient interaction (Haas et 
al., 2005). The dominant-active form of Rab7 (Rab7Q67L) in combination with ArmuS547- 
928 was microinjected in keratinocytes and expressed for three hours. As reported 
previously, Rab7Q67- showed localisation around the perinuclear area when expressed 
alone and this distribution did not differ in combination with ArmuS547-928 (Figure 5.10, 
arrowheads). Armus547-928 showed distribution in the cytoplasm and at sites of cell-cell 
contacts, which did not change upon co-expression with Rab7Q67L either (Figure 5.10, 
arrow). Thus, no obvious sites of co-localisation were observed between Armus547-928 
and Rab7Q67i- (Figure 5.10, merge). Therefore, this microinjection result supports that 
Armus is a GAP for Rab7. 
In conclusion, Armus547_428 is a GAP protein for Rab7 (Figure 5.8) and can 
localise to RILP-induced late endosomal/lysosomal structures (Figure 5.9). No co- 
localisation was observed with the activated form of Rab7 with Anmus547-928 (Figure 
5.10). Instead, the re-localisation of Armus547-928 when RILP is over-expressed provide 
in vivo evidence that Armus is indeed a specific GAP protein for Rab7. RILP structures 
can trap endogenous active Rab7 and presumably interfere with Rab7 functions. 
Armus547-928 may localise to these structures because of the high concentration of active 
Rab'7 sequestered by RILP. Due to time constraints, biochemical interaction between 
Armus547.928 and Rab7 by alternative methods could not be finalised. 
5.2.7 Rab7 signalling is specifically required for the destabilisation of keratinocyte 
junctions by active Arf6 
After Src activation in MDCK cells, Rab7 inactivation prevents junction 
disassembly and shuttling of E-cadherin receptors from endosomes to lysosomes 
(Palacios et al., 2005). Because in keratinocytes (chapter 3) and MDCK cells (Palacois et 
al., 2003) the participation of Rac signalling is distinct during Arf6-induced junction 
disassembly, I wished to address whether Rab7 signalling was also required 
in 
keratinocytes. If required, this can provide a mechanism via which Armus can 
efficiently prevent Arf6 disruptive effects. To investigate this, 
junction stability in 
keratinocytes was analysed when Arf6Q67Lwas co-injected with the 
dominant-negative 
form of Rab7 (Rab7T22N). Co-expression of Rab7T22N together with 
Arf6Q67L was 
optimised for three hours during which time Rab7 
did not influence junction stability 
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(Figure 5.11a, Rab7T22N). Rab7 inactivation successfully blocked the disruptive effect on 
E-cadherin-based junctions caused by sustained Arf6 activation. Co-expressing cells 
have stable E-cadherin junctions and normal cell morphology, similarly to what 
observed in surrounding non-injected cells (Figure 5.11a, Rab7T22N + Arf6Q67- 
arrowheads). Quantification of these experiments showed that 87% of junctions were 
intact when Arf6Q67- and Rab7T22N were co-expressed. This is a significant increase in 
the amount of intact adherens junctions compared to Arf6Q671- expression per se 
(p<0.0004, Figure 5.11b). 
Although Rablla did not show increased GTP-hydrolysis when incubated with 
Armus547_928 in the GAP assay, active Rab11a was able to interact and co-localise with 
Armus547 928 using different techniques (Figures 5.6 and 5.8). Therefore, the effect of 
Rab11a inactivation on Arf6-induced junction disassembly was investigated. A direct 
role of Rab11a is a reasonable question, as Arf6 signalling has previously been 
connected to Rab11-dependent transport via FIP3 and FIP4 (Fielding et al., 2005). 
Dominant-negative Rab11a by itself did not affect the stability of E-cadherin-based 
junctions after three hours expressing, in contrast to the potent disruption of junctions 
induced by sustained Arf6 activation (Figure 5.12a, Rab1la525N arrowheads and Arf6Q67- 
arrows). Over-expression of Arf6a67L together with Rab11as25N showed a small 
inhibition of Arf6-driven junction disruption: increased E-cadherin staining at sites of 
cell-cell contacts (arrowheads) but abnormal cell morphology accompanied by 
concentration of E- cadherin receptors at the perinuclear region. Co-expression of 
Arf6Q67L with Rab11as25N resulted in 41% intact junctions, compared to 7% by active 
Arf6 alone (Figure 5.12b, Arf6Q6 + Rab1las25N, p<0.03). Thus, inactivation of Rab11a 
had a partial yet significant effect on Arf6-induced junction disassembly. 
In addition, to demonstrate specificity, dominant-negative Rabl (Rab1as25N) was 
used as a negative control as it did not associate with Armus547_928 in the 
immunoprecipitation and GAP assay (Figures 5.6a and 5.8). After quantification, the 
percentage of intact junctions in Arf6Q67--expressing cells was 11%, which is 
comparable to 9% intact junctions when Rablas25N was co-injected with Arf6 in 
keratinocytes (Figure 5.12a and 5.12c). 
The above described results support the hypothesis that activation of Rab7, 
which can be modulated by its GAP protein Armus, is specifically required 
for active 
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Arf6 to induce keratinocyte junction disruption. Upon co-expression with active Arf6, 
inhibition of Rabla function did not prevent dissociation of cell-cell contacts (Figure 
5.12). Dominant-negative Rabl1a expression partially blocked Arf6-induced junction 
disassembly (Figure 5.12), suggesting that Rab11a may have a role during this event. 
Together, the data suggests that Armus can integrate important signalling events from 
Rac and Rab7 during Arf6-induced destabilisation of keratinocyte junctions. 
5.2.8 An Armus547_928 mutant defective in binding to Rab11a does not interfere with 
Ar6-induced perturbation of cell-cell contacts 
Arf6-induced E-cadherin junction destabilisation could be partly rescued by the 
dominant-negative form of Rab11a (Figure 5.12). Moreover, Rabl1a binds Armus547 928 
using the yeast-two hybrid and co-immunoprecipitation techniques (Figure 5.6). A 
potential mechanism via which dominant-negative Rab11a could block Arf6-induced 
perturbation of junctions is sequestering of Armus. Because these observations suggest 
a direct link of Armus with Rab 11 a, I investigated junction stability in cells over- 
expressing active Arf6 and an Armus mutant construct unable to interact with Rab11a. 
First, an Armus547 928 mutant needed to be designed that is unable to bind to 
Rab11a. Crystallisation studies have shown that a complex between a GAP and GTP- 
bound GTPases forms via a docking approach, such as p120GAP with H-Ras and the 
yeast GAP protein Gyp1p in complex with the Rab1 homologue Ypt5l (Scheffzek et al., 
1996,1997; Rak et al., 2000). These and other studies have revealed a GTPase binding 
pocket in the GAP domain, where the actual catalysis of GTP hydrolysis takes place. 
Although this binding pocket on the GAP is specific for a given GTPase, it is not clear 
whether the pocket is the only site where binding between the GTPase and GAP 
protein occurs. Several reports have shown mutated GAP proteins that have lost their 
ability to catalyse GTP hydrolysis, such as the critical arginine located in the binding 
pocket, but with such mutations the GAP maintains the ability to interact with the 
GTPase. Other reports have focused on mutations in the GTPase, upon which the 
GTPase looses the ability to interact with the GAP protein (Scheffzek and Ahmadian, 
2005). 
The binding for Rabl1a on Armus547-928 can lie in the region where Rab7 binds, 
but might also be somewhere else on the protein. To create an 
Armus mutant defective 
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in binding to Rab11a, it is important to identify functional regions in the GAP domain 
involved in the exclusive GTPase recognition, rather than conserved regions which are 
essential for the actual GAP activity. The functional regions that might be essential for 
Rab11a binding towards Armus was analysed using the Protein Homology/analogY 
Recognition Engine (PHYRE; Kelley et al., 2000; Bennet-Lovsey et al., 2008). Briefly, 
PHYRE is an automated fold-recognition program designed to predict a folding model 
of the protein of interest and thereby uncovers potential important functional residues. 
Using the PHYRE program for Armus amino acid 547 to 928, an alignment was made 
with the most homologous and previously crystallised yeast TBC/RabGAP protein 
Gyplp (Rak et al., 2000). Thereafter, the Armus consensus functional regions according 
to PHYRE were calculated (D. Kedra, Imperial College London, unpublished data). 
Using this approach, Armus residues predicted to be functional rather than 
conserved amino acids were glutamine at position 713 (Q713), glycine at 714 (G714), 
leucine at 794 (L794) and thryptophan at 810 (W810; Appendix I). The corresponding 
residues on the Gyp1p model available at the Protein Data Bank (PBD) were manually 
inspected. The amino acids Q713, G714, L794 and W810 on Armus corresponded to 
the Gyp1p residues Q378, G379, N485 and W501, respectively. Residues Q378, G379 
and N485 are localised in the proposed binding pocket of the GAP domain that 
interacts with substratum and therefore likely to be important in binding towards the 
GTPase Ypt5l. However, positioning the W501 amino acid on Gyp1p showed no 
localisation in the binding pocket. Instead, it is positioned further away from the 
binding pocket and reasonably deep inwards a protein fold, which possibly can not be 
involved in direct GTPase binding. 
To avoid large conformational changes of the TBC/RabGAP domain, the Q713, 
G714 and L794 amino acids present in Armus547-928 were replaced 
by an alanine (A) 
using site-directed mutagenesis. In addition, the double point-mutants 
Q713A/G714A, 
Q713A/L794A, G714A/L794A and triple point-mutant Q713A/G714A/L794A were 
created. According to the prediction that W810 residue on Armus might not 
be 
implicated in a direct binding with Rab11a, only the single point-mutation 
W810A was 
created on Armus547-928" 
ArmUS547-928 point-mutants were assayed for their ability to interact with 
activated Rablla by immunoprecipitation under the same conditions as previously 
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performed (Figure 5.6). Equal expression of Rablla"Ov in all samples was observed, 
but not for Armus mutants. This result may suggest that co-expression of active 
Rablla affects the expression levels of these specific Armus point-mutants. However, 
in all samples comparable amounts of Armus mutants was precipitated using the anti- 
flag antibody indicating that a saturation of the antibodies was reached. 
As expected, wild-type Armus547 928 showed binding with RabllaS2oV (Figure 
5.13a). Interestingly, Rabllas2ov co-precipitated less efficiently with the point-mutant 
ArmUS547-928L794A and the double point-mutant ArmuS547-928G714A/L794A. This suggests that 
the intact L794 amino acid in Armus TBC/RabGAP domain is important for interaction 
of Rab11as2ov with Armus. Surprisingly, mutation of the W810 amino acid resulted in a 
stronger binding of Rab11as2ov. This occurred in spite of similar levels of precipitation 
of Armus547.928W810A and wild-type Armus547-928. Due to time constraints, the ability of 
Armus mutants to interact with Rab7 could not be addressed. 
Arf6-induced junction disassembly was tested in the presence of Armus547. 
928L794', as this single point-mutant is likely to have less conformational changes than 
the double mutant Armus547_928L794A1G714A. Equal microinjection conditions were taken as 
described for active Arf6 and wild-type Armus547-928. As shown previously, active Arf6 
rapidly perturbed the stability of E-cadherin junctions after three hours expression 
(Figure 5.13b, Arf6a67f-). Interestingly, the level of junction disruption by Arf6Q67- did 
not change when co-expressed with Armus547 928' 794A (Figure 5.13b, Arf6a67L + Armus547- 
928 L794A) . 
Arf6Q671- showed 9% intact junctions and a non-significant change to 19% was 
observed when Arf6Q6 was expressed together with Armus547-928L79 (Figure 5.13c). 
These results suggested that the binding of Rabl1 may be im portant for the 
blockage effect of Armus547_928 during Arf6-induced junction perturbation. 
Alternatively, the point-mutant Armus547 928L794A may not be able to hydrolyse Rab7 and 
is for that reason unable to inhibit destabilisation following Arf6 expression. This 
possibility remains to be tested experimentally. 
5.2.9 Re-distribution of E-cadherin molecules upon Arf6-induced junction disruption 
Upon sustained Arf6 activation, E-cadherin receptors are removed 
from the 
plasma membrane and accumulation of E-cadherin staining occurs 
in a perinuclear 
area. In MCF-7 cells, the build-up of intracellular E-cadherin upon 
Arf6 activation has 
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been demonstrated before but was not characterised (Paterson et al., 2003). Palacios 
and colleagues (2005) showed that upon v-Src-induced junction disruption in MDCK 
cells, E-cadherin receptors are ubiquitinated and internalised towards lysosomes for 
degradation. Similarly to MDCK cells, the observed intracellular accumulation of 
keratinocyte cadherins might be a lysosomal compartment. The fact that Rab7 
signalling has been shown to be necessary for Arf6-induced junction disassembly 
(Figure 5.11), suggests that Arf6 activation causes internalisation of E-cadherin 
followed by targeting to late endosomes and lysosomes for degradation of E-cadherin 
receptors where Rab7 function is essential (Press et al., 1998; Vitelli et al., 1997; Bucci et 
al., 2000). To investigate the identity of the compartment with accumulated E-cadherin 
receptors, co-staining with two lysosomal markers was performed in cells over- 
expressing constitutively active Arf6. 
First, Arf6Q67L was expressed for three hours and co-stained for LAMP1 and E- 
cadherin. The membrane of lysosomes and late endosomes is enriched in highly 
glycosylated transmembrane proteins such as LAMP1 (Granger et al., 1990). Non- 
injected keratinocytes showed staining for LAMP1 at a perinuclear area (Figure 5.14a, 
LAMP1). In Arf6Q67Lover-expressing cells, LAMP1 recruitment was observed around 
the accumulation of internalised E-cadherin receptors but no co-localisation was seen. 
In the merge panel of Figure 5.14a the arrowhead indicates the perinuclear E-cadherin 
accumulation and an arrow points to the adjacent LAMP1 staining detected. 
Second, a parallel experiment was performed as described above, but co- 
stained with endogenous CD63. As for LAMP1, CD63 marks late endosomes and 
lysosomes (Escola et al., 1998; Kobayashi et al., 2000). The enlarged picture in Figure 
5.14b showed no co-localisation of CD63 to the compartment with accumulated E- 
cadherin receptors. However, similarly as observed with LAMP 1, CD63 was recruited 
around this compartment (Figure 5.14b, merge). These results together indicate that 
the observed perinuclear compartment where E-cadherin accumulates is not labelled 
with the lysosomal markers LAMP1 and CD63, as these markers were recruited to but 
remained adjacent to sites of E-cadherin accumulation. Thus in keratinocytes, the 
perinuclear area where E-cadherin receptors concentrate upon Arf6467Lover-expression 
do not represent a lysosomal compartment. This is in contrast with what 
has been 
described in MDCK cells following Src-induced cell-cell dissociation (Palacios et al., 
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2005). The discrepancy observed may be explained by the difference in stimuli used to 
destabilise adherens junctions (Arf6Q671- versus v-Src). In addition, a longer incubation 
period of Arf6Q67L may show transport of the receptors to lysosomes. 
I have shown that activation of Rac and Rab7 are required for Arf6-induced 
perturbation of cell-cell contacts, as the dominant-negative form of these GTPases as 
well as Armus547-928 can block this phenotype (Figures 3.3,5.3 and 5.11). With the 
purpose of gaining insight into the transport route of E-cadherin and identity of the 
perinuclear compartment following Arf6Q67L expression, I determined whether the 
accumulation of E-cadherin is influenced when RacT"N , Rab7T22N, Armus547 928 and 
Rab1las25N are co-expressed with Arf6Q67L. For each microinjection experiment 
presented in the Figures 3.3,5.3,5.11 and 5.12, the number of cells with clear 
intracellular accumulated E-cadherin receptors was expressed as the percentage of 
total over-expressing cells (Figure 5.14c). Inhibiting Rac signalling interfered with the 
perinuclear concentration of E-cadherin receptors, as this was significantly reduced 
from 83% for Arf6Q67Lexpressing cells to 32% co-expressing with RacT17`1 (p<0.00001). 
Rac may be involved at the plasma membrane in endocytic processes (Qualmann and 
Mellor, 2003) that could therefore account for its blockage effect on Arf6-mediated E- 
cadherin internalisation. 
Interference of Rab7 signalling, via a dominant negative approach (Rab7"22N) or 
over-expressing its GAP protein (Armus547_928), showed a reduction in the percentage of 
cells with E-cadherin accumulation at a perinuclear region (28% and 48%, respectively, 
p<0.00002 and p<0.0009). Thus, inhibiting Rab7 signalling prevented internalisation of 
E-cadherin receptors and blocked the concentration of E-cadherin in a perinuclear 
region. Rab7 has a regulatory role at late endosomes and lysosomes (Press et al., 1998; 
Vitelli et al., 1997; Bucci et al., 2000). Although the structures with E-cadherin 
intracellular accumulation were negative for the lysosomal proteins LAMP1 and CD63 
(Figure 5.14a and 5.14b), the reduction in the number of cells with perinuclear E- 
cadherin staining suggests a role for Rab7 in Arf6-induced cell-cell 
dissociation. 
Interestingly, previous studies in MDCK cells showed that v-Src-induced adherens 
junction dissociation and shuttling of E-cadherinto lysosomes is inhibited 
by 
dominant-negative Rab7 although large endosomes containing E-cadherin were still 
observed. This indicated that Rab7 signalling is important 
for transport of E-cadherin 
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from early endosomes to late endosomes/lysosomes (Palacios et al., 2005). In 
keratinocytes, no such early endosomal structures were observed when Rab7T22N or 
Armus547_928 was co-expressed with Arf6Q67L. However, confocal microscopy might be 
required to clarify in which intracellular compartment inhibition of E-cadherin 
transport occurs. 
On the other hand, it could be possible that the perinuclear area with 
accumulated receptors represents a recycling endosome compartment as this is also 
often found localised near the nucleus (Ullrich et al., 1996). Endocytosis of cargo can be 
recycled back to the plasma membrane either directly or via late endosomes and 
recycling endosomes (Stem-nark and Olkkonen, 2001; Segev, 2001). Interfering with 
Rab11a signalling could affect the accumulation of E-cadherin receptors upon Arf6Q67- 
expression if this undergoes a route via recycling endocytosis. Upon inhibition of 
Rablla, a partial rescue of Arf6-disrupted junctions was observed (Figure 5.12) but a 
similar percentage of intracellular accumulated E-cadherin compared to Arf6 alone 
was found (Figure 5.14c; 78% and 82% respectively). Although it can not be excluded 
that inhibiting Rab11 signalling may not prevent internalisation of E-cadherin 
receptors in late endosomes, it is unlikely that the compartment formed upon Arf6Q67L 
expression represents recycling endosomes. 
In summary, the area with accumulated E-cadherin receptors upon Arf6Q67L 
over-expression does not represent lysosomes and is probably not a recycling 
endosomal compartment. As Rab7 signalling is found essential for the accumulation of 
E-cadherin receptors, this compartment may be a late endosomal compartment. It 
could then be possible that incubation over longer time eventually causes breakdown 
of E-cadherin by shuttling to lysosomes. 
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Figure 5.14: Identifying the compartment containing internalised E-cadherin receptors upon Arf6Q67- 
expression. 
(a) Keratinocytes were injected with Arf6Q67L, incubated for three hours and then cells were stained for 
HA-tag, LAMP1 and E-cadherin. Images were taken using confocal microscopy and panels on the right 
show a merge of the three fluorescence images. Arrowhead shows accumulation of internalised E- 
cadherin receptors by active Arf6, arrow points towards LAMP1 staining. (b) Similar experiment as 
performed under (a) but staining for CD63. Arrow points to CD63 recruited to accumulation of E- 
cadherin receptors. White boxes mark the original area of the amplified picture below. Scale bar = 
16µm, insert scale bar = 64µm. (c) Quantification of the percentage of co-expressing cells showing 
accumulated E-cadherin receptors at a perinudear area following Arf6-induced junction disruption. 
p<0.0009; **, p<0.00001; ***, p<0.00002. Error bars represent S. E. M. n >_ 3. 
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5.3 Conclusion 
Full-length Armus can bind to activated Rac and contains a specific GAP 
domain for Rab7. The GAP domain can interact with Rabli, but has no activity 
towards this Rab. The functional role of Rab11a binding to Armus547_928 is not known 
and requires further investigation. In keratinocytes, Armus localises at E-cadherin- 
based cell-cell contacts and can be co-immunoprecipitated specifically with these 
complexes. This chapter provides evidence that the novel protein Armus can integrate 
signalling from Rac and Rab7 small GTPases during keratinocytes junction 
perturbation driven by dominant-active Arf6. During Arf6-mediated junction 
disassembly, Armus remains associated with E-cadherin receptors accumulated in a 
perinuclear area which probably represents a late endosomal compartment. This area 
recruits the lysosomal marker proteins LAMP1 and CD63, but their localisation 
remains adjacent to accumulated E-cadherin. GAP activity of Armus towards Rab7, or 
inhibition of Rab7 signalling both block Arf6-driven junction disassembly potently. 
The participation of Rab7 in this process is specific, as inactive Rab1 (and to a lesser 
extent Rab11a) was not able to fully rescue junction disassembly. 
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5.4 Discussion 
5.4.1 Regulation of Armus 
Armus participates in a cross-talk between two GTPases of different 
subfamilies, Rac and Rab7, during Arf6-driven junction perturbation. A connection 
between Rac and Rab7 has been described by Palacios and co-workers (2005), in which 
v-Scr activation in MDCK cells induces junction disassembly via Arf6 signalling 
towards Rac and also Rab7. In keratinocytes, similar molecules are involved 
downstream of Arf6 compared to the studies in MDCK cells (Figure 3.3 and 5.11) 
where I identify that Armus bridges Rac and Rab7 function. However, the role of 
active Rac in junction destabilisation following Arf6 activation is not similar in both cell 
types. In order to perturb stability of cell-cell contacts in MDCK cells, Arf6 activation 
induces transient downregulation of Rac activity (Palacios et al., 2003). In contrast, the 
activation of Rac is necessary downstream of Arf6 to induce a similar phenotype in 
keratinocytes. Because of the discrepancy in Rac activation, it remains to be tested 
whether Armus can also be involved during junction disruption in MDCK cells. 
Full-length Armus could not rescue junction disassembly but instead localised 
to the compartment with accumulated E-cadherin. This is similar to what observed for 
endogenous Armus indicating that it might participate in the Arf6-induced phenotype 
(Figures 5.4 and 5.5). This observation is opposite to the rescue effect of Armus547-928 
during Arf6-induced junction disassembly (Figure 5.3). It is feasible that Armus547-928 is 
able to hydrolyse GTP-bound Rab7, whereas full-length Armus might be in an inactive 
conformation or regulated in a spatial and temporal manner by other proteins via its 
N-terminal region. 
Over-expression of Armus PH domain (Armus1_169) showed 74% localisation at 
cell-cell contacts (R. Francis, unpublished data). Therefore, the PH domain is most 
likely responsible for localising Armus by binding to specific PtdIns in the plasma 
membrane which is in close proximity to E-cadherin-based cell-cell contacts (Figures 
4.4 and 5.1). However, the association of Armus with E-cadherin junctions can also be 
facilitated by membrane-associated proteins that interact with the PH domain or other 
domains on Armus. This has for example been shown for RN-Tre that transduces 
signals from Rab5 during macropinocytosis via direct association with actin and a- 
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actinin (Lanzetti et al., 2004). Future experiments should elucidate how Armus is 
associated with E-cadherin junctions. 
The activation status of Armus is probably regulated by other regions than the 
PH domain. It is unlikely that Arf6 may activate Armus by directl interaction because 
(i) no obvious co-localisation between Arf6 and Armus, _550-induced vesicles was seen 
(Figure 4.6), (ii) no association of Arf6 was observed with Armus547 928 (Figure 5.5) and 
(iii) no co-localisation of full-length Armus with Arf6Q67L was detected (Figures 5.4 and 
5.5). Instead, the protein that might activate Armus could be active Rac, as it can bind 
to the central coiled-coil domains of Armus and as a result could disrupt Armus' 
dimerisation and/or auto-inhibition status (as discussed in Chapter 4). When Arf6 
signalling activates Rac, Rac could bind Armus and subsequently GTP hydrolysis of 
Rab7 might occur. To prove this hypothesis, the GAP assay with full-length Armus 
needs to be performed. If no GAP activity can be detected, it should be tested whether 
Armus requires active Rac to be able to hydrolyse GTP-bound Rab7. 
5.4.2 Armus inactivates Rab7 
The GTP hydrolysis of both Rab7 and Rab7C022 provide the key evidence that 
Armus has GAP activity and is specific for Rab7 (Figure 5.8). Thus far, stable binding 
between Armus and Rab7 could not be observed and seems to be difficult. In some 
papers it has been shown that wild-type GAP proteins can bind GTP-locked Rabs 
(Dabbeekeh et al., 2007; Pei et al., 2002; Lanzetti et al., 2000), but binding of Rab7Q67- to 
ArmUS547-928 could not be observed using immunoprecipitations. However, other 
papers have not shown a direct interaction between a TBC/RabGAP protein and 
its 
substrate (MIinea et al., 2005; Zhang et al., 2005; Fuchs et al., 2007; Fritolli et al., 2008). 
In 
a large yeast two-hybrid screening using all predicted mouse TBC/RabGAP proteins 
and Rabs, no interaction was observed between full-length Armus (named 
FLJ22452 in 
this paper) and any of the 60 tested Rabs, including Rab74671- (Itoh et al., 
2006). 
An explanation for the difficulty in detecting the TBCRabGAP: 
Rab interaction 
might be two fold: (i) the transient interaction between 
GAPs and their substrates and 
(ii) an auto-inhibited status of the full-length TBC/RabGAP protein, which 
is most 
likely an inactive status (Pufall and Graves, 2002). 
Indications that full-length Armus is 
inactive fit well with latter explanation. For Armus, its 
GAP activity can be regulated 
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by dimerisation status and/or Rac binding, two processes that require experimental 
validation. Perhaps for other TBC/RabGAP proteins similar issues are the reason for 
the difficulty in showing TBC/RabGAP: Rab interaction. Considering this, testing the 
binding of the active GAP construct (ArmuS547-928) to active Rab7 might work using the 
yeast-two hybrid technique. Alternatively, biochemical methods like crystallisation 
and gel filtration assay using purified proteins can be used. 
The transient interaction of TBCRabGAP with the GTP-bound form of a 
specific Rab is an additional explanation for the difficulty in TBC/RabGAP: Rab binding 
studies. More often, binding experiments are performed with a mutation in the critical 
arginine of the GAP together with a constitutively active Rab. In this case, the mutated 
GAP does not display hydrolysis but remains bound to the active Rab. For example, 
the interaction of RabGAP-5R165A with Rab5Q67- was strongest in a yeast two-hybrid 
screen, weaker when either of the wild-type proteins was used and barely detectable 
between two wild-type proteins (Haas et al., 2005). Creating this arginine to alanine 
mutation in Armus on amino acid 676 (Figure 1.10), might help to demonstrate binding 
with its target Rab7. 
Thus, a stable interaction of TBC/RAbGAPs and their target Rabs has 
previously been shown using mutated proteins. However, if this is required for 
showing a stable interaction, than the prediction would be that more binding partners 
of TBC/RabGAP proteins would have been found in a previous large screening (Itoh et 
al., 2006; Haas et al., 2005). This demonstrates that for most TBC/RabGAP proteins, it is 
difficult to show the actual binding with a Rab, and therefore the substrate of only 19 
of the 52 predicted TBC/RabGAP containing proteins are known until now (Table 1.1; 
Bernards, 2003). 
5.4.3 Linking Arf6 and Rabl1a signalling via Armus 
There is a reasonable amount of evidence favouring the link of Rab11a with 
Armus. Armusl_55o-induced vesicles recruit endogenous Rabl1a and these vesicles can 
be disrupted by the activated form of Rabl1a. Furthermore, Rab11a has been shown to 
bind Armus547-928 by immunoprecipitation, yeast two-hybrid assay and partially co- 
localises with Armus547_928 in vivo (R. Francis, unpublished observations). No complex 
of these proteins using gel filtration was observed (N. Bleimling, unpublished data). 
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Thus, all in vivo data point to a potential association of ArmuS547-928 with Rablla while 
the in vitro gel filtration does not confirm this interaction. These findings suggest that 
the association of Rabll with ArmuS547-928 may be dependent on post-translation 
modifications which might not be present on purified proteins produced in bacteria. 
The Armus547_928L794A mutant cannot immunoprecipitate active Rabila or rescue 
junction disassembly after sustained Arf6 activation (Figure 5.13). However, whether 
the mutation L794A on Armus547_928 affects the GAP activity on Rab7 remains to be 
determined. 'thus, it is difficult to discern whether the inability to rescue Arf6- 
disrupted junctions is due to interference with Rabl1a or Rab7 function by lack of GAP 
activity. 
Although the interaction Armus547-928: Rablla is stable enough to be detected, 
Armus TBC/RabGAP shows no activity towards Rab11a. Other reports have also 
observed interaction of several TBC/RabGAP proteins with specific Rab proteins in 
yeast two-hybrid assays, but no actual GAP activity was detected (Itoh et al., 2006; 
Haas et al., 2005). In addition to their function as Rab inhibitors, TBC/RabGAP proteins 
have been suggested to act as a Rab effector protein (Lanzetti et al., 2004). This 
phenomenon was first suggested with RasGAP where signalling from Ras can be 
transduced by direct binding of RasGAP to other effector proteins (Tocque et al., 1997). 
Examples of such interactions have been described for RN-Tre that interacts with actin 
and a-actinin, TBC1D3 that binds the Arf6 effector protein GGA-3 and EP164 that 
interacts with Arf6-GTP (Lanzetti et al., 2004; Hanono et al., 2006; Fritolli et al., 2008). 
Thus it is feasible that Armus binding to Rab11 is genuine and part of a specific 
signalling pathway. 
Rabl1 has a well-established role in trafficking through the recycling endosome 
(Ullrich et -al., 1996). How can Rab11a interfere with the Arf6-driven junction 
disassembly? One possibility is that in cells with sustained Arf6 activation, plasma 
membrane containing E-cadherin receptors is internalised and needs to be recycled to 
the cell surface. By inhibiting the recycling of internalised membranes with 
dominant- 
negative Rab11a, the internalisation rate of E-cadherin receptors might 
be delayed. 
Another possibility is that Arf6 function in the recycling pathway is 
disturbed upon 
blocking Rab11 function. Although Arf6 defines a pathway regulating endocytosis of 
various proteins (Chavrier and Goud, 2001; Donaldson and Jackson 
2000), it has been 
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shown to be involved in the recycling of (31-integrin (Powelka et al., 2004). Moreover, 
this report shows that Arf6 and Rabil act sequentially along a recycling pathway 
mediating (31-integrin recycling. 
In addition, there is evidence for cross-talk between Arf6 and Rabil. During 
cytokinesis, the Rab11 interacting proteins FIP3 and FIP4 function together with Rabll 
in the delivery of recycling endosomes to the cleavage furrow (Hales et al., 2001). FIP3 
and FIP4 exhibit distinct binding sites for active Arf6 and Rab11, and can form a 
ternary complex (Fielding et al., 2005). Interestingly, RNAi has shown that Armus may 
play a role in cell proliferation (R. Francis, unpublished data). Co-localisation studies 
of internalised E-cadherin using endogenous Rab11 or Rab11 effector proteins like FIP3 
and FIP4 could be performed. 
Furthermore, it will be interesting to investigate what the functional 
consequence of the interaction of Rab11a to Armus is. I would expect that Armus per se 
does not influence recycling of endocytosed E-cadherin receptors at steady state as its 
over-expression did not affect cell-cell junction stability compared to control cells 
(Figures 4.4 and 5.3). However, perhaps Armus has a function in endocytic recycling 
but requires stimulation of Arf6 or Rac to interact with Rab11. Future experiments 
should define the functional connection of Armus with Rab11. 
5.4.4 Armus during tumorigenesis 
PARIS-1 (Zhou et al., 2002), Armus (Figure 1.11) and three Armus splice 
variants (Genbank, R. Francis, unpublished data) have been found over-expressed in 
different tumour samples. The over-expression of Armus in tumours shown in Figure 
1.11 was detected by immunostaining and cannot distinguish between different slice 
variants. However, the three Armus variants in tumour samples found in the Genbank 
database all contain the intact TBCRabGAP domain. Two variants lack the PH 
domain and central coiled-coil domains and one lacks the C-terminal coiled-coil 
domain. These findings may suggest that Armus TBC/RabGAP function is implicated 
in the development of these tumours. 
The over-expression of Armus in tumour samples is consistent with an aberrant 
function of Arf6 in tumours. First, we and others have shown that Arf6 activation per 
se (this work and Palacios et al., 2001), downstream of v-Src activation 
(Palacios et al., 
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2002; 2005) or by expression of the Arf6 GEF protein ARNO (Santy and Casanova, 
2001) contribute to disassembly of E-cadherin junctions in epithelial cells. Second, Arf6 
has been shown to regulate tumour invasion in breast cancer cells (Hashimoto et al., 
2003) and melanoma cells (Tague et al., 2004) and in glioma cells via EFA6-stimulated 
GEF activity on Arf6 (Li et al., 2006). Also Rab7 has been found overexpressed in 
different tumours, such as diffuse malignant peritoneal mesothelioma (Davidson et al., 
2006) and autonomous thyroid adenomas (Croizet-Berger et al., 2002). As Rab7 cycling 
is probably important for its function, increased levels of Armus in tumours may be 
accompanied by upregulation of a Rab7 GEF protein that together contribute to an 
increased Rab7 signalling in tumours. 
Other TBC/RabGAP containing proteins have not been intensively studied in 
the context of tumorigenesis. Tre2 is an oncogene formed by chromosomal 
translocation in which the region of the osteoclast cadherin 11 gene is juxtaposed to the 
Tre2 coding sequence (Oliviera et al., 2004). The N-terminal TBC/RabGAP containing 
region of the RN-Tre is identical to Tre2. Unlike RN-Tre, Tre2 does not display any 
GAP activity towards Rab5 (Matoskova et al., 1996; Lanzetti et al., 2000). The reason for 
this is that the protein has several mutations in its TBC/RabGAP domain as well as in 
essential C-terminal regions (Bizimungu et al., 2003; Bizimungu and Vandenbol, 2005). 
Thus, although Tre2 has been found upregulated in cancers, GAP activity is not 
involved in its oncogenic function. The Rab5-specific GAP protein PRC17 was 
identified as an oncogene in a panel of prostate tumours. PRC17 by itself can 
transform mouse fibroblasts, which is abolished when mutations in the conserved GAP 
domain are made. Thus, the GAP activity of PRC17 seems important for its oncogenic 
function (Pei et al., 2002). 
Alterations of lysosomal transport and increased expression of proteases 
(Cathepsins) has been shown to participate in tumour growth and metastasis 
(Fehrenbacher and Jäättelä, 2005). Armus could have a similar function as PRC17, in 
which its actual Rab7-GAP activity for lysosomal function is important for cycling of 
Rab7 during tumour development. In a paper by Haas and colleagues (2007), TBC1D2 
(Armus closest homologue) has been tested as part of a large screen of TBC/RabGAP 
domain proteins, where it did not show involvement in Golgi fragmentation, 
ER-Golgi 
intermediate compartment or VSV-G transport from the ER to the cell surface. 
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Moreover, TBC1D2 did not influence melanosome transport to the cell periphery (Itoh 
and Fukuda, 2006), primary cilium formation (Yoshimura et al., 2006) and its over- 
expression did not block EGFR transport into early endosomes (Fuchs et al., 2007). 
However, a caveat of these reports is that full-length TBC1D2 was used, which our 
data suggest may be inactive (see section 5.4.1). Alternatively, Armus might also have 
other functions that favour tumour growth, i. e. proliferation. Indeed, preliminary 
RNAi experiments showed a possible involvement of Armus in keratinocyte 
proliferation (R. Francis, unpublished data). 
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5.5 Future experiments 
5.5.1 Recruitment of Armus to E-cadherin junctions 
Endogenous Armus is localised to E-cadherin-mediated junctions. It is not clear 
how Armus is recruited to these sites of keratinocyte cell-cell contacts, although this is 
likely mediated by the interaction of the PH domain on Armus with specific Ptdlns. A 
previous performed protein lipid overlay and lipid sedimentation assay did not show 
an interaction of Armus PH domain with lipids (R. Francis, unpublished data). 
Perhaps secondary membrane-associated factors are required for Armus recruitment to 
membranes (Lemmon, 2004) like active Rac. This is supported by the fact the 
exogenous Rac can disrupt Armusl-550 localisation at vesicles. Sequestering active Rac 
by expression of PAK-CRIB will redirect endogenous Armus immunofluorescence 
from membranes. Also lipid binding assays using Armus, _sso and 
full-length Armus in 
the presence of Rac will determine a possible role of Rac in membrane localisation of 
Armus. 
Moreover, other unidentified Armus-interacting proteins may recruit Armus to 
cell-cell junctions. Mass spectrometry and yeast two-hybrid screening using Armus as 
bait can identify novel interacting partners. Alternatively, direct binding of purified 
Armus with E-cadherin and catenins could be performed. 
5.5.2 Signalling from and towards Rac during Arf6-mediated junction disruption 
Future experiments will involve the role of Rac signalling towards Armus 
during Arf6Q67L-mediated cell-cell contact perturbation. If Rac is essential for Armus 
GAP activity by interaction with its central coiled-coil domains, full-length Armus will 
only hydrolyse Rab7 in the presence of active Rac. A GAP activity assay using 
full- 
length Armus will be performed on Rab7-GTP proteins. I suspect that a slow 
GTP 
hydrolysis will be observed, that can be accelerated when Rac-GTP 
is added to the 
reaction. However, when addition of Rac does not influence 
GAP activity, other 
proteins or phosphorylation events might regulate the activity of 
Armus. The 
previously suggested yeast two-hybrid assays and mass spectrometry experiments 
with immunoprecipitation experiments of endogenous 
Armus will then identify 
potential proteins. 
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5.5.3 Identifying the perinuclear compartment with concentrated E-cadherin upon 
Arf6-induced junction perturbation 
Experiments in keratinocytes have shown that the accumulation of E-cadherin 
receptors at a perinuclear area after Arf6Q67I- over-expression does not contain markers 
of lysosomes. However, this result has previously been observed in MDCK cells upon 
v-Src-induced junction dissociation via Arf6 activation (Palacios et al., 2005). It could 
be possible that upon longer incubation times of Arf6Q67L, E-cadherin is transported to 
lysosomes for degradation and will be investigated by co-localisation studies. 
Co-staining of endogenous Rab7 will show whether Rab7 is recruited to sites of 
intracellular E-cadherin accumulation upon Arf6-induced junction destabilisation. 
Alternatively, a Rab7 effector protein could show the participation of active Rab7 in the 
compartment of accumulated E-cadherin receptors. For this, co-expression 
experiments of active Arf6 with the only two identified Rab7 effector proteins RILP or 
Rabring7 could be performed (Cantalupo et al., 2001; Mizuno et al., 2003). 
5.5.4 Dissecting the function of Armus with Rab7 from Rabll 
It would be important to investigate the cellular function of the interaction of 
Rab11 with Armus TBC/RabGAP domain and to examine whether the link of Armus 
with Rab7 and Rab11 can be cut apart and coordinate different cellular processes. As 
Rab11 is important for recycling endocytosis (Casanova et al., 1999) a possible role for 
Armus here could be investigated in cells depleted of endogenous Armus. Perhaps in 
the presence of potential stimulators of Armus (i. e. activated Arf6 or Rac) its 
participation may be more apparent in recycling endocytosis. In addition, over- 
expression of Rab11 mutants in Armus-depleted cells could show whether the link of 
Rab11 to Armus is important for normal endocytic recycling. 
However, when Armus does not play a role in recycling, investigation will be 
done whether the actual binding of Rabl1 to Armus participates during E-cadherin 
junction disassembly driven by Arf6. To elucidate whether Armus 
TBC/RabGAP: Rabll interaction is important during Arf6-mediated junction 
perturbation, comparison of the GAP activity of wild-type and L794A mutated 
Armus547 928 on Rab7-GTP will 
be performed. Moreover, full-length Armus localises at 
the area of accumulated E-cadherin receptors after Arf6 activation 
(Figure 5.4 and 5.5) 
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and co-localisation studies will implicate endogenous Rabl1 and Rab11-specific 
effectors i. e. FIP3/FIP4 (Fielding et al., 2005). 
5.5.5 Upstream components involved in keratinocyte junction disruption 
Future directions will aim to unravel other components of the Arf6- and Rac- 
induced signalling pathways of junction disassembly. In chapter 3, experiments are 
already proposed to investigate ubiquitination-mediated degradation of E-cadherin 
after Rac- and Arf6-induced keratinocyte junction destabilisation. Oncogenic Ras- 
induced cell transformation is dependent on Rac signalling in keratinocytes (Braga et 
al., 2000). It will be interesting to investigate the function of the Arf6, Armus and Rab7 
downstream during Ras-induced junction disassembly. Co-microinjection experiments 
of oncogenic Ras with dominant-negative Arf6, Armus TBC/RabGAP and dominant- 
negative Rab7 will be performed. 
Furthermore, upstream mechanisms for junction disassembly by Arf6 may be 
the Arf6 GEF protein GEP, oo/BRAG2. Interestingly, GEP, oo/BRAG2 can bind a-catenin 
and its PH domain interacts directly to the phosphorylated tail of the EGFR (Morishige 
et al., 2007). Whether activation of GEP, oo/BRAG2 can induce a similar phenotype as 
Arf6Q67f- will be investigated by expressing an activation mutant in keratinocytes. 
Chapter 6 
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6.1 Introduction 
GIT1 is a multidomain protein (Figure 6.1) that can interact with various 
proteins including G protein-coupled receptor kinases (GRKs), focal adhesion kinase 
(FAK), paxillin, piccolo and liprin-a (Premont et al., 1998; Zhao et al., 2000b; Turner et 
al., 1999; Kim et al., 2003; Ko et al., 2003). In addition, GIT1 inactivates Arf6 via its 
Arf AP domain (Vitale et al., 2000; Claing et al., 2001) and binds the Rac GEF (3-PIX via 
its Spa2 Homology Domain (SHD, Zhao et al., 2000b; Manser et al., 1998; Figures 1.9 
and 6.1). For these latter capabilities, GIT1 is good candidate molecule to provide the 
connection between Arf6 and Rac during E-cadherin junction perturbation. 
The first ankyrin repeat on GIT1 mediates its localisation at the cell membrane 
(Di Cesare et al., 2000; Paris et al., 2002; Figure 6.2). Besides this motif, the existence of 
oligomeric GIT1 and (3-PIX complexes in the cell appears to be important for the 
localisation at focal contacts, cell periphery and cytoplasmic complexes throughout the 
cell (Loo et al., 2004; Kim et al., 2001; Turner et al., 1999). These oligomers consist of 
homodimers of both GIT1 and (3-PIX (Premont et al., 2004; Botrugno et al., 2006). 
Interestingly, the Rac effector molecule PAK interacts directly with (3-PIX and is also 
recruited to GIT1-(3-PIX oligomers (Manser et al., 1998; Bagrodia et al., 1998; Brown et 
al., 2002; Di Cesare et al., 2000; Premont et al., 2000; Zhao et al., 2000b). 
In COS-7 cells and fibroblasts, GIT1 and p-PIX have a well-established role at 
integrin-dependent focal contact adhesion that links the extracellular matrix (ECM) to 
the actin-rich cytoskeleton (Zhao et al., 2000b). Primary keratinocytes cultured in low 
calcium medium contain many focal contacts to attach to the ECM. Upon induction of 
calcium-dependent E-cadherin junctions, focal contact structures are not observable 
anymore and (3-integrins relocate to sites of cell-cell contacts (Braga et al., 1995; Larjava 
et al., 1990). Regarding adherens junctions, a role for PAK and p-PIX has been shown 
during wound healing in MDCK cells (Zegers et al., 2003). In this process, essential 
translocation of ß-PIX and PAK from focal contacts at the free cell periphery to sites of 
cell-cell contacts was demonstrated. Co-localisation of P-PIX with the E-cadherin- 
catenin complex protein (3-catenin at sites of cell-cell contacts was observed here. In 
particular the localisation of 3-PIX at cell-cell contacts (Zegers et al., 2003) might 
indicate that this protein has a regulatory function at E-cadherin junctions. 
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Activation mutations or a differential expression of GIT1 in tumours has not 
been reported yet. In contrast, (3-PIX has been shown to be upregulated in different 
breast tumour samples (Ahn et al., 2003) and promotes tumour growth in MCF-7 breast 
cancer cells downstream of PDGFR signalling (Bae et al., 2005). Emerging data suggest 
that GIT1 and (3-PIX are also regulated by phosphorylation (Webb et al., 2006; Mayhew 
et al., 2007). Therefore, it is possible that these proteins are aberrantly activated in 
tumours. For example, GIT1 can be phosphorylated by the oncogene Src (Bagrodia et 
al., 1999), which when latter is activated in MDCK cells, it induces adherens junction 
disassembly via signalling towards Arf6 (Palacios et al., 2001,2005). 
In keratinocytes, Arf6 induces junction disassembly and requires Rac signalling 
(Figure 3.3 and 3.4c). Although the requirement of Rac activation is clear for 
destabilising cell-cell contacts, the mechanism by which Rac is activated by Arf6 is not 
known. One possibility is via recruitment of GIT1-(3-PIX complexes by active Arf6. 
Preliminary data obtained by E. Lozano in our lab showed that full-length GIT1 
rescues Arf6-dependent destabilisation of adherens junctions suggesting that GIT1 
may be involved in this process. Furthermore, expression of full-length GIT1 per se 
affected the stability of cell-cell contacts, but this phenotype was partially reversed 
when PAK signalling was inhibited. Thus, GIT1 could also have a role at adherens 
junctions. For example, ß-PIX and GIT1 heterodimers exist in the cell (Premont et al., 
2004; Botrugno et al., 2006) and our preliminary data showing an inhibition of Arf6- 
induced adherens junction disassembly by GIT1. 
In this chapter, I address which GIT1 domains are responsible for the rescue of 
keratinocyte junctions when co-expressed with activated Arf6 (Figure 6.1). The 
stability of E-cadherin-based junctions will be analysed by co-expression of different 
GIT1-derived mutants with Arf6Q67L and expression of Arf6Q67L in cells depleted of 
GIT1. Conversely, to investigate whether GIT1 is sufficient to perturb E-cadherin 
junctions over-expression of GIT1 mutant constructs per se will be performed. 
Furthermore, I will test whether p-PIX signalling is implicated in junction disassembly. 
As both GIT1 (Di Cesare et al., 2000; Paris et al., 2002) and Armus (Figure 4.4a) over- 
expression form large vesicles, a spatial connection between Armus and GIT1 will be 
explored by co-expression and immunoprecipitation studies. 
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Figure 6.1: Overview of GIT1 constructs. 
Outline of the different GIT1 constructs used in this chapter. Names and characterisation of 
the GIT1 mutants have been shown elsewhere (Totaro et al., 2007; Loo et al., 2004). Yellow stars 
indicate point-mutations D294K and E295R. ArfGAP, Arf6 GAP domain; A, ankyrin repeat; 
SHD, Spat Homology Domain; C, coiled-coil; PBD, Paxillin Bindig Domain. 
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6.2 Results 
6.2.1 GIT1 regulates Arf6 activity during junction perturbation 
As GIT1 full-length protein could block Arf6-driven junction perturbation, I 
looked into the domains on GIT1 that are responsible for this effect. A number of GIT1 
mutant constructs (summarised in Figure 6.1) were expressed with active Arf6 and 
junction stability was analysed. 
As full-length GIT1 functions as an Arf6-specific GAP (Premont et al., 1998; 
Vitale et al., 2000), it could be possible that GIT1 blocks Arf6-induced junction 
disassembly via association of Arf6Q67L to its ArfGAP domain. I investigated the 
participation of this ArfGAP domain in blocking Arf6 function, by co-expression of 
Arf6Q671 with an ArfGAP-deleted mutant (GIT1-C2). In contrast to the rapid junction 
disassembling process by Arf6Q67t-, over-expression of GIT1-C2 by itself did not alter 
keratinocyte junctions (Figure 6.2a, Arf6Q67L arrow; GIT1-C2 arrowhead). Vesicle-like 
structures induced by GIT1-C2 were also observed in microinjected keratinocytes 
(Figure 6.2a, GIT1-C2) as described before in different cell lines (Di Cesare et al., 2000; 
Matafora et al., 2001). Interestingly, when GIT1-C2 was co-injected with Arf6a67L, stable 
keratinocyte junctions were observed between two expressing cells (Figure 6.2a, 
Arf6Q6 + GIT1-C2 arrowhead). Quantitatively, a significant increase to 95% of cells 
containing intact junctions was seen after co-expression of Arf6Q67G with GIT1-C2 
(Figure 6.2c, p< 0.00002). This suggests that the ArfGAP domain on full-length GIT1 is 
not responsible for the blockage effect on junction disruption induced byArf6. 
Another GIT1 domain that could participate in the inhibitory effect on Arf6Q67L 
is the SHD that links Arf6 to Rac activation via binding of the Rac GEF protein ß-PIX 
(Bagrodia et al., 1999). A GIT1 truncation mutant lacking the. ArfGAP 
domain, ankyrin 
repeats and SHD (GIT1-C1) showed a diffuse distribution in the cytoplasm and 
did not 
influence junction stability after three hours of expression (Figure 6.2a, 
GIT1-C1 
arrowhead). Arf6Q67L was able to perturb E-cadherin-based 
junctions when co- 
expressed with GIT1-C1 (Figure 6.2a, Arf6467L + GIT1-C1 arrows) 
to comparable levels 
as control (Arf6 expression by itself, Figure 6.2d). 
This result indicates that the 
additional deletion of the SHD region on 
GIT1-C1 compared to GIT1-C2 is important 
for Arf6 to disassemble junctions. 
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The potential link to Rac activation by Arf6-GM-(3-PIX complex during 
junction disassembly was verified with two other approaches. Firstly, GIT1 full-length 
without the SHD (GIT1-zSHD) was expressed together with Arf6Q67L and did not 
inhibit E-cadherin junction disruption induced by Arf6 (Figure 6.2e, 10% intact 
junctions; Figure 6.2b, Arf6Q67L + GIT1-ASHD arrow). As opposed to Arf6Q67L over- 
expressing keratinocytes (12%, Figure 6.2e), expression of the GIT1-ASHD construct per 
se did not change the cell morphology when compared to non-injected cells (Figures 
6.2e and 6.2b, GIT1-ASHD arrowhead). 
Secondly, GIT1 full-length containing the point-mutations D294K and E295R in 
the SHD region of the GIT1 yeast homologue (GIT1-M4) was tested. These mutations 
in GIT1 were sufficient to abolish binding to p-PIX in an immunoprecipitation assay 
(Loo et al., 2004). GIT1-M4 injections did not cause any changes in the E-cadherin 
distribution, but showed induction of vesicles (Figure 6.2b, GM-M4). The ability of 
GIT1-M4 to disturb Arf6-induced junction disruption was expected to be minimal as 
previous experiments suggest that the SHD and thus the p-PIX connection is important 
for Arf6 to induce this phenotype. Indeed, co-microinjection experiments confirmed 
that GIT1-M4 did not significantly prevent active Arf6 from disrupting adherens 
junctions (Figure 6.2b, Arf6Q671- + GM-M4, arrow). Although the quantification of 
three independent experiments showed an increase in intact junctions from 3% by 
Arf6a67Lalone to 22% when GIT1-M4 was co-expressed, this difference was not found 
significant using a Student's t-test (Figure 6.2f, p<0.14). Further experiments are 
required to test its significance. 
In summary, the above results suggest that the presence of the SHD in GIT1 is 
required for the blockage of Arf6-induced junction disassembly. The GIT1-C1, GIT1- 
OSHD as well as GIT-M4 construct cannot interact with the Rac GEF (3-PIX (Di Cesare 
et al., 2000; Albertinazzi et al., 2003; Loo et al., 2004) and do not inhibit the effect of Arf6 
on junction stability. Hence, this implies that the direct connection of GIT1 with p-PIX 
appears to be important for the required Rac activation by Arf6 during junction 
perturbation. 
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Figure 6.2: A functional SHD domain on GIT1 is important for the blockage of Arf6-induced 
junction disassembly. 
(a) Plasmids encoding Arf667- and GIT1-mutant constructs containing the SHD, coiled-coil and PBD 
domain (GIT1-C2) or coiled-coil and PBD domains (GIT1-C1) or (b) full-length GIT1 constructs 
deleted in the SHD (GIT1-ASHD) or containing the D294K and E295R point-mutations (GIT1-M4) were 
microinjected in the nucleus of keratinocytes and allowed to express for three hours. 
Immunolabbeling for HA-tagged Arf6Q67L, flag-GIT1 constructs and E-cadherin was performed and 
pictures of over-expressing cells were taken. Arrows indicate destabilised keratinocyte junctions and 
arrowhead point to intact adherens junctions. Scale bar = 504m. (c) Quantification of the number of 
intact junctions observed between cells over-expressing Arf667L, GIT1-C2 or a combination of these 
plasmids. *, p<0.00002. (d) Similar quantifications as in (c) with Arf6Q67L and* GM-C1, or 
(e) with 
Arf6Q67- and GIT1-ASHD, or (f) with Arf6Q67- and GM-M4. Error bars show S. E. M. n=3. 
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6.2.2 Optimal depletion of GIT1 affects the formation of stable E-cadherin-based 
junctions 
To confirm the involvement of endogenous GIT1 in cell-cell junction 
perturbation induced by Arf6Q67L, a siRNA approach was considered. Firstly, I 
determined which members of the GIT1 family were expressed in keratinocytes. An 
RT-PCR of GIT1 and the 64% homologous family member GIT2 (Premont et al., 2000) 
was performed using cDNA from normal keratinocytes. Both GIT1 and GIT2 were 
found expressed in keratinocytes, although GIT2 expression seemed to be lower than 
GIT1 (Figure 6.3a). GIT1 and GIT2 might have possible overlapping functions and 
have been shown to form heterodimers (Paris et al., 2003; Premont et al., 2004). Thus, a 
knockdown of GIT2 additionally to GIT1 might be necessary to confirm the 
involvement of GIT in Arf6-mediated junction disruption. On the other hand, the 
cellular function of GIT1 and GIT2 might not overlap. This is supported by the fact 
that GIT2-enlarged vesicles are not positive for Rab11, although this protein is located 
at GIT1-induced vesicles (Paris et al., 2002). If GIT1 and GIT2 regulate different 
functions, GIT2 knockdown experiments could also be used as control to show the 
specific involvement of GIT1 during Arf6-driven junction perturbation. 
Secondly, the knockdown conditions for GIT1 were optimised. A GM-specific 
antibody was initially optimised for Western blot detection and was found best at a 
dilution of 1: 250 (Figure 6.3b). Thereafter, a specific siRNA oligo designed by the 
company Dharmacon (GIT1#1) was tested for depletion of the endogenous GITI 
protein. A similar experiment was proposed as carried out for the PAK1 siRNA in 
chapter 3, where siRNA conditions were optimised in cells grown in low calcium 
medium and cell-cell contacts induced 30 minutes prior to microinjection of Arf6Q67-. 
An excellent knockdown of the GIT1#1 oligo was found 72 hours post-transfection of 
50nM oligo compared to the control oligo treatment (Figure 6.3c). However, after three 
independent experiments a consistent knockdown with this oligo could not be 
observed in the following experiments. As the PAK1#1 oligo transfections were taken 
as a positive control in these experiments (Figure 3.6c), 
failure of transfection 
conditions and cell passage was ruled out. A reason for this 
defect could be instability 
of GIT1 #1 oligo. 
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Subsequently, a SMARTpool set containing four individual GIT1 siRNA oligos 
(named oligo GIT1#2, GIT1#3, GIT1#4 and GIT1#5) were tested for depletion of 
endogenous GIT1. Under similar conditions as first observed for GIT1#1, no 
knockdown using the four GIT1 oligos independently was found (Figure 6.3d). 
Moreover, by reducing the incubation time to 48 hours no depletion was observed 
(Figure 6.3e). As the depletion of GIT1 by two out of four SMARTpool oligos was 
guaranteed, I decided to retest the optimal knockdown time and concentration. To 
begin with, a pool of oligos was transfected at a concentration of 50nM and 1OOnM 
upon depletion of GIT1 was analysed after 48 hours or 72 hours incubation (Figure 
6.3f). Again, no reduced GIT1 protein level was observed at any of the tested 
conditions in two different experiments. Thereafter, knockdown was tested using a 
multiple transfection strategy. A recently published report showed optimal 
knockdown of GIT1 by transfection of 200nM GIT1 SMARTpool at three consecutive 
days and the cells were used 72 hours after initial transfection (Jones and Katan, 2007). 
A 100nM and 200nM pool of GIT1 oligos was transfected, where after 24 hours from 
the first transfection cells were again transfected with similar amount. Subsequently, 
cell lysates were extracted 48 or 72 hours after the first transfection. 
Using this approach, a consistent knockdown of GIT1 was found repeatedly at a 
concentration of 200nM at 48 and 72 hours (Figure 6.3g). In addition, levels of actin, E- 
cadherin and ß-catenin proteins were not affected upon depletion of GIT1 (Figure 
6.3h). Finally, the assembly of calcium-dependent E-cadherin junctions was tested 
under these siRNA conditions as this is essential in the further planned experiments. 
However, GIT1 siRNA cells and to a lesser extent the control siRNA cells, showed a 
perturbed induction of E-cadherin junctions. Several keratinocytes could not form the 
cadherin-mediated junctions after both treatments (Figure 6.3i, arrow), and 
particularly in GM-treated cells a punctated E-cadherin staining at sites of cell-cell 
contacts was often detected (Figure 6.3i, arrowheads). Because the 
defect of E-cadherin 
assembly was observed in both GIT1 and control siRNA keratinocytes, the amount of 
oligos and transfection reagent used could be harmful 
for normal cellular processes. 
However, the apparent punctated E-cadherin staining in GM-depleted 
keratinocytes 
indicates that this occurrence could be a consequence of GIT1 knockdown. 
Thus, optimisation of knockdown for endogenous 
GIT1 in keratinocytes was 
CHAPTER 61 216 
a 
1000 
900 
800 
700 
GIT1 GIT2 
d 48h 
i actin 
GIT1 
f 
siRNA GITI pool 
48h 72h 
32 32 
öö0 ööö 
r- 0 Lo v- 0 
C 
24h 48h 72h 
F- c ý- c c v v Cý v 
w, º GIT1 
72h 
014 CY) 14t Lf) F- * It 
., v; GITI 
actin 
g siRNA GIT1 pool 
48h 72h 
0 00 0 00 
T- N C) 00 T- N0 
GITI 
actin 
h 0 G 
0. ý 
siRNA: FD uo 
E-cadherin 
ß-catenin 
e 
s.. 
C, 
t 
Cß 
V 
W 
Figure 6.3: Optimisation of GIT1 knockdown in keratinocytes. 
(a) RT-PCR of human GIT1 and GIT2 using cDNA template from keratinocytes. (b) Optimisation of GIT1 
antibody for Western blotting with keratinocyte lysates. (c) Time-course of GIT1 knockdown in keratinocytes 
with 50nM GIT1#1 and non-targeting oligos (control) lysed at 24,48 or 72 hours post-transfection and 
subjected to Western blotting. n=3. (d, e) Transfection of different GIT1 oligos (GIT1#2, GIT1#3, GIT1#4 or 
GIT1#5) at 50nM followed by analysis on SDS-PAGE after 48 hours (d) or 72 hours post-transfection (e). n= 
4. (f) Transfection of 50nM or 100nM of a SMARTpool of GIT1 oligos (containing oligos GIT1#2-5) and 
incubated for 48 or 72 hours. n=2. (g) Double transfection of GIT1 SMARTpools (0 and 24h) using 100nM or 
200nM oligos. Cells were lysed at 48 or 72 hours. n=3. (h) Protein levels of GIT1, actin, E-cadherin and ß- 
catenin in cells treated with GIT1 siRNA oligos. n=3. (i) Comparison of induction of cell-cell contacts by 
addition of calcium in GM-knockdown and control cells. Arrows point to absence of cell-cell contact, 
arrowheads indicate punctated adherens junctions. Scale bar = 50µm. n=2. 
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difficult. Initial depletion conditions for GIT1 (50nM of GIT1#1 and 72 hours post- 
transfection) were not reproducible using additional oligos (GIT1#2-5). Thereafter, an 
optimum concentration to diminish GIT1 levels was found after 48 hours incubation 
with a pool of 200nM GIT1 oligos, in combination with a similar treatment of 200nM 
oligos 24 hours after the first transfection. However, under latter conditions E- 
cadherin-dependent cell-cell junctions did not assemble properly. Due to this 
drawback, the proposed microinjection experiments with Arf6Q6 were not performed 
at this stage. 
6.2.3 GIT1-derived constructs containing a SHD domain can perturb E-cadherin- 
mediated junctions 
Since GIT1 appears to participate downstream of Arf6-induced junction 
destabilisation (Figure 6.2), I questioned whether expression of GIT1 mutants is 
sufficient to perturb adherens junctions. GIT1 and its truncation versions shown in 
Figure 6.1 were expressed in keratinocytes for eight hours. Full-length GIT1 induced 
junction perturbation as shown previously by E. Lozano. E-cadherin staining was 
observed from corner to corner in between two GIT1 over-expressing cells (Figure 6.4a, 
arrowhead GIT1 panel) while in other cells staining was discontinuous (arrow). Five 
independent experiments were evaluated and averaged at 76% intact junctions in full- 
length GM-expressing cells, which was a significant change when compared to non- 
injected control cells (Figure 6.4b, GIT1 p<0.03). 
Remarkably, expression of the GIT1-C2 truncation mutant that does not contain 
the GIT1 ArfGAP and ankyrin repeats had a severe disruptive effect on adherens 
junctions (Figure 6.4a, arrow GIT1-C2 panel). Quantifications of the percentage of 
expressing cells with complete or partially destabilised junctions showed a significant 
change of intact junctions following GIT1-C2 microinjection (Figure 6.4b, GIT1-C2). 
The GIT1-C1, GIT1-M4 and GIT1-ASHD constructs that all lack a functional 
SHD domain showed no changes in cell morphology in comparison with controls 
(Figures 6.4a and 6.4b). Longer expression time was allowed (around 18 hours) to 
investigate whether the different GIT1 constructs were sufficient to induce junction 
disruption in this time-frame. However, these experiments were not feasible as only a 
few expressing cells could be obtained under these conditions. Thus, after eight hours 
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full-length GIT1 and GIT1-C2 that contain a functional SHD were able to induce 
keratinocyte junction destabilisation, but not the GIT1 mutants GIT1-C1, GIT1-M4 and 
GIT1-ASHD. 
Considering the link of GIT1 and GIT1-C2 with (3-PIX via the SHD domain, 
opposed to the GIT1-C1, GIT1-ASHD and GIT1-M4 constructs which were found 
harmless on junction stability, it could be possible that Rac activation via (3-PIX causes 
junction perturbation. As dominant-negative Rac (RacT'7N) efficiently prevents junction 
disruption by active Arf6, I asked whether RacTl7Nwas also required for GIT1-induced 
junction disassembly. Unfortunately, the optimisation of DNA concentration for co- 
expression of GIT1-C2 and RacT"I`l has proven difficult and due to time constraints this 
was not further pursued. 
Taken together, full-length GIT1 and the shorter truncation construct GIT-C2 
can disrupt E-cadherin-based junctions due to a functional SHD domain (Figure 6.4). 
The higher level of junction disruption seen after GIT1-C2 expression might lie in 
distinct activation levels of full-length GIT1 and GIT1-C2 due to intra-molecular 
conformations (Totaro et al., 2007). Although the mechanism involved in this 
phenotype is not known, (3-PIX and subsequent activation of Rac could be involved. 
6.2.4 Linking ß-PIX with Arf6 and GIT1 signalling 
The previous results suggested that (3-PIX participates in the signalling 
pathway during Arf6-induced junction disassembly. Like GIT1 and GIT1-C2, (3-PIX 
could potentially disturb E-cadherin junctions by modulation of the Rac activity. The 
cellular localisation of wild-type (3-PIX and its effect on stability of adherens junctions 
was investigated. During the eight hour expression of (3-PIX, small vesicles were 
induced in some but not all cells (Figure 6.5a, zoom arrow). Over-expression of (3-PIX 
did not significantly perturb mature E-cadherin-based junctions (Figure 6.5a, 
arrowhead; Figure 6.5b, 96% of intact cell-cell contacts). An effect on junctions with 
wild-type (3-PIX might not be observed as, similar to other GEFs, an active mutant of (3- 
PIX could be necessary to accomplish this. 
Further on, participation of full-length p-PIX during Arf6-driven junction 
disassembly was tested by co-expression. Like observed with wild-type GIT1 (E. 
Lozano, unpublished observations), (3-PIX might inhibit Arf6Q67L effect on junctions. 
ý; 
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Cloning of either (3-PIX or Arf6Q67L needed to be performed as both constructs used 
until now were HA-tagged. I decided to clone Arf6Q67L into the pEGFP-C1 vector using 
the PCR technique. However, injections of the new GFP-Arf6Q67L construct did not 
show any perturbation of E-cadherin junctions (data not shown). Possibly, the bulky 
GFP-tag stretching 238 amino acids interferes with the functionality of the 175 amino 
acid long small GTPase Arf6Q67L (accession number NP_001654). Unfortunately due to 
time restrictions, other cloning strategies could not be explored. 
Another possibility to test the involvement of (3-PIX downstream of Arf6 is via a 
siRNA approach. I have shown that this strategy works well for Rac-induced junction 
disassembly on PAK1 siRNA cells (Figure 3.7). Depletion of endogenous (3-PIX could 
demonstrate its requirement during Arf6-mediated junction perturbation. 
Subsequently, optimisation to obtain (3-PIX depletion was investigated with a 
SMARTpoo1 of oligos consisting of four different siRNA oligos (ß-PIX#1, (3-PIX#2, (3- 
PIX#3 and f3-PIX#4). Each individual oligo and a pool of these oligos were tested at 
50nM for knockdown by extracting the lysates at 48 or 72 hours post-transfection 
(Figures 6.6a and 6.6b, respectively). However, no knockdown was observed in any of 
the three independent trials attempted. 
As the GIT1 and ß-PIX proteins are known to form oligomeric complexes 
(Premont et al., 2004), similar turnover rate and thus siRNA conditions of these 
proteins might be suitable. As performed for GIT1 (Figure 6.3g), knockdown of p-PIX 
was tested with 200nM of a pool of four oligos using two transfections at time zero and 
24 hours hereafter. Cell lysates were analysed for knockdown by Western blotting and 
indeed showed a depletion of ß-PIX under these conditions (Figure 6.6c). In addition, 
protein levels of a-catenin showed no difference between knockdown and control cells. 
However, assembly of junctions under these conditions was found poor (Figure 6.6d). 
Many cells could not form junctions with neighbouring cells and sometimes gaps 
in 
between cells was observed (arrow). 
Taken together, the data suggest that the optimised siRNA treatment 
performed could be toxic and result in subsequent cell detachment 
from the 
substratum, consistent with the results obtained for GIT1 depletion 
(Figure 6.3i). I 
used 200nM of a SMARTpoo1 of four different (3-PIX-specific oligos which according 
to 
Dharmacon two out of four oligos are guaranteed to provide a knockdown. 
Thus in 
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Figure 6.5: Over-expression of ß-PIX does not influence E-cadherin junction stability. 
(a) Wild-type ß-PIX was injected and expressed for eight hours. Pictures of immunolabelled HA- 
(3-PIX and E-cadherin were taken. Arrowhead points to intact keratinocyte junctions, arrow 
indicate p-PIX-induced vesicles. Scale bar = 50µm, scale bar zoom = 325µm. (b) Quantification of 
ß-PIX over-expressing cells (+) or control non-injected cells (-) showing intact junctions. Error bar 
represents S. E. M. of three independent experiments. 
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principle, double transfection of 100nM of a single (3-PIX oligo should be able to 
deplete endogenous ß-PIX. Using this 100nM oligo concentration, assembly of cell-cell 
contacts might be improved. On the other hand, the double transfection per se might 
be the reason for the poor assembly of cell-cell contacts. 
Alternatively, another method of siRNA could be adopted, such as optimisation 
of siRNA in normal keratinocyte medium opposed to low calcium cells. Transfection 
of a vector-based siRNA would not be suitable as transfection efficiency of plasmids in 
keratinocytes is currently only about 30%. Moreover, transfection occurs randomly 
over the cell population so that only few transfected neighbouring cells can be 
observed (personal observation). A vast amount of transfected adjacent cells is 
required to analyse junction stability in knockdown and Arf6Q67L-expressing cells. 
Thus, due to time constraints and the technical issues above, the involvement of (3-PIX 
during Arf6-driven junction disassembly by siRNA could not be performed. 
6.2.5 GIT1-C2 co-localises with Armusl_sso on vesicular structures 
Confocal analysis of Raca61L-expressing cells shows E-cadherin junction 
disruption accompanied with endocytic vesicles containing flag-Rac and E-cadherin 
receptors (E. Lozano, unpublished data). Close examination of E-cadherin distribution 
in GIT1- and GITl-C2-expressing cells was not carried out at this stage in the project, 
although both over-expressed proteins induce vesicle formation where E-cadherin 
receptors could localise in (Figure 6.4). Thus, it is not clear how E-cadherin receptors 
are removed from the plasma membrane and where these proteins are transported to. 
I have shown that the novel protein Armus (chapter 5) and GIT1 (this chapter) 
are involved during Arf6-mediated junction disassembly. Interestingly, full-length 
Armus and the Armus N-terminal containing the PH domain and two central coiled- 
coils (Armusi-550) both induce a vesicular phenotype (Figures 4.3 and 4.4), 
in a similar 
pattern as observed with GIT1 and the GIT1 truncation mutant 
GIT1-C2 (Figures 6.2 
and 6.4). This raises the question of whether vesicles induced 
by Armus and GIT1 
represent the same intracellular compartment. Two lines of evidence suggest 
that this 
may be the case. First, Rab11 co-localised with Armus1.550-educed vesicles 
(R. Francis, 
unpublished data) and GIT1-C2-positive structures (Matafora et al., 
2001; Albertinazzi 
et al., 2003). Second, over-expression of activated Rac, 
but not dominant-negative Arf6, 
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inhibits vesicle formation induced by Armusl-550 (Figures 4.5 and 4.6) or GIT1-C2 
(Matafora et al., 2001). Because of these common characteristics, I tested whether 
Armus, 
_sso and GIT1-C2 co-localised. Confocal analysis demonstrated that Armus, _sso 
and GIT1-C2 almost completely co-localised on vesicular structures (Figure 6.7, 
Armus, 
_sso + 
GIT1-C2 arrowhead). This suggests that these molecules might be linked 
together functionally. 
Next, I investigated whether Armus and GIT1 can interact with each other. An 
immunoprecipitation experiment using COS-7 cell lysates over-expression GIT1 and 
Armus alone or in combination was carried out. As a positive control, the previously 
reported p-PIX and GIT1 interaction detected by immunoprecipitation was tested 
(Bagrodia et al., 1999; Albertinazzi et al., 2003; Loo et al., 2004). To start with, cell lysates 
over-expressing GIT1 and ß-PIX were subjected to the assay using a rabbit anti-flag 
antibody. Western blot analysis with mouse anti-flag recognised the p-PIX protein in 
the lysates and immunoprecipitation samples, although (3-PIX only contains a HA-tag 
(Figure 6.8a, P-PIX middle lane). As a result, the sample containing GIT1 and (3-PIX 
showed non-specific precipitation of HA-tagged (3-PIX (Figure 6.8a, GIT1 + (3-PIX last 
lane). While not recognised by an anti-flag antibody, Armus co-precipitated non- 
specifically with flag-coated beads (Figure 6.8b, Armus first lane). Therefore, the co- 
precipitation of Armus with GIT1 was also interpreted as non-specific (Figure 6.8b, 
Armus + GIT1 last lane). 
The buffer used in this experiment was similar to the (3-PIX and GIT1 
immunoprecipitation assay described by Albertinazzi et al. (2003). However, the 
published report used ß-PIX specific antibodies to co-precipitate GIT1 whereas I used a 
flag-antibody to immunoprecipitate GIT1 and co-precipitate 3-PIX. Unfortunately, 
because of time restrictions optimising immunoprecipitation of the positive control 
using HA- or ß-PIX-specific antibodies could not be tested. Taken together, co- 
localisation of Armus1.550 and GIT1-C2 on vesicles has been shown (Figure 6.7). 
As Armus co-precipitates with E-cadherin receptors (Figure 5.1) it would be 
possible that by an interaction of Armus with GIT1 or (3-PIX, the latter two proteins 
may also associate with E-cadherin. However, immunoprecipitation of GIT1 with E- 
cadherin was not detected and (3-PIX bound non-specifically in this assay (Figure 5.1). 
In MDCK cells, localisation of ß-PIX at adherens junctions has been observed (Zegers et 
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al., 2003). Whether (3-PIX also associates with keratinocyte junctional components 
requires further investigation, which could not be performed due to time constraints. 
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Figure 6.7: Armusl_sso and GIT1-C2 co-localise on vesicles. 
An Armus mutant containing the PH domain and central coiled-coils 
(Armus1 550) and GIT1 mutant lacking the ArfGAP domain and ankyrin 
repeats (GIT1-C2) alone or in combination were expressed for three hours, 
followed by staining for myc-Armus and flag-GIT1. Coincident staining 
appears yellow in the merge image. Panels at the bottom show a zoomed 
image of the boxed area in the respective fluorescence image. Arrowheads 
indicate immunopositive vesicles. Scale bar = 16µm, scale bar enlarged 
picture = 64µm. Number of independent experiments is three. 
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Figure 6.8: Non-specific interaction of Armus and ß-PIX with flag- 
coated beads. 
(a) COS-7 cells were transfected with plasmids encoding flag-GIT1 and 
HA-ß-PIX and subjected to an immunoprecipitation assay using anti-flag 
antibody. Western blotting was performed with an anti-flag antibody. 
(b) Similar experiment as under (a) using flag-GIT1 and Venus-Armus. 
Immunoblotting with anti-flag and anti-GFP antibodies was performed. 
IP, immunoprecipitation; Lys, lysates. Pictures represent two 
independent experiments. 
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6.3 Conclusion 
In this chapter I have shown that the inhibition on Arf6-induced junction 
destabilisation by GIT1 is not a result of direct binding of Arf6 to the ArfGAP domain 
on GIT1. Instead, it involves the functionality of the SHD of GIT1 that is responsible 
for ß-PIX interaction and subsequent Rac GEF activation. These results are consistent 
with the previous data in chapter 3 where active Rac is required for Arf6-mediated 
disruption of cell-cell contacts. Unfortunately, the GIT1 and (3-PIX siRNA experiments 
could not be carried out to reinforce the implication of these proteins in Arf6 signalling 
on keratinocytes. A connection with Armus and GIT1 is likely as these proteins co- 
localise at the same vesicle-like structures. Possible biochemical interaction between 
Armus: GIT1, Armus: (3-PIX and E-cadherin: (3-PIX need further optimisation. 
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6.4 Discussion 
6.4.1 Arf6 signals through GIT1-ß-PIX-Rac in order to induce adherens junction 
disassembly 
The results in this chapter suggest that GIT1 and (3-PIX are essential for Arf6- 
mediated junction disassembly. Homo-dimerisation of GIT1 occurs via its coiled-coil 
domain containing a leucine-zipper (Paris et al., 2003; Premont et al., 2004). All 
exogenous GIT1 mutants used in the study tested with active Arf6 contained an intact 
coiled-coil domain (Figure 6.1) and are thus able to interact with endogenous GIT1. 
Yet, this possibility does not affect the interpretation of our results, as different GIT1 
mutants behaved as predicted from the presence/absence of specific domains. 
Titration of active Arf6 by full-length GIT1 is excluded as a mechanism for its 
inhibition of junction disruption, as the GIT1 truncation mutant GIT1-C2 without the 
ArfGAP domain and ankyrin repeats can rescue Arf6 disruption (Figure 6.2). This 
result is consistent with the transient nature of interactions between a GAP and its 
substrate and the inability of a GAP to hydrolyse active mutants (Scheffzek and 
Ahmadian, 2005; Bos et al., 2007). The blockage of junction disruption by full-length 
GIT1 and GIT1-C2 is mediated by the SHD, because GIT1-derived mutants that do not 
have a functional SHD cannot inhibit this process (Figure 6.2). Thus, the interaction of 
GIT1 and GIT1-C2 with endogenous (3-PIX is essential for the blockage of junction 
disruption induced by Arf6. Importantly, this hypothesis is supported by the fact that 
GIT1 and GIT1-C2 expression by themselves can induce junction disassembly (Figure 
6.4), which is likely to occur via (3-PIX association and thus Rac activation. None of the 
GIT1 mutants with a malfunctioning SHD can disrupt cell-cell contacts when 
expressed by themselves (Figure 6.4). 
The reason that GIT1-C2 can disrupt E-cadherin junctions more potently than 
full-length GIT1 (Figure 6.4), may reflect a difference in intra-molecular conformation 
and thus activity status of these proteins. A recent paper shows that the 
GIT1 N- 
terminal first ankyrin repeat associates with the GIT1 C-terminal SHD resulting in an 
auto-inhibited intra-molecular conformation (Totaro et al., 2007). 
C-terminal truncated 
GIT1 mutants bind paxillin and liprin-a with higher affinity compared to 
full-length 
GIT1. Release of the intra-molecular conformation of full-length GIT1 increases 
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binding to paxillin and liprin-a and correlates with increased effects on cell spreading. 
This data suggests that GIT1-C2 is more active than the full-length GIT1 and as a 
consequence could have a greater effect on keratinocyte adherens junctions. 
The results obtained with the GIT1 constructs independently (Figure 6.4) and in 
combination with active Arf6 (Figure 6.2), indirectly involves (3-PIX in keratinocyte 
junction destabilisation. Unfortunately, a direct participation of (3-PIX could not be 
provided in this chapter. Furthermore, it is reasonable to suggest that a mutant of (3- 
PIX that does not exhibit Rac GEF activity (e. g. (3- PIXL238R11239S; Manser et al., 1998) could 
inhibit junction destabilisation induced by activated Arf6. A constitutively active 
mutant of ß-PIX has not been reported to date, but could in principle be capable of 
inducing cell-cell contact dissociation. Basic fibroblast growth factor (bFGF)-induced 
phosphorylation of (3-PIX on amino acids S525 and T526 results in activation of Rac 
(Shin et al., 2002). An activation mutation on these two amino acids could be tested as 
a constitutively activated form of ß-PIX. Alternatively, wild-type P-PIX might be able 
to induce junction disruption via increased Rac activation when longer expression than 
eight hours is allowed (Figure 6.5). 
6.4.2 PAK binds ß-PIX but does not participate during Arf6-mediated junction 
disruption 
In chapter 3,1 have demonstrated that PAK1 signalling is not required for Arf6 
to destabilise cell-cell adhesion (Figures 3.5 and 3.8). In contrast, PAK1 is essential for 
Rac-mediated keratinocyte junction perturbation (Figure 3.7). Thus, PAK1 is an 
important downstream effector for Rac in the process of cell-cell contact destabilisation, 
but not when this event is induced by Arf6. This is intriguing considering that 
Rac is 
activated by Arf6 (Koo et al., 2007; Manser et al., 1998; Bagrodia et al., 1999; 
Zhao et al., 
200b; D'Souza-Schorey et al., 1997) and necessary for keratinocyte junction disruption 
induced by Arf6Q671- (Figures 3.3 and 3.4). 
PAK has also been shown to function upstream of Rac 
(Mauser et al., 1998; 
Obermeier et al., 1998). In this case, the mechanism of PAK activation occurs regardless 
of the activity status of the GTPases Cdc42 or Rac and 
is mediated by the GIT1-ß-PIX 
complex (Manser et al., 1998; Loo et al., 2004). Once auto-phosphorylated, 
PAK cannot 
bind (3-PIX or Nck anymore (Zhao et al., 2000a). Furthermore, 
PAK has been shown to 
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acts as a 'scaffolding' molecule for GIT1 and (3-PIX to localise at focal contacts (Brown 
et al., 2002; Zhao et al., 2000b). Over-expression of the PAKAID causes localisation of 
GIT1 to focal contacts, whereas the kinase active form of PAK (PAKT423E) induces focal 
contact disassembly. Moreover, over-expression of GIT1 per se also promotes focal 
contact destabilisation. Data obtained in this project shows that activated PAK (Figure 
3.9) and GIT1 (Figure 6.4) can promote adherens junction disassembly, as described for 
focal contacts. Interestingly, preliminary data suggests that PAKAID can block GIT1- 
induced junction (E. Lozano, personal communication). However, it is not clear 
whether the GIT1-induced phenotype is dependent on PAK signalling upstream or 
downstream of Rac. 
The effect of active Arf6 on focal contact stability has not been investigated in 
keratinocytes and cannot be compared with adherens junction disassembly. However, 
it is evident that junction disassembly induced by Arf6 and GIT1 are dissimilar. Arf6 
typically causes a rapid disruption of cell-cell contacts accompanied by accumulation 
of E-cadherin receptors in a perinuclear area (Figure 6.2) whereas GIT1 and GIT1-C2 
require longer incubation and do not show the build-up of E-cadherin intracellularly 
(Figure 6.4). The distinct disruption pattern of junctions induced by Arf6 and GIT1 
may be the result of differences in Arf6Q671- and GIT1 activity levels, spatio-temporal 
regulation as well as the possibility that Arf6 stimulates additional pathways than 
GIT1 can. Similar differences in disruption pattern of cadherin adhesion have also 
been observed after Rac or PAK activation when compared to Arf6 (Figures 3.1 and 
3.9). 
6.4.3 Linking Armus, GIT1 and /3-PIX during Arf6-mediated junction disassembly 
Beta-PIX binds GIT1 (Bagrodia et al., 1999; Albertinazzi et al., 2003) and localises 
at GITl-C2-positive vesicles (Di Cesare et al., 2000). GIT1-C2 has been shown to co- 
localise with Armus, _sso-induced vesicles 
(Figure 6.7). Armus is connected to active 
Rac as this GTPase can bind to Armus central coiled-coil domain (R. Francis, 
unpublished observations) whereas p-PIX links to Rac via its DH domain (Manser et 
al., 1998). It is feasible that p-PIX can be considered as a possible interactor of Armus. 
Armus has been shown to associate with E-cadherin receptors whereas GIT1 
does not. A possible association of (3-PIX with Armus or E-cadherin requires 
further 
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investigation (Figures 6.8 and 5.1). As GIT1 and (3-PIX exist together as high molecular 
weight complexes in the cell (Premont et al., 2004; Botrugno et al., 2006), one could 
speculate that the lack of GIT1 association with E-cadherin might exclude (3-PIX 
involvement. Moreover, the lack of GIT1 association with E-cadherin in Figure 5.1 
could rule out a possible Armus binding to GIT1. Localisation of Armus could differ 
from the localisation of GIT1 and (3-PIX oligomers at steady-state. Subsequently, a 
cellular activation mechanism could cause phosphorylation of Armus, GIT1 and (3-PIX 
and consequently an interaction of these proteins. For example, this can occur 
downstream of Arf6 activation leading to E-cadherin junction disruption. Active Rac 
does not require Armus GAP function to disrupt junctions, although Arf6 does. It 
would be interesting to test whether GIT1 and GIT1-C2 require Armus function during 
junction perturbation. If GIT1 does not require Armus function this suggests that GIT1 
induces junction disassembly via a mechanism similar to Rac. Overall, future 
experiments should establish a possible direct connection of GIT1-(3-PIX-Rac-Armus. 
On the other hand, a direct interaction of Armus with GIT1 or p-PIX might not 
occur at steady state but a functional link between these molecules could be facilitated 
by active Rac. This idea is reasonable as this implies a logical order of signalling 
during Arf6 junction disruption (further discussed in chapter 7). Therefore, a direct 
interaction of Armus with GIT1 and p-PIX by over-expression might not be observed. 
Yet, formation of complexes consisting of GIT1, (3-PIX, Armus and Rac could be 
induced upon the appropriate stimuli. 
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6.5 Future experiments 
6.5.1 The Arf6-GIT1-ß-PIX-Rac pathway during junction disassembly 
Arf6Q67L co-expressing with GIT1 has been shown to inhibit junction 
disassembly, although similar experiments remain to be performed with (3-PIX. Either 
wild-type (3-PIX or a mutant lacking Rac GEF activity ((3-PIXL238RI2395; Manser et al., 
1998) will be expressed in combination with Arf6Q671- to show its involvement by 
analysing junction stability. Re-optimisation of siRNA of GIT1 and ß-PIX using 
different oligos will be tried. Alternatively, short hairpin RNA (shRNA) will be used to 
deplete endogenous GIT1 and (3-PIX. The major advantage of shRNA over siRNA is 
the long-lasting gene silencing (Alexander et al., 2007) but shRNA has not been tested 
in primary keratinocytes yet. 
Once efficient knockdown of GIT1 and P-PIX has been established, a control 
experiment to show specific involvement will be performed with siRNA of family 
members of GIT1 (i. e. GIT2), P-PIX (i. e. a-PIX) or other known Arf6 GAP or Rac GEF 
proteins. 
6.5.2 GIT1-mediated junction disruption 
Preliminary data suggest that junction destabilisation induced by GIT1 alone is 
dependent on Rac and PAK activation, but a possible activation of PAK upstream of 
Rac by GIT1 over-expression needs to be excluded. The pattern of GIT1-induced 
junction disassembly inspected by confocal microscopy could compare the 
internalisation of E-cadherin receptors with Rac461- over-expression. Comparison of 
PAK phosphorylation after Rac461L, GIT1 and Arf6Q67L over-expression could also be 
performed to compare PAK activation by these proteins. This will be investigated by 
transfection of these proteins in keratinocytes followed by Western blot probing with a 
phospho-specific PAK antibody (for example against the PAK auto-phosphorylation 
site T423). I would expect that PAK is activated after GIT1 and RacQ61L over-expression, 
but not in the sample containing active Arf6. Furthermore, Rac siRNA followed by 
over-expression of GIT1 and measuring the activity levels of PAKT could give insight 
into PAK signalling upstream or downstream of Rac. 
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Dominant-negative Rac is expected to block GIT1-induced junction 
perturbation as this Rac mutant can sequester GEFs and could therefore prevent (3-PIX 
activation by GIT1. A similar experiment as attempted previously (section 6.2.3) but 
with dominant-negative Rac and GIT1-C2 incorporated into different vector backbones 
will be performed. Another option is microinjection of GIT1-C2 together with a 
domain that could sequester active Rac, for example the CRIB motif of PAK (Bokoch, 
2003). 
The contribution of (3-PIX-mediated Rac activation during junction disassembly 
induced by GIT1 or GIT-C2 will be assessed by expressing wild-type or dominant- 
negative ß-PIX. In addition, junction stability after GIT1-C2 expression could be 
analysed in cells deprived of (3-PIX and Rac. 
6.5.3 Association of Armus with GIT1 or fi-PIX 
The co-localisation of GIT1-C2 and Armus, _sso observed 
in enlarged vesicles 
might be mediated by active Rac. GIT1 and (3-PIX have already been shown to 
associate with endogenous Rac (Di Cesare et al., 2000). Armus association with this 
complex will be tested by immunoprecipitation of endogenous proteins from normal 
keratinocyte lysate. 
Endogenous GIT1 and (3-PIX may localise to E-cadherin-mediated keratinocyte 
junctions as observed for Armus and can be tested by irnmunostaining. It is not clear 
which interactions (protein or lipid) modulates the cellular distribution of these 
proteins. It would be of interest testing the PH domains of Armus and (3-PIX as well as 
the ankyrin repeats on GIT1 for interaction with similar membranes. However, a 
spatial connection of Armus, GIT1 and (3-PIX may only be observed when an 
appropriate stimulus is given. A possible localisation of endogenous GIT1 and p-PIX 
on the perinuclear compartment that accumulates junctional components after over- 
expression of active Arf6 will be tested. 
Finally, it should be investigated whether Armus can interact directly with 
GIT1 or (3-PIX. The binding assay using over-expression of these proteins in 
COS-7 
cells requires optimisation using GIT1-, Armus- and ß-PIX-specific antibodies. 
Coating 
of the Protein A beads with BSA prior to the assay may also minimise non-specific 
binding. Moreover, the mutant GIT1-ASHD that lacks the SHD domain and as a result 
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cannot interact with ß-PIX will be included as a negative control in this binding assay 
(Albertinazzi et al., 2003). 
Co-localisation of (3-PIX and Armus following over-expression will be carried 
out to gain more information about a potential interaction between these two proteins. 
It could be possible that the distribution of both proteins occurs on vesicular structures. 
In addition, to establish a link between GIT1 and Armus, depletion of Armus may 
influence the GIT1-mediated disassembly of junction. siRNA conditions of Armus are 
already optimised in the lab (F. Maximiano, unpublished data) and only GIT1 or GIT1- 
C2 over-expression in low calcium cultures will require optimisation. 
Chapter 7: Final discussion 
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7.1 Regulation of Armus function 
During the course of my PhD I gained insights into the function of a novel 
protein, Armus. Armus consists of a PH domain, three coiled-coils and TBC/RabGAP 
domain. The Armus PH domain is predicted to localise Armus at the plasma 
membrane and its two central coiled-coils provide an unique active Rac-binding 
domain. Previously identified TBC/RabGAP proteins and their Rab targets are poorly 
characterised, yet TBC/RabGAP-containing proteins regulate essential cellular 
processes. Armus functions as a bona fide GAP protein for Rab7 via its TBC/RabGAP 
domain and may play a role in vesicular trafficking at late endosomes/lysosomes and 
autophagosomes. Therefore, Armus has the unique potential to integrate Rac and 
Rab7 signalling. 
In analogy to the regulation of other GAPs and GEFs (Bos et al., 2007), Armus 
function is most likely regulated by (i) its localisation to specific sites at membranes, (ii) 
dimerisation via the coiled-coil domains and (iii) auto-inhibition via binding of the 
TBC/RabGAP domain to the central coiled-coils. 
Firstly, in vivo Armus associates and co-localises with E-cadherin receptors. The 
distribution of Armus to its specific localisation at sites of cell-cell contacts is probably 
provided via its PH domain. In addition, localisation provided by the PH is essential 
for vesicle formation induced by of full-length Armus and Armus N-terminal fragment 
(Armusl-550)" Besides membrane localisation, Armus PH domain may have other 
binding and functional properties, which have not yet been explored. For example, PH 
domains have been reported to mediate protein-protein interactions (Lemmon, 2004). 
For some GAPs and GEFs, the PH domain can associate with the catalytic domain and 
thereby modulate its activity (Bos et al., 2007; Schmidt and Hall, 2002). As Armus PH 
domain does not appear to bind to lipids (data not shown), additional binding partners 
for Armus PH domain remain to be established. 
However, Armus mutants lacking the PH domain are also able to localise at 
cell-cell contacts i. e. mutants containing the TBC/RabGAP and 
last coiled-coil domain 
or only the last coiled-coil domain. A potential explanation 
is that the C-terminal 
domain of Armus interacts with itself. This interaction is 
likely to occur in vivo with 
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endogenous Armus, thereby targeting them to membranes via the PH domain of the 
endogenous molecule (see below). 
Secondly, the possibility of dimerisation is supported by co- 
immunoprecipitation and co-localisation studies. However, the stronger evidence for 
dimerisation is the ability of Armus, _sso to 
induce enlarged vesicles in vivo. Often, 
interfering with Rab signalling results in the formation of enlarged vesicles, such as 
expression of active Rab5 (Roberts et al., 1999; Mc Bride et al., 1999). This phenotype 
may result from defective vesicle fusion, transport or docking by inhibiting Rab cycling 
that perturbs downstream Rab signalling. Yet, the Armus, _sso 
fragment that does not 
contain the TBC/RabGAP domain is yet able to induce the formation of vesicles. The 
formation of vesicles induced by Armus is dependent on the PH domain and central 
coiled-coils (present on Armus, _sso) as either 
domain alone is not sufficient to induce 
enlarged vesicular structures. An explanation for the formation of enlarged vesicles by 
Armus1550 may involve dimerisation with endogenous Armus using the central coiled- 
coils. This may allow inactivation of the TBC/RabGAP domain of endogenous Armus. 
Thirdly, Rac activation perturbed vesicle formation by Armus, _sso, 
but not 
dominant-negative Rac suggesting that interaction of active Rac with Armus coiled-coil 
domains is responsible for this disruption. It is conceivable that Rac-GTP binding to 
the central coiled-coil domains can release the dimerised and/or auto-inhibited 
conformation of Armus. Similar activation mechanisms of dimeric auto-inhibited 
proteins are observed in other Rho effectors such as PAK1 and mDia (Lammers et al., 
2005; Nezami et al., 2006; Copeland et al., 2007). As a consequence, Rac activation may 
locally stimulate full-length Armus GAP activity and inhibit Armust_55o-induced vesicle 
formation. This hypothesis remains to be formally tested. 
7.2 Destabilisation of keratinocyte junctions by Arf6 and Rac 
At steady state, adherens junctions are dynamic adhesive structures as E- 
cadherin receptors are constitutively internalised and recycled back to the plasma 
membrane (Le et al., 1999; Yap et al., 2007). The half-life of E-cadherin receptors at the 
plasma membrane in mature cell-cell contacts is around five 
hours (Shore and Nelson, 
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1991). Breakdown of adherens junctions is an important step during tumour 
development (Thiery, 2002; Sahai and Marshall, 2002). E-cadherin-mediated junction 
destabilisation induced by different stimuli (HGF/SF, v-Src or Arf6Q67i) can be achieved 
by increased internalisation, inhibition of recycling or enhanced degradation of E- 
cadherin receptors (Palacios et al., 2001,2002,2005). Alterations of E-cadherin receptor 
trafficking by aberrant signalling of Arf6, Rac and different Rabs contributes to 
downregulation of cell-cell adhesion. Therefore, understanding the underlying 
mechanism of adherens junction disassembly mediated by these th Pases may improve 
specific cancer therapeutics. 
Inappropriate activation of Arf6 can rapidly mediate loss of E-cadherin from 
sites of cell-cell contacts in keratinocytes, most likely via promoting internalisation of 
E-cadherin by co-operation of Rabs as shown previously in MDCK cells (Palacios et al., 
2002,2005). In keratinocytes, Arf6 promotes activation of Rac to perturb junctions 
(Figure 7.1). In contrast, in MDCK cells, Rac inactivation is required for cell-cell 
contact disruption (Palacios et al., 2002,2003). An explanation for the discrepancy 
regarding Rac requirement downstream of Arf6 might be (i) cell-type specific 
regulatory mechanisms and/or (ii) the way in which Arf6 was activated (Palacios et al., 
2002,2003; D'Souza-Schorey et al., 1997; Franco et al., 1999; Radhakrishna et al., 1999; 
Santy and Casanova, 2001). For example, treatment with HGF/SF or over-expression of 
v-Src activates Arf6 and subsequently disrupts cell-cell junctions in MDCK cells 
(Palacios et al., 2001,2003) whereas in keratinocytes over-expression of constitutively 
active Arf6 induces a similar phenotype (this work). 
The mechanism via which Arf6 induces Rac activation during keratinocyte 
junction disassembly is not known. Arf6 has been demonstrated to activate Rac in 
different cell types to promote actin rearrangements at the plasma membrane and 
increase cell motility (Franco et al., 1999; Brown et al., 2001; Santy and Casanova, 2001). 
Arf6-dependent Rac activation in these processes occurs via distinct molecular 
mechanisms including GIT1- (3-PIX, DOCK180/Elmo or Kalarin-5 (Manser et al., 1998; 
Bagrodia et al., 1999; Zhao et al., 2000b; Santy et al., 2005; Koo et al., 2007). I find that 
Arf6 activates Rac via GIT1-ß-PIX to disrupt keratinocyte junctions (Figure 7.1). The 
functionality of the SHD domain on GIT1 appears to be essential in this process. SHD 
binds to and recruits 13-PIX to GIT1 complexes enabling activation of Rac. Thus, (3-PIX 
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function is shown to be important during keratinocyte junction disruption (albeit 
indirectly). In support to this data, GIT1 expression by itself is able to disrupt adherens 
junctions via a mechanism that may be dependent on Rac signalling. Thus, in addition 
to the GIT1-(3-PIX role in regulation of focal contacts, cell motility and neurite 
outgrowth (Zhao et al., 2000b; Di Cesare et al., 2000; West et al., 2001; Albertinazzi et al., 
2003), I found a novel function for GIT1-(3-PIX in the regulation of adherens junctions 
in keratinocytes (this work). 
Once endogenous Rac is activated by constitutively active Arf6, however, 
distinct signalling pathways are triggered when compared to expression of 
constitutively active Rac by itself. This is supported by three lines of evidence: (i) 
distinct pattern of junction disassembly, (ii) accumulation of E-cadherin at distinct 
intracellular compartments and (iii) the involvement of different effector proteins. 
First, constitutively active Rac (RacQ61') perturbs E-cadherin junction stability 
that initiates with the removal of E-cadherin receptors from the corners between two 
expressing cells at sites of cell-cell contacts. In the case of Arf6Q67L expression, rapid 
and complete disruption of E-cadherin junctions occurs accompanied by cell 
detachment and rounding up. 
Second, junction destabilisation induced by RacQ61L shows internalised E- 
cadherin receptors in small endosomal structures. Upon Arf6-induced disruption of 
cell-cell adhesion, but not those mediated by RacQ61L, accumulation of E-cadherin 
receptors was observed in a poorly characterised perinuclear vesicular compartment. 
Such accumulation of E-cadherin receptors upon v-Src activation was previously 
identified as lysosomes in MDCK cells (Palacios et al., 2005) although in keratinocytes 
lysosomal markers do not localise in this compartment. The observed difference 
remains to be further investigated but may be a cell-type specific regulatory 
mechanism or stimulus-specific (i. e. v-Src (Palacios et al., 2003,2005) versus Arf6Q6 
(this work)). 
Third, depletion of E-cadherin receptors from the plasma membrane is 
dependent on PAKT signalling when constitutively active Rac is expressed. However, 
Arf6 perturbation of cadherin adhesion does not require PAK1 but rather signalling 
from the novel Rac effector Armus (Figure 7.1). PAK1 has been shown to be involved 
in tumour progression (Kumar et al., 2006) and may induce serine/threonine 
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Figure 7.1: Molecular mechanism of Rac- and Arf6-induced junction perturbation. 
Diagram showing the components involved during Rac-GTP- and Arf6-GTP-induced destabilisation of 
keratinocyte junctions based on results described in this thesis and published knowledge of protein- 
protein interactions. (a) RacQ61L induces internalisation of E-cadherin receptors that localise in 
endosomal structures. PAK1 is specifically required for RacQ61L to mediate destabilisation of junctions. 
Disruption of cell-cell contacts by Rac61i- does not require Armus function. In contrast, (b) expression of 
Arf6Q67L causes disruption of adherens junctions accompanied by accumulation of E-cadherin receptors 
at a perinuclear area. This process requires GIT1-p-PIX-mediated Rac activation followed by Armus 
signalling to Rab7 and is partially dependent on Rab11 (dashed line) but independent of PAK signalling. 
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phosphorylation of proteins important for Rac-driven internalisation of E-cadherin 
receptors. It is not known whether PAKT co-localises on vesicles containing E-cadherin 
and Rac461L, but this may be possible as PAK1 promotes and localises to 
macropinocytic vesicles upon PDGF stimulation (Dharmawardhane et al., 2000). 
Another Rac effector protein, IQGAP, has been shown to localise at adherens 
junctions and, by interacting with (3-catenin, IQGAP competes with a-catenin for 
binding at E-cadherin complexes (Kuroda et al., 1996,1998). Upon over-expression of 
IQGAP, dissociation of a-catenin mediates destabilisation of cell-cell adhesion (Fukata 
et al., 1999). However, as IQGAP can bind to active Rac, these results cannot exclude 
that junction perturbation by IQGAP results in titration of active Rac inside the cell. 
Rac-dependent cadherin destabilisation does not require Rab7 inactivation by 
the novel Rac-binding protein Armus (Figure 7.1). However, it is still possible that 
Rab7 signalling is involved but may not be regulated by Armus during Rac-induced 
junction perturbation. Armus seems to regulate cell-cell contacts specifically when 
junctions are perturbed by Arf6 activation (Figure 7.1). When Arf6Q67L was over- 
expressed, Armus co-localises with internalised E-cadherin at a perinuclear 
compartment supporting the hypothesis that Arf6 can activate Armus in a regulated 
manner so that Rab7 cycling is temporally and spatially restricted. Accumulation of E- 
cadherin at a perinuclear area after Arf6Q671 expression was partially reversed by co- 
expression of Armus TBC/RabGAP domain, inactivation of Rac or Rab7, but not 
Rabl1a. 
Our data suggest that Armus may dimerise via its coiled-coil domains and 
adopt an auto-inhibitory conformation. In this scenario, I predict that binding of active 
Rac to Armus central coiled-coils region can disrupt Armus auto-inhibited state and, in 
turn, Armus can promote the inactivation of Rab7 proteins via its specific 
TBC/RabGAP domain (Figure 7.1). Whether Armus GAP activity is activated by Rac 
interaction remains to be formally tested, although such mechanism is highly likely as 
shown previously for other Rho targets (Bokoch, 2003; Pufall and Graves, 2002; 
Yamaguchi et al., 2006; Copeland et al., 2007). Rab7 signalling is important during 
Arf6-driven junction destabilisation for both keratinocyte (Figure 7.1) and MDCK cells 
(Palacios et al., 2005). Furthermore, I found that GIT1 and Armus co-localise on 
enlarged vesicular structures induced by a truncation mutant of GIT1 that lacks the 
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ArfGAP domain and ankyrin repeats (GIT1-C2) or Armus PH domain and coiled-coils 
(Armus1.550)" Taken together with the link of GIT1 (Di Cesare et al., 2001) and Armus to 
Rab11 (this work), these results imply that these proteins are spatially and functionally 
connected. 
In summary, junction disassembly induced by constitutively active Rac and 
Arf6 are different. Although the outcome is the same i. e. cell-cell adhesion disruption, 
the different pattern observed suggests that distinct mechanisms are triggered by 
active Rac or Arf6 to regulate E-cadherin stability. Yet, Rac signalling is an essential 
component downstream of Arf6 during junction disruption. This result indicates that 
(i) these GTPases can cross-talk and (ii) the spatio-temporal regulation of endogenous 
Rac activation by Arf6 may trigger specific/unique signalling pathways downstream of 
Rac. Consistent with this possibility, clear morphological and cellular differences were 
observed following activated Rac or Arf6 expression (kinetics and pattern of cadherin 
removal from junctions, accumulation of cadherin receptors at different intracellular 
compartments). In addition, PAK1 signalling is required for Rac461-- but not Arf6Q67. - 
mediated junction destabilisation. Conversely, Arf6, but not Rac, requires Armus 
signalling during the breakdown of adherens junctions. 
It remains to be determined which other pathways are stimulated by Arf6 and 
Rac activation per se. It would be interesting to investigate whether upstream proteins 
like oncogenic Ras and growth factors use similar components of the pathways 
described herein to induce cellular transformation during tumour development. 
Understanding the molecular mechanisms promoting cell-cell junction disruption may 
provide useful leads of anti-cancer therapy that can be taken into a clinical setting. 
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